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Abstract 
 
Rett syndrome (RTT) is a neurological disorder characterized by severe 
impairment of motor and cognitive functions, caused in >95 % of patients by de 
novo mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2) 
gene. The protein product of this gene, MeCP2, is widely expressed but 
especially abundant in postmitotic neurons of the central nervous system (CNS). 
However, there remains a fundamental lack of knowledge about the downstream 
pathways involved in gene function. Both Mecp2 knock-out and knock-in mutant 
mice present many of the overt neurological features seen in RTT patients. Both 
provide a very useful model for testing potential therapeutic applications. The 
current lack of effective therapies together with the monogenicity of the 
disorder and established reversibility of the phenotype in mice suggest that 
replacement of the MECP2 gene is a potential therapeutic option worthy of 
exploration, mainly using viral based delivery of MECP2-based gene constructs. 
Significant challenges remain, both in the efficiency of delivery of gene 
constructs to target cells and controlling construct-derived toxicity. 
 
In this study, I have explored the potential for augmentation gene therapy in 
RTT mice. First, I determine the best RTT mouse model and modify behavioral 
tests for RTT mice in preparation for the experiment testing therapeutic agents.  
Second, I assessed escalating doses of viral vector containing human MECP2_e1 
isoform coding sequences cloned into an AAV2 vector backbone with AAV9 capsid 
(scAAV9) under control of the murine Mecp2 endogenous core promoter 
(MeP229), a first generation vector, to ascertain the dose that has greater 
efficacy and lower toxicity after delivery to young adult Mecp2 knockout male 
mice. Third, I assess the safety and effectiveness of a new AAV vector construct 
design aiming to reduce the toxicity observed with the first-generation vector. 
This was carried out by direct brain injection in male neonates proving the 
efficacy of this vector. 
 
In the mouse behavioural studies, symptomatic hemizygous male and 
heterozygous female mice were used for assessment the two mouse models. The 
results demonstrated that in males, the Mecp2 knockout mouse model differed 
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significantly from their wild-type cage mates in terms of survival, body weight 
and a range of behavioural tests, while the T158M Mecp2 knock-in model 
presents with a somewhat milder phenotype. In contrast, in females, the 
knockout and knock-in heterozygotes show the same severity of the RTT-like 
phenotype in the behavioural tests. A notable finding was that in the RTT mouse 
models motor ability is improved by the addition of their own bedding into the 
testing arena (distance moved in open field arena with bedding incresed around 
60% in male knockout mice). Locomotor activity assessment in openfield test 
demonstrated that male knockout mice have significantly lower locomotor 
ability than the knock-in and WT, both in males and females, whereas the 
treadmill motor challenge test rotarod test demonstrated significantly different 
results in each group. In the novel object recognition test, a test of memory, the 
RTT mouse model showed differences from WT, while there was some learning 
capability shown on rotarod motor learning skills. The social interaction test in a 
reduced-size three chamber arena demonstrated that the RTT mouse did not 
engage in any interaction with a stranger mouse. Both anxiety tests 
administered, a light-dark test and a splash test, demonstrated that the RTT 
mouse models do not present with anxiety. The breathing test for apnoeas using 
the whole-body plethysmography apparatus demonstrated a significantly 
different level of breathing abnormality in knockout and knock-in mice. 
 
In the second phase of experiments, I showed that AAV-mediated delivery 
of MECP2 to Mecp2 null mice by systemic administration, and utilizing a minimal 
endogenous promoter, was associated with a narrow therapeutic window and 
resulted in liver toxicity at higher doses. Lower doses of this vector significantly 
extended the survival of mice lacking MeCP2 or expressing a mutant T158M 
allele but had no impact on RTT-like neurological phenotypes. Modifying vector 
design by incorporating an extended Mecp2 promoter and additional regulatory 
3′-UTR elements significantly reduced hepatic toxicity after systemic 
administration. Moreover, direct cerebroventricular injection of this vector into 
neonatal Mecp2-null mice resulted in high brain transduction efficiency, 
increased survival and body weight, and an amelioration of RTT-like phenotypes. 
My results show that controlling levels of MeCP2 expression in the liver is 
achievable through modification of the expression cassette. However, it also 
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highlights the importance of achieving high brain transduction to impact the 
RTT-like phenotypes. 
 
In summary, I have shown that the male Mecp2 knockout model is appropriate 
for use in screening studies for the treatment of RTT, while the female T158M 
Mecp2 knock-in model is suitable for long-term studies. I demonstrated that 
tests involving motor function in RTT mouse models should add the mouse’s own 
bedding into the arena to increase spontaneous mobility. An applicable test for 
mobility and motor defects is the rotarod test, and for learning, social 
interaction, and anxiety is the novel object recognition test using a resized 
three-chamber arena and splash test, respectively. 
I showed that the first-generation vector at an intermediate dose (1012 
vg/mouse) presents some therapeutic benefits in terms of extending survival and 
improving bodyweight, however it also causes liver toxicity. I discovered that 
newer cassette design vectors scAAV9/JeT/MECP2, scAAV9/sPA (sPA), and 
scAAV9.47/MECP2 (9.47) are no better in terms of efficiency and toxicity than 
the first-generation vector. I have demonstrated the successful application of a 
second-generation vector to deliver exogenous MECP2 to RTT mouse models with 
the same efficacy as with the first-generation vector, but with reduced liver 
pathology. I have also shown that without the physical barrier to the delivery of 
the viral vector to brain, the second-generation vector is likely to be useful for 
RTT therapy as it shows limited spread of the virus outside the brain and was 
able to significantly decrease the aggregate RTT-like severity score.   
 
  
5 
 
Table of Contents 
Abstract   2 
List of Tables   10 
List of Figures   11 
Acknowledgement  16 
Author’s Declaration   17 
Publications  18 
Abbreviations   19 
Chapter 1 Introduction ................................................................... 22 
1.1 General introduction ............................................................... 22 
1.2 Clinical manifestations of RTT ................................................... 23 
1.3 Genetic basis of RTT ............................................................... 24 
1.3.1 Rett Syndrome and MECP2 ................................................... 24 
1.3.2 MECP2 structure ............................................................... 25 
1.3.3 MeCP2 Functions ............................................................... 27 
1.4 Animal models of Rett syndrome ................................................. 29 
1.5 Behavioural tests in the mouse model .......................................... 30 
1.6 Reversibility of the RTT phenotype and treatment strategies. .............. 32 
1.6.1 Treatment strategies for RTT ................................................ 32 
1.6.2 Gene therapy approaches .................................................... 32 
1.7 Adeno-associated virus (AAV) as a potential gene therapy vector .......... 35 
1.7.1 AAV-based vectors and mammalian cell transduction ................... 35 
1.7.2 Self-complementary AAV ..................................................... 36 
1.7.3 AAV capsid ...................................................................... 38 
1.7.4 Clinical application and potential in RTT .................................. 39 
1.8 Design of gene therapy approaches ............................................. 40 
1.8.1 choice of regulatory elements & vector ................................... 40 
1.8.2 Optimal time for gene therapy interventions ............................. 42 
1.8.3 Local or global MECP2 delivery .............................................. 43 
6 
 
1.8.3 To target specific types of cells in the brain: astrocytes or neurons?
 ........................................................................................ 46 
1.8.4 Other gene-targeted strategies in RTT ..................................... 47 
1.9 Summary and aim .................................................................. 50 
Chapter 2   Material and Methods ....................................................... 52 
2.1 General molecular biology materials ............................................ 52 
2.2 General solutions ................................................................... 54 
2.3 Mouse models of RTT .............................................................. 55 
2.3.1 source of the Mecp2-KO mouse and Mecp2 T158M knock-in models ... 56 
2.3.2 Breeding strategy of Mecp2-KO and Mecp2 T158M knock-in mice ...... 56 
2.3.3 Ethic and husbandry .......................................................... 57 
2.3.4 Genotyping ..................................................................... 57 
2.3.3.1 DNA extraction and PCR genotyping ................................... 57 
2.3.3.2 Agarose gel electrophoresis ............................................. 59 
2.3.5 Allocating animals to experimental groups and blinding system ....... 59 
2.3.6 Phenotypic severity scoring and weight measurement .................. 60 
2.4 Behavioural tests ................................................................... 60 
2.4.1 Open field test ................................................................. 63 
2.4.2 Novel object recognition test ................................................ 63 
2.4.3 Rotarod performance test .................................................... 64 
2.4.4 Treadmill motor challenge test (Exercise tolerance) .................... 65 
2.4.5 Social interaction test ........................................................ 65 
2.4.6 Light/Dark box test ........................................................... 66 
2.4.7 Splash test ...................................................................... 67 
2.4.8 Breathing test (Whole body plethysmograph) ............................. 68 
2.5 Adeno-associated viral vectors and Vector administration .................. 69 
2.5.1 Vector preparation ............................................................ 69 
2.5.2 Vector injection ............................................................... 70 
7 
 
2.5.2.1 Tail vein injection ........................................................ 70 
2.5.2.2 Cerebroventricular injection into neonatal mice .................... 70 
2.6 Immunohistochemistry (IHC) ...................................................... 71 
2.7 Image analysis ...................................................................... 72 
2.8 Statistical analysis ................................................................. 73 
Chapter 3 Validation of behavioural tests in RTT mouse models ................... 74 
3.1 Introduction ......................................................................... 74 
3.2 Study aims ........................................................................... 75 
3.3 Method ............................................................................... 76 
3.4 Results ............................................................................... 81 
3.4.1 RTT model genotyping by PCR ............................................... 81 
3.4.2 Phenotype severity assessment in KO and KI mice ....................... 82 
3.4.2.1 Male ........................................................................ 82 
3.4.2.2 Female ..................................................................... 84 
3.4.3 Establishment and validation of detailed behavioural tests in the male 
RTT mouse models ................................................................... 85 
3.4.3.1 Open field test ............................................................ 85 
3.4.3.2 Novel object recognition test ........................................... 87 
3.4.3.3 Rotarod test ............................................................... 88 
3.4.3.4 Motor learning............................................................. 89 
3.4.3.5 Treadmill motor challenge test ........................................ 90 
3.4.3.6 Social interaction test ................................................... 91 
3.4.3.7 Light-dark box test ....................................................... 92 
3.4.3.8 Splash test ................................................................. 93 
3.4.3.9 Breathing test ............................................................. 94 
3.4.4 Establishment and validation of detailed behavioural tests in female 
RTT mouse models ................................................................... 95 
3.4.4.1 Open field test ............................................................ 95 
8 
 
3.4.4.2 Novel object recognition test ........................................... 96 
3.4.4.3 Rotarod test ............................................................... 97 
3.4.4.4 Motor learning............................................................. 98 
3.4.4.5 Treadmill motor challenge test ........................................ 99 
3.4.4.6 Social interaction test .................................................. 100 
3.4.4.7 Light-dark box test ...................................................... 101 
3.4.4.8 Splash test ................................................................ 102 
3.4.4.9 Breathing test ............................................................ 103 
3.5 Discussion ........................................................................... 104 
Chapter 4 Assessment of safety and efficacy of vector-derived MeCP2 on the 
progression of the RTT-like phenotype in a dose escalation study ................ 111 
4.1 Introduction ........................................................................ 111 
4.2 Aims ................................................................................. 112 
4.3 Methods ............................................................................. 112 
4.4 Results .............................................................................. 113 
4.4.1 1st generation vector safety and efficacy at different doses by IV 
delivery in the Mecp2 KO mouse model of RTT ................................. 113 
4.4.2 1st generation vector transduction efficiency and level of vector-
derived MeCP2 in the brain in Mecp2 KO mice .................................. 117 
4.4.3 1st generation vector transduction efficiency and level of vector-
derived MeCP2 in the liver in Mecp2 KO mice ................................... 119 
4.4.4 Effect of IV delivery of 1st generation vector on survival, bodyweight 
and phenotype severity score in Mecp2T158M/y mice ............................ 124 
4.4.5 The expression of 1st generation vector in Mecp2T158M/y brain ......... 126 
4.5 Discussion ........................................................................... 126 
Chapter 5 Development of a novel MECP2 expression cassette with enhanced 
safety features ............................................................................ 129 
5.1 Introduction ........................................................................ 129 
5.2 Study aims .......................................................................... 130 
9 
 
5.3 Methods ............................................................................. 130 
5.4 Results .............................................................................. 132 
5.4.1 The efficacy and safety of SpA, JeT and 9.47 vectors in the KO 
mouse model, dosing at 1012 vg/mouse by IV injection. ....................... 132 
5.4.2  Development of a Second-Generation Vector that Reduced Liver 
Toxicity after Systemic Administration........................................... 136 
5.4.3 Neonatal Cerebroventricular Injection of the Second-Generation 
Vector Improved the RTT-like Aggregate Severity Score ...................... 141 
5.4 Discussion ........................................................................... 144 
Chapter 6 General discussion ........................................................... 148 
6.1 Major findings ...................................................................... 148 
6.1.1 Phenotypic characteristics and behavioural test results in the RTT 
mouse models. ....................................................................... 150 
6.1.2 Dose escalation with AAV/MECP2 revealed a narrow therapeutic 
window following systemic administration and resulted in liver toxicity ... 151 
6.1.3 Development of a second-generation vector that reduced liver toxicity 
after systemic administration and the efficiency of the second-generation 
vector improved the RTT-like aggregate severity score via neonatal 
cerebroventricular injection ....................................................... 153 
6.2 Technical considerations ......................................................... 153 
6.3 Significance of this study ......................................................... 155 
6.4 Future studies ...................................................................... 157 
6.5 Summary ............................................................................ 160 
References ................................................................................. 162 
  
10 
 
List of Tables 
 
Table 1-1. Summary of behavioural tests of published studies in RTT mouse 
models. 31 
Table 1-2. Summary of experimental design and outcomes of published studies of 
gene therapy interventions in Rett syndrome mouse models. 41 
Table 2-1 General molecular biology reagents 52 
Table 2-2 Primer sequences and sizes of amplified PCR products for Mecp2+/- and 
Mecp2+/T158M genotyping 52 
Table 2-3 List of AAV vectors 53 
Table 2.4 – General molecular biology solutions 54 
Table 2-5 Breeding scheme for Mecp2-KO and Mecp2 T158M knock-in mice  56 
Table 2-6 Setting of PCR reaction for genotyping of Mecp2-null mice, 
Mecp2T158M mice and their WT littermates 58 
Table 2-7 The conditions of thermocycling for genotyping  58 
Table 2-8 phenotyping score 61 
Table 3-1 Order of behavioural experiments performed for each mouse in 
behavioural tests in male RTT mouse models 77 
Table 3-2 Order of behavioural experiments performed for each mouse in 
behavioural tests in female RTT mouse models 80 
  
11 
 
List of Figures 
 
Figure 1.1 Clinical manifestations of Rett syndrome Representative diagram 
showing the characteristic RTT clinical presentation  24 
Figure 1.2 Composition and splicing pattern of MECP2 gene  26 
Figure 1.3 MeCP2 protein structure  28 
Figure 1.4 Therapeutic targets and potential pharmacological strategies 
currently being explored in animal models for the treatment of Rett 
syndrome  33 
Figure 1.5 Summary of current challenges for RTT gene therapy  34 
Figure 1.6 AAV-based vector transduction  37 
Figure 2.1 the open field arena which is recorded by IR camera   63 
Figure 2.2 Novel object test phase and recognition training  64 
Figure 2.3 Setting up of Arena for social interaction test  66 
Figure 2.4 Two-compartment arena used in the light-dark box test  67 
Figure 2.5 This experiment is a test of mouse stress by observing the 
grooming behaviour in its home cage   68 
Figure 2.6 Images of the whole-body plethysmograph used for assessment of 
the breathing phenotype  69 
Figure 2.7 Cerebroventricular injection in neonatal mice   71 
Figure 3.1 Results of PCR genotyping of wild-type, hemizygous and 
heterozygous mice from both lines; Mecp2 KO and Mecp2 T158M  81 
Figure 3.2 Composite body weight measurements and severity score in wild-
type, Mecp2-/y and Mecp2T158M/y mice  83 
Figure 3.3 Composite body weight measurements and severity score in wild-
type, Mecp2+/-and Mecp2+/T158M female mice (6-8 months old)   84 
Figure 3.4 The comparison of locomotor assessment in wild-type and  
Mecp2-/y male mice in open field arena with and without bedding  86 
12 
 
Figure 3.5 The general locomotor assessment in WT, Mecp2-/y and 
Mecp2T158M/y male mice  86 
Figure 3.6 Discrimination index for learning and cognition baseline in novel 
object recognition test in WT, Mecp2-/y and Mecp2T158M/y male mice in 15 
minutes  87 
Figure 3.7 Rotarod performance of WT, Mecp2-/y and Mecp2T158M/y male mice 
using rotarod machine  88 
Figure 3.8 Motor learning curve of WT, Mecp2-/y and Mecp2T158M/y male mice 
using rotarod machine over 3 days  89 
Figure 3.9 Treadmill motor test of WT, Mecp2-/y and Mecp2T158M/y male mice  90 
Figure 3.10 Social interaction test in WT, Mecp2-/y and Mecp2T158M/y male 
mice  91 
Figure 3.11 Exploration and anxiety-related measures of the light-dark test 
in WT, Mecp2-/y and Mecp2T158M/y in male mice  92 
Figure 3.12 Anxiety assessment of wild-type, Mecp2-/y and Mecp2T158M/y male 
mice by splash test  93 
Figure 3.13 Persistent breathing phenotype in WT, Mecp2-/y, Mecp2T158M/y 
male mice   94 
Figure 3.14 The general locomotor assessment in WT, Mecp2+/-, Mecp2+/T158M 
female mice  95 
Figure 3.15 Discrimination index of learning and cognition baseline in novel 
object recognition test in WT, Mecp2+/-, Mecp2+/T158M female mice in 15 
minutes  96 
Figure 3.16 Motor deficit test of WT, Mecp2+/-, Mecp2+/T158M female mice 
using rotarod machine  97 
Figure 3.17 Motor learning curve of WT, Mecp2+/-, Mecp2+/T158M female mice 
using rotarod machine over 3 days  98 
Figure 3.18 Motor function and locomotion assessment in WT, Mecp2+/-, 
Mecp2+/T158M female mice  99 
13 
 
Figure 3.19 Social interaction test in WT, Mecp2+/-, Mecp2+/T158M female 
mice  100 
Figure 3.20 Exploration and anxiety related measures of the light-dark test 
in WT, Mecp2+/-, Mecp2+/T158M female mice  101 
Figure 3.21 Anxiety assessment of WT, Mecp2+/-, Mecp2+/T158M female mice 
by splash test  102 
Figure 3.22 Persistent breathing phenotype in WT, Mecp2+/-, Mecp2+/T158M 
female mice  103 
Figure 4.1 MECP2_e1/Myc fusion constructs were cloned into AAV2 
backbones under a MeP promoter  113 
Figure 4.2 Survival plot of Mecp2 KO mice treated with 3 different doses of 
scAAV9/MeP/MECP2  114 
Figure 4.3 Graph showing the average body weight of wild-type and Mecp2-/y 
treated with vehicle and Mecp2-/y treated with 1012 vg/mouse dose  115 
Figure 4.4 RTT-like severity score of wild-type and Mecp2-/y treated with 
vehicle and Mecp2-/y treated with 1012 vg/mouse dose  116 
Figure 4.5 Flattened confocal stack images of the CA1 region of the 
hippocampus taken from Mecp2-/y mice treated intravenously with different 
doses of the 1st generation vector  117 
Figure 4.6 Dose-dependent transduction efficiency (Mycpositive nuclei as a 
proportion of DAPI-positive nuclei) across different brain regions  118 
Figure 4.7 Intravenous injection of AAV9/hMECP2 into wild-type mice 
resulted in toxicity at the high dose  119 
Figure 4.8 Vector biodistribution analysis of mice injected intravenously 
with 1012 vg/mouse showing high transduction efficiency in the liver and 
heart and low transduction efficiency in the CNS  120 
Figure 4.9 Intravenous injection of 1st generation vector resulted in high 
level of vector-derived MeCP2 expression in the liver  121 
Figure 4.10 Toxicity issues revealed after systemic administration of high 
vector dosage  122 
14 
 
Figure 4.11 Diagram Showing AAV vector constructs  123 
Figure 4.12 Comparison of liver toxicity between 1st generation Mecp2 
vector treatment and the GFP vector treatment in Mecp2 KO mice injected 
with 1013 vg/mouse  123 
Figure 4.13 The comparison between WT, KO and treated Mecp2T158M/y 
cohort in different parameter  124 
Figure 4.14 Survival plot, bodyweight measurements and bodyweight 
measurements of WT and Mecp2T158M/y KI mice treated vehicle and 
Mecp2T158M/y KI mice treated with the moderate dose of 1st generation 
vector  125 
Figure 4.15 Transduction efficiency in the brain of treated mice  126 
Figure 5.1 Diagram showing AAV vector constructs of vectors  131 
Figure 5.2 Survival of Mecp2 KO mice treated with SpA containing vector, 
vector utilising JeT, and vector utilising AAV9.47 capsid  132 
Figure 5.3 Body weight measurement of Mecp2 KO mice treated with SpA 
containing vector, vector utilising JeT, and vector utilising AAV9.47 capsid  133 
Figure 5.4 of Rett-like phenotype severity score of Mecp2 KO mice treated 
with spA containing vector, vector utilising JeT, and vector utilising 
AAV9.47 capsid  134 
Figure 5.5 summary of Novel vector design features and efficacy  135 
Figure 5.6 Comparison of liver toxicity between 1st generation vector 
treatment and the novel vectors treatment (1012 vg/mouse; for 30 days ) in 
WT mice aged 35 days)  135 
Figure 5.7 Design of the 2nd generation vector construct 137 
Figure 5.8 Therapeutic Efficacy of Second-Generation Vector after Systemic 
Delivery to Mecp2−/y Mice 138 
Figure 5.9 Expression of vector-derived MeCP2 in the livers of mice treated 
with second-generation vector compared with first-generation vector 139 
15 
 
Figure 5.10 Comparison of liver toxicity between 1st generation vector 
treatment and the novel vectors treatment (1012 vg/mouse; for 30 days) in 
WT mice aged 35 days)  140 
Figure 5.11 Survival plot, bodyweight measurements and bodyweight 
measurements of Mecp2-/y and WT neonatal mice treated with the 426-
vector 1x1011 vg/ mouse and Mecp2-/y and WT mice treated with vehicle by 
direct brain injection.  142 
Figure 5.12 Direct Brain Delivery of Second-Generation Vector to Neonatal 
Mecp2−/y Mice Revealed Therapeutic Efficacy 143 
Figure 5.13 Distribution analysis of 2nd generation vector delivered MeCP2 in 
mouse brain by direct brain injection method 144 
Figure 6.1 Mechanism of action of CRISPR/Cas system 160 
 
  
16 
 
Acknowledgements 
 
The completion of this thesis was made possible by the financial support of a 
PhD scholarship awarded by, Ministry of Science and Technology, Thailand. I 
would like to thank them for this support throughout the PhD program. 
I am eternally grateful to a number of people for their help and support 
throughout my studies. In particular to my supervisors Dr Stuart Cobb and Dr 
Mark Bailey for giving me this great opportunity to undertake a fascinating and 
challenging project, and for their continuous guidance, advice and constructive 
criticism.  
I would like to thank my assessors Dr Deborah Dewar and Dr Leanne McKay for 
their advice and suggestions during the course of my PhD. 
It is a pleasure to thank those whose contributions made this thesis possible 
especially Dr Kamal Gadalla, Dr Lieve Desbonnet and Dr Alex Surget. 
I am grateful also to Dr Steven Gray, Prof Brian Morris and Dr John Riddell for 
their technical assistance and fruitful collaboration. 
I have been fortunate to work with some fantastic people over the past few 
years. Special thanks go to Dr Bushra Kamal, Dr Paul Ross, Dr Rebecca 
Openshaw, Dr Daniela Minchella, Dr Elaine Hunter, Dr Noha Bahey, Dr Ralph 
Hector and John Craig for their kind help and support during my PhD. 
I owe my deepest gratitude to the University of Glasgow Senate and Disability 
service especially Ms Shona Robertson, Ms Fiona Gray and Ms Lesley-Anne 
Morrison who provided a great deal of support during a difficult time when I had 
a severe eye problem through the last year of my PhD. 
Finally, I would like to thank my family who gave me mental support, especially 
my beloved grandma and John. 
  
17 
 
Author’s Declaration 
 
I declare that, except where explicit reference is made to the contribution of 
others, this thesis is the result of my own work and has not been submitted for 
any other degree at the University of Glasgow or any other institution. 
 
Signature:    
Thishnapha Vudhironarit 2019 
 
 
  
18 
 
Publications 
Some of the work contained in this thesis has been published in part: 
 
Manuscripts 
Gadalla, K. K. E., T. Vudhironarit, R. D. Hector, S. Sinnett, N. G. Bahey, M. E. S. 
Bailey, S. J. Gray, and S. R. Cobb, 2017, Development of a Novel AAV Gene 
Therapy Cassette with Improved Safety Features and Efficacy in a Mouse Model 
of Rett Syndrome: Mol Ther Methods Clin Dev, v. 5, p. 180-190. 
 
Oral presentation 
 “AAV-mediated MECP2 Gene Delivery in Mouse Models of Rett Syndrome.” at 
“The 13th Asia Pacific Federation of Pharmacologist (APFP) Meeting” on 
February 2016   
19 
 
Abbreviations 
 
AAV  Adeno-associated virus 
ANOVA  Analysis of variance 
BBB  Blood brain barrier 
Bp  Base pair 
Cas CRISPR-associated 
CNS  Central nervous system 
CMV  Cytomegalovirus promoter 
CpG  Cytosine-guanine dinucleotide 
CO2  Carbon dioxide 
CRISPR clustered regularly interspaced short palindromic repeats 
CTD  C-terminal domain 
DAPI  4’,6-diamidino-2-phenylindole 
DNA  Deoxyribonucleic acid 
FO Familiar object 
GFAP  Glial fibrillary acidic protein 
GFP  Green fluorescent protein 
HEMI Hemizygous 
HET Heterozygous  
Hp1  Heterochromatin protein 1 
IC  Intracranial 
ICM intra-cisterna magna 
IV  Intravenous 
IU  Infection unit 
IT intratracheal injection 
ITR  Inverted terminal repeat 
JET scAAV9/JeT/MECP2 or Jet promotor vector 
KI  Knock in 
KO  Knockout 
LTP  Long term potentiation 
LTR  Long terminal repeat 
MAP2  Microtubule associated protein 
MBD  Methyl-CpG-binding domain 
20 
 
MECP2  Human Methyl-CpG-binding protein 2 gene 
Mecp2  Mouse Methyl-CpG-binding protein 2 gene 
MeCP2  Human Methyl-CpG-binding protein 2 protein 
Mecp2  Mouse Methyl-CpG-binding protein 2 protein 
MECP2_e1  Methyl-CpG-binding protein 2 isoform e1 
MECP2_e2  Methyl-CpG-binding protein 2 isoform e2 
ME1  Mecp2_e1 
MeP Mecp2  
N 
endogenous core promoter 
Number 
MiR microRNA 
NeuN  Neuron nuclear antigen rbfox3 
NHEJ Non-homologous end joining 
NLS  Nuclear localisation signal 
NO Novel object 
NOR Novel object recognition test 
NTD  N-terminal domain 
ORF open reading frames 
PB  Phosphate buffer 
PBS  Phosphate buffer saline 
PCR  Polymerase chain reaction 
PEI  Polyethylenimine 
PSC  Premature stop codon 
RE Regulatory elements 
RefSeq Reference Sequence 
Rep Replication 
scAAV  self-complementary Adeno-associated virus 
SD  Standard deviation 
SEM  Standard error of mean 
SMA Spinal muscular atrophy 
SpA scAAV9/sPA or short polyA vector 
ssAAV  Single-stranded Adeno-associated virus 
Syn1  Synapsin1 promoter 
TFIIB Transcription factor IIB 
RNA  Ribonucleic acid 
21 
 
rpm  revolutions per minute 
RTT  Rett syndrome 
TRD  
vg 
Transcription repression domain 
vector genome 
WT  Wild-type 
YB1 Y box binding protein 
 
  
22 
 
Chapter 1 Introduction 
1.1 General introduction 
RTT (Rett syndrome) is a paediatric neurological disorder with postnatal onset. 
RTT is the leading cause of severe mental retardation in females after Down 
Syndrome. It was first described by Andreas Rett (Rett, 1966). After this, it was 
re-described in 1983 by Bengt Hagberg (Hagberg et al., 1983). In 1999, it was 
shown that RTT was caused primarily by mutations in an X-linked gene, MECP2 
(Amir et al., 1999). After this, Mecp2 knockout mouse models were developed by 
a number of groups (Chen et al., 2001) and there have been many attempts 
made to apply therapeutic interventions to prevent or delay the onset of the 
RTT-like phenotype or reverse the signs after onset. The initial successes 
reported have demonstrated the tractability of the problem of ameliorating 
several aspects of the phenotype and have highlighted the potential to treat RTT 
patients by addressing the pathogenetic pathway’s early stages and going 
beyond mere amelioration of downstream consequences.  
 
In this thesis, Mecp2 knockout mice have been used in evaluating a therapeutic 
approach based on viral vector-mediated delivery of a wild-type copy of MECP2 
to cells that lack this protein. Delivery of exogenous MECP2 to the brain is a 
challenging approach not only due to the obstacles inherent in delivering 
substances to the CNS, but also due to the impediments to transducing large 
numbers of cells and in maintenance of exogenous levels of MeCP2 within the 
limits of physiology to prevent toxicity relating to overexpression. The 
evaluation of outcomes pertaining to these experiments should provide 
information about drawbacks, benefits, challenges and prospects of application 
of gene therapy in the treatment of Rett syndrome.     
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1.2 Clinical manifestations of RTT 
RTT (OMIM 312750) has traditionally been considered a neurodevelopmental 
disorder and is a primary cause of severe mental retardation in girls, with an 
incidence of around 1 in 10,000 female births (Neul et al., 2010). 
 
The characteristics of RTT include the fact that it occurs exclusively in females 
and a constellation of clinical features (Neul et al., 2010). The features that 
distinguish RTT from autism spectrum disorders, which RTT has often been co-
classified with, include apparent normal growth in the initial 6-18-month period. 
However, reduced head circumference and birth weight are also observed 
(Leonard and Bower, 1998), after which there ensues a period of developmental 
regression, with the patients displaying deficits in social interaction (features 
being similar to autism, figure 1-1), impaired speech and mobility, loss of hand 
skills and development of stereotypical movements of the hands (repetitive and 
continuous twisting, wringing, clapping hand automatism when awake). This 
phase of regression is followed by a stationary or recovery phase lasting for 
years, with some patients regaining the lost skills partially. Nonetheless, a phase 
of late motor deterioration generally takes place thereafter with features of 
motor disabilities of a severe nature (Hagberg, 2002).  
 
One of the common characteristics of RTT is epilepsy. Onset occurs primarily 
during the stationary phase (Hagberg, 2002). However, after the age of 20 years, 
there is usually a decrease in severity. Other characteristics include 
abnormalities which are musculoskeletal in nature in the form of scoliosis, which 
often has onset during school ages, subtle distal deformity of bones of the lower 
limbs is also observed in many patients (Hagberg, 2002). There is a high 
frequency of autistic like features during regression in RTT and this includes un-
responsiveness to social prompts, indifference to the surrounding environment, 
hypersensitivity to sound and expressionless facial features (Chahrour and 
Zoghbi, 2007).  
 
RTT’s autonomic features include frequent apnoea when awake, breath holding, 
and episodic hyperventilation. Among RTT patients, intestinal distention and 
constipation, gastro-oesophageal reflux, and swallowing dysfunction are 
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observed as well (Hagberg, 2002). Most features mentioned above result directly 
from the primary CNS deficits; however, several can also be influenced by 
peripheral effects.  
 
The severity and the clinical presentation of RTT vary widely. Certain features 
must be present in patients for the diagnosis of typical RTT, or there may be 
differences enabling their assignment to one of a range of atypical RTT 
diagnoses (Neul et al., 2010). 
 
 
 
Figure 1.1 Clinical manifestations of Rett syndrome Representative diagram 
showing the characteristic RTT clinical presentation.* indicates main criteria 
essential for typical RTT diagnosis. 
 
1.3 Genetic basis of RTT 
1.3.1 Rett Syndrome and MECP2 
Cases of RTT are generally a result of dominantly-acting de novo mutations 
(Chen et al., 2001) in MECP2, which encodes a protein product known as MeCP2. 
There have been reports of over 600 pathogenic MECP2 mutations (RettBase: 
http://mecp2.chw.edu.au/ ), including frameshift, nonsense and missense 
mutations, as well as large deletions. Pathogenic mutations in MECP2 mostly 
cause RTT in heterozygous females, although MECP2 mutations have an 
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association with other phenotypic outcomes (Bienvenu and Chelly, 2006), 
including milder forms of learning disability and, in rare cases, autism (Moretti 
et al., 2006). Boys who inherit a mutant MECP2 allele that would cause typical 
RTT in a heterozygous female are more severely affected, presenting with 
infantile encephalopathy and generally not surviving infancy. The differences 
existing between the female and the male phenotypes exists as a result of the 
cell proportions in the nervous system that express the mutant allele. All cells 
expressing MeCP2 will express the mutant allele only in hemizygous males. 
However, in the brains of the females, because of X chromosome inactivation 
(XCI), there is development of a mosaic cellular network at the level of 
expression with some cells expressing the normal allele and others expressing 
the mutant allele. This way, the pathology that is associated with the mutant 
allele has undergone dilution (at the level of the network) in the brains of the 
females, at least for the actions that pertain to mutations’ direct cell-
autonomous effects.  
 
1.3.2 MECP2 structure 
MeCP2 is a nuclear protein predominantly and was first discovered through its 
affinity for DNA sequences that contain methylated 5’-CpG-3’ dinucleotides. It 
belongs to the MBD (methylated DNA binding domain) protein family, several of 
whose members can act as repressors of transcription (Klose and Bird, 2006).  
The MECP2 gene is located within chromosome Xq28, is approx. 68kbp in length 
and comprises four exons (Dragich et al., 2000). There are two encoded proteins 
translated from two major transcripts. The two main transcript splice isoforms 
are MECP2_e1 and MECP2_e2, encoding proteins of 498 and 486 amino acids, 
respectively, which differ only at the N-terminus (Figure 1.2) (Mnatzakanian et 
al., 2004). MECP2_e2 uses a translational start site within exon 2 whereas 
MECP2_e1 does not include exon 2 (figure 1.2A). Both isoforms are considered to 
have two primary functional domains (figure 1-3), an Me-CpG binding domain 
(MBD; 85 amino acids) and a transcriptional repressor domain (TRD; 104 amino 
acids in length). The coding sequence for the MBD is split between exons 3 and 
4, while the TRD, amino acids 207 to 310, is encoded by exon 4 (Nan et al., 
1997). Exon 4 also encodes the 3′ UTR which in the human gene is up to 8.5 kb 
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long, depending on which of two major polyadenylation signals are used. MeCP2 
is expressed widely throughout the body, including in postnatal neurons, where 
there is specifically high expression (LaSalle et al., 2001). MeCP2 is quite 
strongly conserved in mammals - MeCP2_e2 shows 95% identity at the amino acid 
level between human and mouse, while there is 100 per cent identity between 
these species across the MBD (Nan et al., 1996). 
A) 
 
B) 
 
 
Figure 1.2 Composition and splicing pattern of MECP2 gene (A) Representative 
figure showing the splicing patterns of the MECP2 gene. Two mRNA isoforms are 
generated; MECP2_e1 and MECP2 _e2. The two isoforms generate two protein 
isoforms of MeCP2 with differing N-termini due to the use of alternative 
translation start sites (bent arrows) (B) Alignment of the _e1 (GenBank accession 
no. NM_001110792.1) and _e2 (GenBank accession no. NM_004992.3) isoforms of 
MeCP2, showing the different N-termini (yellow and green highlights). 
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MeCP2_e2 shows 95% identity at the amino acid level between human and 
mouse, while there is 100 per cent identity between these species across the 
MBD (Nan et al., 1996). 
 
Mecp2_e1 is a plentiful isoform in the brain (Mnatzakanian et al., 2004) and is 
translated with higher efficiency in vivo (Kriaucionis and Bird, 2004). Mutations 
in exon 1 are sufficient to produce neurological manifestations. In contrast, no 
specific exon 2 mutations associated with RTT have been observed thus far 
(Mnatzakanian et al., 2004). A report recently showed that during neuron-
induced toxicity, MeCP2_e2 is upregulated and its driven overexpression in 
healthy neurons enhanced apoptosis. Moreover, it has been found to be 
neuroprotective (Dastidar et al., 2012). Another study in which MeCP2_e2 was 
knocked down demonstrated the dispensability of this isoform.    
Nonetheless, further analysis has shown that Mecp2_e2 allele mutations have 
association with survival disadvantage and placental defects. 
1.3.3 MeCP2 Functions  
The functions of MeCP2 are mediated primarily by the two primary functional 
domains, the MBD and TRD. These domains interact with histone deacetylase and 
the Sin3a repressor complex among other proteins (Nan et al., 1997; 1998). 
MeCP2 protein has two NLS (nuclear localization signals) responsible for nuclear 
targeting of Mecp2 (Nan et al., 1996) and a C-terminal segment that helps it 
bind to the core of the nucleosome. MeCP2 is expressed in neuronal stem cells in 
Xenopus (Jung et al., 2003). However, in mammals Mecp2 is not expressed in 
neural precursors, indicating that it is unlikely that Mecp2 is involved in neuronal 
differentiation or early cell fate decisions, but rather is involved in maintenance 
and neuronal maturation (Kishi and Macklis, 2004). During development, 
expression of MeCP2 is absent or very low in immature neurons and increases 
during neuronal maturation, reaching its highest level in postmitotic neurons and 
remaining high through adult life (Kishi and Macklis, 2004). Mecp2 knocked out in 
the adult brain of the mice results in very similar motor and neurological deficits 
to those observed in germline knockout mice which suggests MeCP2’s necessary 
role in maintaining neuronal function (McGraw et al., 2011). 
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Figure 1.3  MeCP2 protein structure. 
Representative figure showing the distinct functional domains of MeCP2. Apart 
from the N-terminus, both MeCP2 isoforms are identical and contain several 
functionally distinct domains: NTD, N-terminal domain; MBD, methyl binding 
domain; ID, inter domain; TRD, transcription repression domain; CTD, C-terminal 
domain; NLS; nuclear localisation signals.Locations of 9 of the most common 
point mutations in RTT are indicated (●). Below each domain are indicated 
major (bold) and other (grey) interactors and functions). HP1; heterochromatin 
protein 1, TFIIB; transcription factor IIB, YB1; Y box binding protein 1. This 
figure was adapted from Gadalla et al., 2011 and Xu et al., 2013. 
 
 
Biophysical studies have probed the specificity of MeCP2 binding and have 
reported on the interaction (through hydration within the main groove) with 
methylated DNA and the interaction with nucleosomes (Yang et al., 2011). 
Despite this knowledge, the precise biological function of MeCP2 remains 
unclear. Alternative or additional functions proposed include selective 
activation/enhancement of gene expression, processing of RNA (Young et al., 
2005), and regulation of chromatin (Nikitina et al., 2007).  It was established 
that the distribution of MeCP2 across the genome is largely in parallel with the 
density of methylation and occurs, in neurons at least, to the exclusion of 
histone H1.  The data suggests MeCP2 plays a major role in suppressing 
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transcription through large-scale actions genome wide, perhaps via global 
dampening of transcriptional noise.   
 
1.4 Animal models of Rett syndrome 
The status of RTT is that of a relatively common monogenic disorder that has 
created enough interest to further investigate the underlying pathology. The 
interest has largely emanated from the need to develop rational therapies for 
patients. However, fuller understanding of neuronal dysfunction and the 
underlying pathology in RTT may also provide insight into the pathophysiology of 
neurodevelopmental disorders more generally (Neul and Zoghbi, 2004).  As 
MECP2 mutations lead to RTT via loss of function effects, modelling of RTT has 
been conducted using Mecp2 knockout mice. Due to the high levels of 
conservation of this protein in mammals (see 1.3.2), studying the effects of 
mutations of Mecp2 in mice has been suggested to be appropriate in order to 
understand further the RTT phenotype and potential therapeutic avenues. 
 
There are many models that have successfully recapitulated several of the 
cardinal traits which characterise RTT in humans, albeit there are key 
variations. An early RTT animal model was generated by deleting exon 3 
(encoding 116 amino acids, the majority of which comprise portions of the MBD) 
(Chen et al., 2001). An Mecp2-/y male mouse, where Mecp2 was knocked out 
either specifically in the central nervous system, or globally, appears to be 
normal for the first few weeks of life. However, as the disease progresses, the 
mice display hypoactivity, a decrease in bodyweight, an increase in trembling, 
and end with premature death around the age of 10 weeks. Contrastingly, 
heterozygous females (Mecp2+/-) have a mosaic network at the cellular level 
(due to XCI) and comprise a mixture of cells expressing the WT and mutant 
Mecp2 alleles. This has similarity with RTT patients, with apparent normal 
growth in the initial four-month period followed by gait and ataxia 
abnormalities, reduction of activity, and weight-gain. 
 
After discovering that the MECP2 gene is a cause of 96% of typical RTT cases, 
(Amir et al., 1999; Chahrour and Zoghbi, 2007), the RTT mouse models were 
created (Chen et al., 2001; Guy et al., 2001; Shahbazian et al., 2002). The first 
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generation of RTT mouse models involved deletion of exons 3 and/or 4 (Chen et 
al., 2001; Guy et al., 2001). Subsequently, RTT mouse models were constructed 
to have the most common mutations seen in RTT patients (Brown et al., 2016; 
Chen et al., 2001; Pelka et al., 2006; Shahbazian et al., 2002).  
 
1.5 Behavioural tests in the mouse model 
After the creation of the RTT mouse models, there were further dramatic 
improvements in investigative techniques with regards to RTT disease 
progression (Goffin et al., 2011; Guy et al., 2001) and possible reversibility 
(Robinson et al., 2012). To investigate this more intensively, behavioural tests 
are required to characterise the RTT mouse models, especially to clarify the 
baseline of each systemic impairment before instigating treatment.  
The Mecp2 null mouse is the first line to study the characteristics in the RTT 
mouse model (Chen et al., 2001; Guy et al., 2001). Most of the studies recorded 
body weight and aggregate phenotype severity RTT score which originated in 
studies carried out by Guy et al. in 2007 as a standard to report the condition of 
the RTT mice, with some papers reporting on breathing abnormality tests. 
Following this, the Mecp2 knock-in lines that mimic the most prevalent MECP2 
mutations in humans were created. The research showed characteristics 
compared with the Mecp2 knock-out mice in terms of the basic behavioural tests 
(body weight, aggregate phenotype severity RTT score and breathing) including 
additional behavioural tests for example, mobility, anxiety and learning tests. 
Recent studies have focussed on the treatment of RTT using these Mecp2 knock-
in lines. Several reports show comparisons between the treatment in Mecp2 
knock-in and knock-out mice with several additional behavioural tests 
(table 1-1). 
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Table 1-1. Summary of behavioural tests of published studies in RTT mouse models. 
Tests of mouse behaviour Experimental paradigm References 
Test for mobility and 
motor function 
Open field (Zhou et al., 2017), (Chin et al., 2018), (Vigli et 
al., 2018), (Vogel Ciernia et al., 2017), (Mantis 
et al., 2009), (Matagne et al., 2013) (Matagne et 
al., 2017), (Zhong et al., 2016), (Gadalla et al., 
2013) 
(McGill et al., 2006) 
 Home cage spontaneous 
activity 
(Vigli et al., 2018), (Ross et al., 2016), (Garg et 
al., 2013) 
 Forelimb grip strength (Zhong et al., 2016), (Zhou et al., 2017), 
(Johnson et al., 2016) 
 Balance beam (Ross et al., 2016), (Robinson et al., 2012) 
 Accelerating rotarod (Ross et al., 2016), (Vogel Ciernia et al., 2017), 
(Robinson et al., 2012), (Matagne et al., 2017) 
 Treadmill (Ross et al., 2016), (Gadalla et al., 2013) 
 Grid walking (Zhong et al., 2016), (Johnson et al., 2016) 
Breathing activity Plethysmography (Johnson et al., 2016), (Zhong et al., 2016), 
(Ross et al., 2016) 
(Gadalla et al., 2013), (Robinson et al., 2012), 
(Matagne et al., 2017) 
Test for memory Novel object recognition test (Gogliotti et al., 2016),  
(Schaevitz et al., 2013), (De Filippis et al., 2012) 
(Matagne et al., 2013) 
 Y-maze test (Vigli et al., 2018) 
 Fear conditioning (Gandaglia et al., 2018) 
(Gogliotti et al., 2016), 
Test for anxiety Light-dark exploration (Vogel Ciernia et al., 2017) 
(McGill et al., 2006) 
 Elevated plus-maze (Matagne et al., 2017) (Matagne et al., 2013), 
(McGill et al., 2006) 
 Elevated zero maze (Matagne et al., 2013), (De Filippis et al., 2012) 
Social approach Three-chamber social test (Gogliotti et al., 2016), (Vogel Ciernia et al., 
2017), (Vigli et al., 2018), (Zhou et al., 2017), 
(Zhong et al., 2016) 
 
There are many behavioural paradigms for testing each behavioural phenotype, 
but the most appropriate paradigm for behavioural testing in the RTT mouse has 
not been greatly documented due to its many physical limitations.  It is often 
not possible to use the standard behavioural tests. Therefore, it is necessary to 
study and improve detailed behavioural testing for it to be suitable for 
experimental RTT model animals in standardized research in biomedical 
research. 
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1.6 Reversibility of the RTT phenotype and treatment 
strategies.  
1.6.1 Treatment strategies for RTT 
In the last decade, the preclinical studies on mice including behavioural and 
neurological, which resulted from abnormal development of the brain have been 
potentially reversible across an array of neurodevelopmental disorders models 
(Costa et al., 2002). The Mecp2 knockout phenotype’s reversibility demonstrated 
in mice (Guy et al., 2007) has stimulated various groups to explore therapeutic 
approaches designed to reverse the RTT–like dysfunction or to ameliorate, delay 
or prevent its onset. Two major intervention approaches have been suggested: 
to target the primarily underlying cause (i.e. a loss in MECP2’s function 
mutation) or to target processes further downstream in the pathogenetic 
pathway (Figure 1.4).      
1.6.2 Gene therapy approaches 
For disorders resulting from loss of function mutations, the primary gene therapy 
approach involves gene augmentation. In the case of RTT, this involves 
delivering a construct that contains the WT copy of the coding regions of MECP2 
to the cells affected (i.e. brain neurons predominantly) to restore to those cells 
the functions of the gene, and, in turn, to establish improvement in functions at 
the cellular, molecular network, regional, and whole animal level. The 
challenges to these approaches (Figure 1.5) include finding an appropriate 
method of controlling exogenously derived gene expression and ensure high 
transduction efficiency in appropriate cells while minimizing transduction of 
inappropriate cells. MeCP2 level regulation within transduced cells is an issue 
that is particularly challenging as dosage sensitivity is found with MeCP2 and in 
the brain cells of both mice and humans - MeCP2 overexpression can lead to a 
severe phenotype (del Gaudio et al., 2006). Additionally, in females, gene 
therapy for X-linked dominant disorders must accommodated the fact that 
because of XCI (X chromosome inactivation), around half of the transduced cells 
already express WT MeCP2 at normal levels. 
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Figure 1.4 Therapeutic targets and potential pharmacological strategies 
currently being explored in animal models for the treatment of Rett 
syndrome 
Underlined headings indicate therapeutic targets; compounds that have been 
reported in the literature to be effective in improving behavioural outcome 
measures or physiological function in vivo are shown in italics. Taken from (Katz 
et al., 2016). 
 
 
AAV vectors are an attractive vector of choice for targeting disorders of the 
nervous system (see 1.7 below). The strategies based on AAV for gene therapy 
have been applied for both periphery and CNS (Wagner et al., 1998).  Some of 
these are in an advanced preclinical stage or in phase 1/2 clinical trials, for 
example, for Parkinson’s disease and haemophilia B (Samulski and Muzyczka, 
2014). The construction of AAV vectors with serotype 9 capsid (AAV9) show some 
promise in achieving high efficiency in CNS transduction after systemic 
administration (Foust et al., 2009).  
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Figure 1.5 Summary of current challenges for RTT gene therapy. Intravenous 
(IV) injection of vector is likely to produce high peripheral expression, 
particularly in the liver (1), with potential accompanying toxicity. The BBB (2) 
presents a challenge that prevents many types of vector from accessing the CNS. 
This problem can be overcome by direct CNS injection (3) using an IC route or 
routes that target the cerebrospinal fluid: ICM or IT injection. In the brain it is 
very important to transduce as many neurons as possible (4) to achieve maximal 
therapeutic effect. Among neurons, only neurons expressing the mutant allele 
and thus lacking functional MeCP2 should be targeted, ideally (5). In the 
transduced neurons the level of exogenous MeCP2 expression needs to be 
maintained at physiological levels (6) to avoid overexpression-related toxicity. 
BBB: Blood–brain barrier; IC: Intracranial; ICM: Intra-cisterna magna; IT: 
Intrathecal. This figure was adapted from (Gadalla et al., 2015). 
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1.7 Adeno-associated virus (AAV) as a potential gene 
therapy vector 
 
AAV, a non-enveloped virus 22-25nm in length, is a member of the parvoviridae 
family and requires a helper virus in order to replicate, hence, it is classified as 
a dependovirus (Daya and Berns, 2008). Most humans are seropositive for AAV 
infection; however, in most of the infections are latent in the absence of the 
helper virus, with latency involving site-specific integration into a locus within 
chromosome 19q13.4 (Kotin et al., 1992). Effectiveness of AAV as a vehicle for 
gene therapy is derived from (1) its ability to transduce dividing and non-dividing 
cells; (2) a wide cellular tropism; (3) low immunogenicity; (4) stable transgene 
expression; and (5) absence of disease production in humans (McCarty et al., 
2004). 
 
AAV2 is the most widely studied AAV serotype and, as a result, AAV vectors 
developed to date are based on the AAV2 genome backbone comprised of a 
linear, single stranded DNA of 4.7kb (Srivastava et al., 1983). The genome is 
composed of two inverted terminal repeats (ITRs) which flank two open reading 
frames (ORF) (figure 1-6a). ITRs act as priming sites for the synthesis of the 
complementary strand by DNA polymerase. In addition, they are involved in AAV 
genome packaging, transcription and site-specific integration (Daya and Berns, 
2008). The left ORF houses the Rep (replication) gene that encodes four Rep 
proteins. Rep78 and Rep68 are produced under control of the P5 promoter, act 
as regulatory proteins and are critical for virus replication (Pereira and 
Muzyczka, 1997). Rep52 and Rep40 are produced under control of the P19 
promoter and account for the accumulation of single-strand viral DNA used for 
packing inside capsids. The right ORF contains the Cap gene (figure 1-6a). This 
encodes three capsid proteins (VP1, VP2 and VP3 in 1:1:10 molar ratio) and is 
produced under the P40 promoter (Grieger and Samulski, 2005).  
 
1.7.1 AAV-based vectors and mammalian cell transduction  
Recent AAV based vectors have the Cap and Rep genes replaced by the 
transgene cassette and are flanked by the two ITRs that provide the cis signal 
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vital for packaging and priming for the creation of the second strand (Samulski 
et al., 1982), (Schnepp et al., 2005). Also included in controlling transgene 
expression are other post transcriptional regulators. Additional plasmids 
required for packaging and supply encoding sequences for Rep and Cap genes, 
the adenovirus helper genes (E4, VA and E2A) respectively. 
Either de novo synthesis of the second strand or strand annealing (SA) of 
complementary strands from two infecting viruses contribute to the generation 
of the second strand of DNA (figure 1-7); (Nakai et al., 2001). AAV packages the 
plus or minus DNA strands with equal efficiency (Berns, 1990). However, 
impeding the SA pathway (by packaging the vector solely with either the positive 
or negative strands) did not impact transduction efficiency of ssAAV. This 
indicates that de novo synthesis has a major role in second strand synthesis 
during transduction (Zhong et al, 2008). The rAAV genome requires synthesis of 
the complementary strand inside the nucleus to start gene expression. Failure to 
achieve transgenic expression is generally due to incapacity to generate 
complementary strands and should therefore be considered a rate-limiting step 
in the vector transduction process (Miao et al., 2000). 
1.7.2 Self-complementary AAV 
Viral genome trafficking to the nucleus and second strand generation are the 
most vital steps in the rAAV transduction process (Ferrari et al., 1996). 
Completion of the second strand shows a transitory period of genome instability 
that can compromise gene expression (Wang et al., 2007). Two of these crucial 
steps can be bypassed by packaging AAV with both sense and non-sense strands 
together to form self-complementary AAV (scAAV), enabling the complementary 
strands to produce a dimeric inverted repeat genome (Carter and Rose, 1972). 
scAAV vectors increase transduction efficiency and rapid onset of transgene 
expression compared to ssAAV vectors (McCarty et al., 2001). Low transduction 
in ssAAV can result from of a lack of competency in generating the second 
strand, vital for gene expression. Contrastingly, for scAAV, the formation of the 
second strand is independent of host cell-directed DNA synthesis (McCarty et al., 
2001). Rapid onset and an estimated 15-fold increase in transgene expression is 
also displayed by the scAAV vector when compared to the ssAAV (Ren et al., 
2005). However, the reduction of the cloning capacity to roughly half that of the 
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ssAAV vector limits extensive applications of scAAV in gene therapy. 
Nevertheless, scAAV can still be useful in several applications and its limitation 
can be partially overcome via reduction/optimization of the size of the promoter 
and transcription regulatory elements (Li et al., 2008). The use of AAV capsids 
can also facilitate larger genome size insertion for example, capsid 5 (Grieger 
and Samulski, 2005). 
 
 
 
Figure 1.6 AAV-based vector transduction.  
Representative diagram showing the transduction of AAV-based vector; (1) virus 
binding to heparin sulphate proteoglycan, (2) virus endocytosis to the early 
endosome followed either by (3) maturation to late endosome and degradation 
or (4) escape early endosome and (5) translocation to the nucleus. (6) in the 
case of ssAAV (green circles), the single stranded DNA must be converted to 
double stranded DNA either by de novo synthesis (6a) or strand annealing 
between plus and minus strands (6b) followed by (7) transcription of the 
transgene. Whereas, in the case of scAAV (red circles), once inside the nucleus it 
can bypass the 2nd strand synthesis via intramolecular annealing and start 
transcription faster than the ssAAV vector. HSPG; heparin sulphate proteoglycan, 
ssAAV; single-stranded Adeno-associated virus, scAAV; self-complementary 
Adeno-associated virus. 
 
7  
  6a 6b 
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1.7.3 AAV capsid 
Despite the presence in infected individuals of AAV2 capsid in tissues and cells, 
certain cells show resistance to infection with AAV2 (Gigout et al., 2005). Using 
differing AAV serotypes in a pseudo-typing approach allows for extended tissue 
tropism. Analysing the difference in transduction efficiency and expression levels 
between capsids 1-9 indicated that AAV virus pseudo-typed with capsids 7 and 9 
respectively, presented the highest expression levels, with the most rapid onset 
being that of capsids 1, 6, 7, 8 and 9. Subsequently, capsid 9 showed optimal 
viral genome distribution and the greatest protein levels (Zincarelli et al., 2008). 
Further studies indicate high transduction efficiency of capsids 8 and 9 in liver, 
skeletal muscle and the pancreas post IV injection with high cardiac tropism for 
AAV9 virus (Inagaki et al., 2006). 
 
The BBB challenges gene delivery as it impedes the passing of large drug 
molecules, proteins and viruses. As a result, it is a vital factor in protecting the 
brain from pathogens and toxins. Virus based gene delivery applications are 
prevented from entering the brain. However, gene delivery into the brain in 
animal and human studies has been achieved by direct brain injection to the 
target area via the vector. This approach however presents challenges and can 
require multiple injections to induce the therapeutic effect. To add to this, the 
short-lived disruption of the BBB using hyperosmotic drugs for example, 
mannitol, can permit gene delivery to the brain using small-sized vectors 
(McCarty et al., 2009). Studies of AAV9 have demonstrated its ability to act as a 
potential vector for gene delivery to the brain following a peripheral injection. 
This negates the need to disrupt the BBB (Duque et al., 2009; Foust et al., 
2009). Generating the scAAV9 vector further improved the ability to transduce 
the CNS with a 10-100 times more efficacy than ssAAV9 (Gray et al., 2011b). As a 
result, scAAV9 is the focus in numerous studies to determine transduction 
efficiency and cell type specific tropism following differing means of 
administration. 
 
Foust et al. (2009) indicated that due to the BBB, age-dependent differential 
cell tropism was a factor, while Saunders et al. (2009) disagreed, indicating the 
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BBB is fully functional in neonatal mice. Gray et al. (2011b), however, indicated 
that adult peripheral injection of scAAV9 could produce high neuronal 
transduction, 2X glial transduction. Interestingly, the same study indicated that 
peripheral injection of scAAV9 in non-human primates resulted in limited brain 
transduction and decreased neuronal transduction. However, it is unknown 
whether reduced transduction efficiency in the brain is dose-dependent, if so, 
whether it can be altered by dose modification. 
 
1.7.4 Clinical application and potential in RTT 
Advances in vector/capsid design of adeno-associated virus-based vectors have 
led to an extensive preclinical and phase 1 clinical study to implement these 
vectors in the treatment of human diseases (Warrington and Herzog, 2006). Data 
has shown that AAV vectors produce significant therapeutic effects when 
treating cystic fibrosis (Wagner et al., 1998), (Moss et al., 2004) and haemophilia 
B (Kay et al., 2000); (Manno et al., 2003). Many CNS disorders are being tested 
for potential AAV mediated gene therapy, some of which include amyotrophic 
lateral sclerosis (Azzouz et al., 2000); (Kaspar et al., 2005), spinal muscular 
atrophy (SMA) (Valori et al., 2010), Huntington’s disease (McBride et al., 2003), 
(Kells et al., 2004), lysosomal storage disorders (Sferra et al., 2004), Parkinson’s 
disease (Eslamboli et al., 2005), (Feigin et al., 2007) and Canavan’s disease 
(Klugmann et al., 2005). In the case of RTT therapy, AAV is encouraging as it can 
cross the BBB when pseudo-typed with AAV9 capsid (Foust et al., 2009), can 
infect neurons efficiently, mediate long-term transgene expression (Herzog et 
al., 1997), (Arruda et al., 2005), (Jiang et al., 2006) and does not integrate 
sporadically into host chromosomes (Duan and Kollman, 1998); (Nakai et al., 
2001). Recently, MECP2 gene therapy publications have set the scene for plans 
for clinical trials using AAV9, generating hope for caregivers of RTT patients 
(Coenraads et al., 2017); (Gadalla et al., 2017), (Matagne et al., 2017), (Sinnett 
and Gray, 2017); (Tillotson et al., 2017). 
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1.8 Design of gene therapy approaches 
1.8.1 choice of regulatory elements & vector 
The RTT phenotype is mainly the result of effects on the central nervous 
system’s postmitotic and long lived neurons (Chen et al., 2001); it is clear that  
ex vivo strategies involving cells’ removal from the patient and subsequent 
replacement would not be viable, and thus, in vivo delivery of the therapeutic 
transgene into the brain is required. The current use of vectors for gene therapy 
has generally been based on retroviruses, and lentivirus (Kay et al., 2001) of an 
AAV (adeno-associated virus). Lentiviral vectors can transduce non-dividing cells 
and drive long-term, stable expression in neurons (Scherr et al., 2001). These 
vectors cannot cross the BBB (blood–brain barrier), however, even following the 
disruption with mannitol (McIntyre et al., 2008), and must be delivered by 
injection directly into the brain parenchyma. In addition to this, they show a 
very limited capacity of spreading beyond the injection site (Brooks et al., 
2002). Safety issues are also inevitable around potentially causing insertional 
mutagenesis, although non-integrating versions have been developed 
(Nightingale et al., 2006). The demonstration of potential delivery for the 
lentiviral transgene was carried out by Rastegar and colleagues in improving the 
Mecp2 phenotype – derivation of Mecp2-null neurons from neuronal stem cells in 
culture. Lenti-treated neurons displayed more branching than unaffected 
controls; and dendritic growth (Rastegar et al., 2009). Lentiviral approaches 
have gone towards specific neurological disorders clinical development targets, 
brain nuclei or regions. The ubiquitous nature of MeCP2 expression across the 
nervous system can render lentiviral technologies in RTT insert, unless the aim is 
targeting limited range of specific traits, for example, targeting brainstem 
nuclei to correct problems related to breathing (Julu et al., 2001). 
AAV9 displays promise in relation to RTT gene therapy and has the potential to 
cross the blood-brain barrier, efficiently infecting neurons and mediating 
transgene expression in the long term (Herzog et al., 1997). 
 
For delivery of WT MECP2 in ssAAV9 vectors to neonatal mice by direct brain 
injection, the initial choice of promoter was chicken β-actin, which results in a 
high efficiency of brain transduction (Table 1-2). Transgene expression occurred 
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mostly in neurons and generated MeCP2 levels similar to those seen 
endogenously. Further, the treated mice showed improvement of the RTT-like 
phenotype trajectory in term of the prolonged survival and amelioration of 
severity score and locomotion (Gadalla et al., 2013). 
 
Table 1-2. Summary of experimental design and outcomes of published studies of gene 
therapy interventions in Rett syndrome mouse models. 
 
Route of 
administration 
Age/Sex Virus/promoter Dose/mice 
(vg) 
Transduction  
efficiency 
Result Reference 
Intracranial 
Neonate
/ 
male 
ssAAV9/CBA 9.3 x 109 ∼40% 
 Prolonged 
survival 
 Reduced 
phenotype severity 
 Rescued nuclear 
volume Rescued 
soma size 
 Improved 
locomotion 
(Gadalla et 
al., 2013) 
Intracranial 
Neonate
/ 
male 
scAAV9/ MeP 
(426 bp) 
1 × 1011 ∼40% 
 Improved 
survival 
 Reduced 
phenotype severity 
 Reverse 
neurological 
symptoms 
(Tillotson 
et al., 
2017) 
Intravenous 
Young 
adult/ 
male 
scAAV9/MeP 
(229 bp) 
5 × 1011 
∼2–4% of 
neurons 
 Improved 
survival 
✓ Normalization of 
phenotype 
GABA level 
(Gadalla et 
al., 2013) 
Intravenous 
Adult/ 
male 
scAAV9/ MeP 
(730 bp) 
3 × 1012 ∼25% 
 Prolonged 
survival 
 Reduced 
phenotype severity 
 Rescued soma 
size 
(Garg et 
al., 2013) 
Intravenous 
Adult/ 
female 
scAAV9/ MeP 
(730 bp) 
3 × 1012 N/A 
✓ Stabilization of 
phenotype 
(Garg et 
al., 2013) 
Intravenous 
Adult/ 
male 
scAAV9/ MeP 
(223 bp) 
1 × 1011 ∼10-20% 
 increased body 
weight 
 Delayed 
phenotype severity 
 increased 
tyrosine 
hydroxylase levels 
in the A1C1 and 
A2C2 
 increased Mecp2 
expression found 
in midbrain 
(Matagne et 
al., 2017) 
 
 
In the same study, expression of WT MECP2 delivered systemically in an scAAV9 
vector was driven by a small, 229bp fragment of the endogenous Mecp2 
promoter. The result of this was a lower efficiency of transduction in the brain, 
although it was associated with improvement in survival of male Mecp2 null 
mice. Reports from another study indicate identical findings in male mice and 
stabilization of the phenotype in heterozygous female mice (Garg et al., 2013).  
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For optimal safety and efficacy in the applications of gene therapy, there are 
two primary considerations – the target cell proportion being transduced, and 
the transgene products levels in each transduced cell. In a STOP-Cre mouse 
model of RTT, genetic reversal experiments demonstrated a strong correlation 
between degree of amelioration of the phenotype and the proportion of cells 
that express MeCP2 after reversal.(Guy et al., 2007) However, in AAV9 studies 
(Gadalla et al., 2013), significant amelioration of the phenotype was linked with 
transgene expression in around 25-40% of brain cells.  
However, the transduction efficiencies achieved thus far have not been able to 
completely rescue the RTT-like phenotype to the level of wild type, requiring 
higher efficiency of transduction. Where levels of MeCP2 are concerned, there is 
significant evidence suggesting that a reduced level of functional MeCP2 would 
lead to RTT-like phenotypes, whereas overexpression of MeCP2 or Mecp2 
duplication would result in other neurological effects (Collins et al., 2004). The 
level of transgenic protein is likely to be influenced mainly by the promoter used 
in the construct. In an early study comparing two promoters, the endogenous 
core promoter of murine Mecp2 and the well-characterised chicken β-actin 
promoter (Gray et al., 2011a), results showed that both promoters can drive 
exogenous MeCP2 expression at approximately physiological levels.  
 
 
1.8.2 Optimal time for gene therapy interventions  
RTT is considered to result from a lack of neuronal maturation and MeCP2 
playing a key role in both maintenance and neuronal development processes. 
Early restoration of Mecp2 expression found in pre-symptomatic mice led to 
apparently normal development (Guy et al., 2007). Delayed re-activation of 
Mecp2 in symptomatic mice can normalize lifespan and phenotypic recovery 
(Guy et al., 2007). In another study, brain-specific expression of Mecp2 early in 
life showed neuronal size normalization, motor activity improvement, 
development of delayed phenotype, and prolonged lifespan.  These are reduced 
typically in the Mecp2-null mouse (Chen et al., 2001).  From the literature 
related to the preclinical gene therapy published to date, MECP2 delivery either 
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in adult mice or in mouse neonates can produce phenotype and survival benefits. 
This indicates that across a wide array of ages, therapeutic interventions can be 
effective.  
However, there is no clarity yet as to whether there is a critical time window 
during which Mecp2 delivery will be producing improvements which are more 
robust, as systematic testing has not yet been conducted. This may be of direct 
relevance to clinical considerations as improvements in early diagnostic testing 
are made. The appearance of the RTT phenotype several months postnatally 
(generally eight to eighteen months) could present a window that is particularly 
effective for intervention prior to the onset of overt RTT features if diagnosis of 
early pre-symptomatic molecular in nature were to become cost effective and 
practical. During infancy, such early treatment would also dramatically reduce 
the viral vector amount required (if peripherally required) for treatment. 
However, the extent of phenotypic amelioration after treating adult mice would 
predict that administration carried out later to older adults or girls with RTT 
Syndrome would also be effective (Guy et al., 2007). Irrespective of the 
intervention time, an important requirement is that there should be longevity of 
transgene expression as Mecp2 deletion from neurons that are mature is 
deleterious (McGraw et al., 2011). There have been several reports of AAV-
mediated transgenes that persist for long periods that includes reports 
pertaining to continued expression of greater than six years following delivery in 
primates and following greater than eight years in dogs (Stieger et al., 2009). 
Further, a gene therapy clinical trial conducted recently has shown gene 
expression persistently for at least 10 years following gene delivery of AAV 
mediated in the human brain (Leone et al., 2012). 
1.8.3 Local or global MECP2 delivery 
RTT modelling in mice has played a pivotal role in studying the requirement for 
MeCP2 in different areas of the brain, in different types of cells in brain (Chao et 
al., 2010) and at various development stages, in addition to testing the 
reversibility of RTT-like phenotypes (Guy et al., 2007). The brain is the most 
important contributor to RTT pathology as brain-specific Mecp2 knockout leads 
to development of the RTT-like phenotype, while peripheral knockout leads to a 
phenotype very similar to wild-type in almost all respects (Ross et al., 2016). It 
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could be the case that the effect of a lack of MeCP2 in the peripheral tissue is 
masked by the profound phenotype related to its lack in the CNS.  Clinical and 
mouse model data, however, do suggest that several aspects of the KO 
phenotype, particularly affecting lung, liver and bone, may originate in 
peripheral effects (De Felice et al., 2014; Ross et al., 2016). 
 
Direct delivery of exogenous MECP2 to the brain using ssAAV9 (Gadalla et al., 
2013) emphasizes the brain’s crucial role in ameliorating most of the 
phenotype’s gross aspects. Failure in correcting certain features resembling RTT, 
such as abnormalities in breathing, may reflect cells’ insufficient transduction in 
areas of the brain pertaining to those phenotypes or lacking expression in the 
peripheral tissues which may contribute to the given phenotype. Independent 
studies suggest that systemic delivery of MECP2 vectors (Table 1.2) using scAAV9 
confers extended survival despite low numbers of transduced cells in the brain. 
The first report shows the transduced neurons at around 2-4% with peripheral 
tissues taking up majority of the virus particles, especially the liver. In another 
study, the dose was increased six-fold (Garg et al., 2013), leading to brain 
transduction being increased and greater phenotypic improvement in null male 
mice and stabilization of the phenotype in female heterozygous mice. These 
studies show how important it is to achieve an appropriate therapeutic dose. A 
high viral titer is essential for getting good coverage. Detection of transduction, 
on the other hand, may depend on vector construct overexpression, which is 
undesirable.  
 
The restoration of MeCP2 in the brain is described as achieving improvement of 
the RTT-like phenotype. Two methods can be used in delivering therapeutic 
constructs into the CNS: systemic delivery (for example, intravenous injection) 
which results in passing through the blood brain barrier and direct delivery 
routes into the CNS. Both approaches are approved for clinical trials using AAV in 
other neurological disorders. The reactivation experiments of Mecp2 
demonstrate a strong correlation between the magnitude of phenotypic rescue 
and the proportion of brain cells that express MeCP2 (Robinson et al., 2012). 
Systemic administration of vector, while more desirable from the standpoint of 
clinical translation, results in limited transduction of cells in the CNS and 
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restricts the vector choice options to those which can cross the BBB (Yang et al., 
2014; Zhang et al., 2011). 
 
Further, attempting to increase the dose in order to achieve higher expression in 
the CNS will have an accompanying increase in expression level in peripheral 
tissues, especially in the liver (Figure 1.5). As several peripheral tissues usually 
express low MeCP2 levels relative to neurons, this could lead to toxicity (Gadalla 
et al., 2013). Modification of vector constructs to de-target the liver, minimizing 
off target effects and enhancing CNS expression, may be critical if systemic 
delivery is to be feasible.  
 
The level of exogenous MECP2 varies according to the promotor used; a weak 
promotor produced near physiological levels of exogenous MeCP2 (80% of the WT 
levels) whereas a stronger promotor, such as PGK promotor (Owens et al., 2002) 
produced relatively high cellular levels (200% of the WT levels). This is 
particularly important when considering the danger of MeCP2 overexpression-
induced toxicity in humans as patients with MECP2 duplication show overt 
neurological deficit (Meins et al., 2005), (Friez et al., 2006). In addition, the 
Mecp2 overexpression model shows the phenotype severity increasing as MeCP2 
increased beyond normal levels (Chao and Zoghbi, 2012) with the worst 
phenotype observed with 2-3 fold increase of MeCP2 levels (Luikenhuis et al., 
2004).  
 
Previous studies using a self-complementary AAV9/MeP229-hMECP2-myc-BGHpA 
vector (first generation vector), extended the survival of Mecp2y/- male mice 
when injected intravenously (IV) between post-natal day 28 and 2nd at day 35 
(Gadalla et al., 2013). This IV gene therapy resulted in high transgene expression 
in the liver as well as significantly increased levels of alanine aminotransferase 
(ALT), an indicator of liver toxicity. (Gadalla et al., 2013). After IV treatment 
with 1 x 1011 viral genomes (vg) of the first generation vector, the level of total 
MeCP2 expression (measured by PCR technique) in WT liver, was around six 
times that observed within the brain (Gadalla et al., 2013). This liver tropism 
and hepatic transgene expression observed after IV treatment can be attributed 
to the AAV capsid (Gray et al., 2013) and the use of a small endogenous Mecp2 
promoter fragment (MeP229), (Gadalla et al., 2013), (Gray et al., 2011b) 
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respectively. In conclusion, the first generation presents possible efficiency, 
however, vector design and administration route would need to be optimized 
before being used in humans. Increasing severity of hindlimb clasping and 
abnormal gait were unexpected side effects in previous publications of MeCP2 
gene transfer studies. (Garg et al., 2013; Matagne et al., 2017) 
To consider the availability of current vector technology, achieving high 
efficiency of transduction in the brain following systemic administration is 
challenging. Therefore, direct CNS delivery is necessary in achieving CNS 
transduction as appropriate. The widespread action of MeCP2 throughout the 
nervous system indicates that strategies of gene augmentation should be 
targeting the whole brain rather than selectively targeting crucial regions of the 
brain. To achieve widespread coverage of the brain, while avoiding 
overexpression within the brain has been a challenge and requires appropriate 
regulatory/promoter elements development in gaining a level of control over 
levels of overexpression. 
  
1.8.3 To target specific types of cells in the brain: astrocytes or 
neurons? 
MeCP2 expression has been recognized in numerous tissues (LaSalle et al., 2001), 
but is particularly plentiful in postmitotic neurons. The disorder’s key 
neurological manifestations are indicative of a more severe effect on the 
neurons compared to other cell types. However, recognition is increasing 
regarding glial cells’ possible role in phenotype development and its recovery 
(Lioy et al., 2011). 
 
It has been found that mice only lacking MeCP2 in neurons have shown overt 
RTT-like symptoms, while mice which express MeCP2 in neurons have shown an 
apparent normal phenotype (Luikenhuis et al., 2004). This bulk of observable 
knockout phenotypes come from a loss of function by Mecp2 in neurons (Ross et 
al., 2016). The improvements which are phenotypic after delivery mediated by 
AAV9 of MECP2 in young adult mice and neonatal, has mainly been due to its 
expression in neurons (Gadalla et al., 2013). 
 
Further complications arise with many reports showing greater importance of 
MeCP2 expression in some neuronal subpopulations. For instance, if Mecp2 is 
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specifically silenced in inhibitory GABAergic cells, a subtle range of 
neuropsychiatric phenotypes that are RTT-like are revealed which include 
repetitive, autistic-like behaviours. Another study shows the silencing of Mecp2 
in neurons containing tyrosine hydroxylase. It was found that mice display 
breathing problems and motor abnormalities which include an increase in the 
incidences of apnoeas which suggest that dysfunction of aminergic systems may 
be responsible for breathing phenotypes in RTT (Samaco et al., 2009). 
Interestingly, preservation of MeCP2 expression in some subtypes of neuron in 
genetically engineered mice was associated with reduced phenotype severity 
and extended survival (Goffin et al., 2014). Direct delivery of the gene to cells 
with the use of cell type-specific promoters is an alternative option in treating 
specific aspects of the RTT phenotype at the gene level.  
1.8.4 Other gene-targeted strategies in RTT  
Considering the challenges of gene therapy in RTT – the need to regulate and 
maintain the levels of MeCP2 expression in a physiological manner – provisional 
need by an ideal therapy of MeCP2 derived exogenously could be avoided, 
although it can result in endogenous WT MeCP2 expression under its regulatory 
control which are normal and endogenous. One viable approach when the cause 
of RTT is a nonsense mutation in the final exon is translational read-through 
delivered via pharmacotherapy. 
 
In this approach, mRNA produced from the mutant allele undergoes translation 
under conditions where the premature stop codon is skipped. Therefore, it 
produces a protein that is WT at all residues except that translated from the 
mutant codon itself. Early truncating mutations account for around 40% of 
typical RTT patients. This can be treated with the use of gentamycin and the 
compounds related to it, inducing ribosomal read-through of premature stop 
codons (Manuvakhova et al., 2000).  
 
In vitro experiments have demonstrated the production of full-length MeCP2, 
produced in cell lines that harbour various nonsense mutations following 
gentamycin treatment, although with a rather lower level of process efficiency, 
which ranges between 17-32% depending on the effective concentration of 
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gentamycin and the identity of the mutation (Brendel et al., 2009). This low 
efficiency of production of full-length MeCP2 after aminoglycoside treatment, 
along with the well-known aminoglycoside toxicity (ototoxicity and 
nephrotoxicity) suggests that this approach may not be ideally translational. In 
the search for translationally beneficial approaches, other compounds with 
improved safety profiles are instead being tested. New generation 
aminoglycosides, such as NB84, NB54 and PTC12, are being trialled; these have 
lower toxicity and greater efficacy compared to gentamycin (Welch et al., 
2007). Not much is known about these compounds ability to cross the BBB and 
therefore, their likeliness and efficiency to treat CNS disorders including RTT 
remains unknown.  
 
Another approach consists of reactivating the previously inactive MECP2 gene on 
the X chromosome. XCI is a random process resulting in around 50:50 cell 
mixture of each type (mutant and normal), albeit there is variation of the XCI 
ratio between individuals and tissues. In the process of brain development, 
mutant and normal cells are closely intermingled in a mosaic pattern of a fine 
scale with some clustering tendency (Guy et al., 2007). 
 
The therapeutic strategy, which involves reactivation of the inactive X, may 
need to target only mutant cells depending on whether biallelic expression 
results in dominant negative effects of the mutant allele or not. A recent 
publication suggests that there is no occurrence of such effects, at least for 
some mutations (Pitcher et al., 2015).  
 
Activation of X-linked genes is possible by reducing the levels of genomic 
methylation by using 5-azacytidine - this has been tried in cell culture (Mohandas 
et al., 1981). However, this type of approach is a blunt instrument and has a low 
chance of being of therapeutic utility. A study conducted recently used small 
molecules to inhibit X-chromosome inactivation factors. Expression of MeCP2 
from the inactive X in cultured fibroblasts from RTT patients was demonstrated 
(Bhatnagar et al., 2014). Pharmacological activation of the inactive X is 
reversible ,and thus reactivation needs the continued presence of the drug.  
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For inactive X reactivation to work effectively as RTT’s therapeutic strategy, 
many key hurdles must be surmounted. Firstly, in cells currently expressing the 
normal allele, the silent X’s reactivation will lead to potentially detrimental 
effects of the mutant allele. However, recent evidence suggests that the 
disruptive interactions are unlikely between mutant domains and wild type of 
MeCP2 and when in the same cells, they are co-expressed.  
 
Secondly, the safety and the properties of CNS bioavailability of the potentially 
small molecule activators of the X-chromosomes would need to be within 
acceptable limits. Thirdly, the dependency of expression and efficacy on dose 
and on prior proportion of cells already expressing the normal MeCP2 allele are 
presently unknown and would require assessment in detail.   
 
Finally, a major potential problem with this approach is that it involves 
reactivation of the entire inactive X, with the additional potential for problems 
arising from gene dosage inbalances and pathological overexpression of many 
genes on the X (which X-inactivation evolved to combat). However, female mice 
that lack STC1, a primary X-inactivation factor, results in expression of genes 
from both X chromosomes and is associated with normal phenotype, so there 
may be previously unknown compensatory mechanisms (Bhatnagar et al., 2014). 
There is no knowledge so far as to whether similar compensatory mechanisms 
operate in humans. However, as the reactivation process of X-chromosome that 
is pharmacologically-induced is reversible, there are safety benefits with other 
interventions that are based on the gene.  
 
The discussed possible solutions so far are associated with the challenge that the 
mutant allele’s continuous presence in cells poses. The most attractive 
conceptually, but potentially challenging technically, is an approach that is 
gene-based which, at the genomic level would be to edit the mutation and turn 
it into a WT allele. The WT allele would perform, and the cell would function 
normally for the remainder of its life.  
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1.9 Summary and aim 
Rett syndrome (RTT) is an uncommon neurodevelopmental disorder which occurs 
mainly in girls and is characterised by neurological, motor and social disabilities. 
MECP2 gene mutations are responsible for > 95% of typical RTT cases. Mouse 
models of RTT have been helpful tools to assess RTT at the molecular and 
cellular levels and help to estimate the efficacy of possible therapeutic 
interventions. A previous study demonstrated the reversibility of the phenotype 
in mouse models after reactivation of endogenous Mecp2, which provides 
evidence that it may be possible to treat and or prevent RTT in patients. 
Behavioural testing in RTT mouse models has mostly focussed on the overt RTT-
like phenotype while specific in-depth behavioural tests in RTT mouse models 
are relatively still lacking. A curative treatment for RTT has not yet been 
achieved, while the exact function of MeCP2 protein and its downstream effects 
are not clear. Therapeutic intervention at the Mecp2 gene level either by 
reactivation of the inactive X chromosome, which contains a normal Mecp2 
allele or by viral-mediated delivery of exogenous copy of normal Mecp2 offer 
attractive possible strategies. There are some studies that suggest AAV9-based 
delivery systems have potential for delivery of transgenes to the CNS and suggest 
a possible application for these vectors in exogenous delivery as a first step to 
developing gene therapy strategies in RTT models.  
 
The main aim of this thesis was to investigate the effectiveness of gene therapy 
in mice modelling Rett syndrome by investigating AAV9-mediated delivery of 
MECP2 in genetic mouse models of RTT. Specific goals were as follows: 
 
1. To establish a battery of behavioural tests for mouse models of RTT 
encompassing cognition and memory, social activity, anxiety, and motor 
function specific in RTT mouse models. 
2. To investigate dose escalation of scAAV/MECP2 by systemic delivery in 
knock-in and knockout Mecp2 mouse models. To further examine the 
transduction efficiency, pattern and levels of transgenic Mecp2 expression 
and to ascertain the phenotypic consequences that result. 
3. To explore the potential for overexpression-related toxicity and 
identify the tolerated threshold of MeCP2 overexpression. 
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4. To develop and test second-generation scAAV/MECP2 vectors that 
reduce the toxicity and target neurons in the brain more efficiently than 
the first generation vectors. 
5 To identify the best vector to use in long-term studies in female 
Mecp2+/- mice.  
 
The overall objective of my thesis research was thus to take the next step 
in developing a gene therapy-based approach in Rett syndrome. 
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Chapter 2   Material and Methods 
2.1 General molecular biology materials 
 
Table 2-1 General molecular biology reagents 
Reagents Supplier 
DNAreleasyTM Anachem Ltd 
Nuclease Free Water Qiagen Cat.no 129115 
Maxima Hot Start Green PCR Master 
mix (2X) Water 
Thermo Scientific Part No. K1062 
1kb DNA ladder NEB  Cat.no N3232 
Rabbit anti-Myc  Abcam Cat.no ab9106 
Mouse monoclonal anti-MeCP2  Sigma Cat.no WH0004204M1 
Chicken anti-GFP  Abcam, Cat.no ab13970 
Alexa Fluor 488 goat anti-mouse/rabbit 
(1/500) 
Invitrogen Cat.no A-11029, A-11008 
Alexa Fluor 546 goat anti-mouse/rabbit 
(Invitrogen; 1/500) 
Invitrogen Cat.no A-11003, A-11010 
Alexa Fluor 647, goat anti-mouse  Jackson ImmunoResearch Laboratories 
Cat.no 112-495-003JIR 
DAPI nuclear stain (1/1,000) Sigma Cat.no D9542 
 
Table 2-2 Primer sequences and sizes of amplified PCR products for Mecp2+/- 
and Mecp2+/T158M genotyping 
Primer name Nucleotide Sequence 5’-3’ Supplier 
New P5  TGGTAAAGACCCATGTGACCCAAG IDT 
P7 WT REV GGCTTGCCACATGACAAGAC IDT 
New P6 KO REV TCCACCTAGCCTGCCTGTACTTTG IDT 
Ex4 Fwd A GTTAGCTGACTTTACATAG IDT 
GFP Fwd 3A GGACGAGCTGTACAAGTAA IDT 
Me2 UTR1 CGGGAAGCTTTGTCAGAGC IDT 
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Table 2.3 List of AAV vectors 
All the vectors listed below are viral vectors based on an AAV2 backbone. The 
encoded product of the vectors is human MeCP2_e1 protein. The vectors were 
manufactured and supplied by Dr Steven Gray, University of North Carolina 
(UNC), USA. 
 
Name Capsid  Promoter  Coding seq. Tag  pA Reference  
1st generation AAV9 MeP 229 hMECP2_e1 Myc  bGH (Gadalla et 
al., 2013; 
Gray et al., 
2011a) 
Jet promoter AAV9 Jet  hMECP2_e1 Myc  bGH (Tornøe et 
al., 2002) 
Short 
synthetic 
polyA 
AAV9 MeP 229 hMECP2_e1 Myc  Short 
polyA 
(Levitt et 
al., 1989) 
Liver de-
targeted 
AAV9.47 MeP 229 hMECP2_e1 Myc  bGH (Karumuthil-
Melethil et 
al., 2016; 
Pulicherla et 
al., 2011) 
426 promoter-
RDH 
AAV9 MeP 426 hMECP2_e1 Myc  Micro 
RNA 
binding 
(Gadalla et 
al., 2017; 
Sinnett and 
Gray, 2017) 
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2.2 General solutions 
Table 2.4 – General molecular biology solutions 
Solution Composition 
5x DNA loading dye SDS 0.5% (w/v), Xylene cyanol 0.25% 
(w/v), Bromophenol blue 0.25% (w/v) 
and 
FicollR 400 1.5% (w/v) in 3x TBE. 
Ethidium Bromide Stock solution: 10 mg/ml in H2O 
(Sigma, E-1510) 
0.5x TBE buffer 1. 108 g Tris base, 55 g Boric acid, and 40 
ml 0.5 M EDTA pH 8.0. then add H2O to 
2 L. 
Place the flask on a magnetic stirrer 
until completely dissolved 
0.2 M Phosphate buffer (PB) 8.740 g of Sodium dihydrogen 
Phosphate (NaH2PO4) in 1000 ml H2O 
Add 20.442 g of diSodium Hydrogen 
Phosphate (Na2HPO4) and mix well.  
Adjust pH to 7.4 with 1N NaOH 
50% Ethanol  500 ml of 100% ethanol, 500 ml of 
distilled water 
0.1 M PB Made from a dilution of 0.2 M PB 
0.3M Phosphate Buffered Saline Triton 
X-100 (PBST) 
17.532 g of Sodium Chloride, 0.2M 
Phosphate Buffer 100 ml, 3ml of Triton 
X-100 and mix well. 
10mM Sodium Citrate pH6.0 2.941 g of Trisodium Citrate, Adjust pH 
to 6.0 with 1N HCL 
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2.3 Mouse models of RTT 
The Rett syndrome mouse models used in this research were Mecp2 null (KO), 
which does not produce MeCP2 protein (Guy et al., 2001), and a knock-in model, 
Mecp2T158M (T158M mice), which produces mutant MeCP2 carrying the p.T158M 
substitution (Brown et al., 2016). Both sexes were investigated.  
In terms of KO line, these comprised of male WT (Mecp2+/y), female WT 
(Mecp2+/+) male hemizygous KO (Mecp2-/y) and female heterozygous (Mecp2+/-) 
mice. The generation of mutant mice in this line involved the cre-lox mediated 
excision of exon 3 (Guy et al., 2001). Hemizygous male KO mice develop a 
severe phenotype from about 4-6 weeks after birth. The body of this line also 
less than the WT at the same age (around 8-11 g at five weeks). Therefore, they 
need more taken care after the phenotypes start (around five-week of age). KO 
mouse model is suitable for short-term screening studies to enable the rapid 
assessment of the effects of putative therapeutic interventions on RTT-like 
phenotypes. In contrast to the hemizygous male mice, heterozygous female KO 
mice display RTT-like phenotypes with a later onset and more gradual 
progression. (Garg et al., 2013) The phenotype in female KO mice is milder and 
slow progress when compared with male KO mice, however, obviously opposite 
from the male is the bodyweight. The mostly of KO female mouse has 
overweight (>30 g at 8 weeks) when compared with the WT female (around 25 
g). These KO female mice are a more accurate genetic model of RTT in females, 
most assessments have been conducted in male KO mice.  
There are a number of common mutations causing Rett syndrome including 
missense mutations (p.R106W, p.R133C, p.T158M, and p.R306C) and nonsense 
mutations p.R168X, p.R255X, p.R270X, and p.R294X (Neul et al., 2008). In 
addition to using the Mecp2-KO line, experiments were also conducted using a 
Mecp2T158M knock-in (KI) mouse, which models the most common mutation in 
RTT patients (Neul et al., 2008). This generates defective MeCP2 protein, 
harbouring the substitution of methionine for threonine at amino acid position 
158 (T158M) in exon 4, which affects the DNA binding domain (MBD). This allele 
has GFP fused downstream of the mutant MeCP2 protein. The T158M hemizygous 
male mice show early-onset and severe RTT phenotypes as same as the KO male 
line, but the phenotype and the bodyweight is less severity than KO males (more 
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than 11 g at five weeks) (Brown et al., 2016). However, the close husbandry also 
is needed in this line. The heterozygous female T158M mice show the progression 
of the RTT-like phenotypes and overweight after 6-8 months as same as in the 
female KO mice (Brown et al., 2016). 
2.3.1 source of the Mecp2-KO mouse and Mecp2 T158M knock-in 
models  
Both the Mecp2 knock-out and the Mecp2-T158M knock-in mouse lines were 
created and supplied by Professor Adrian Bird’s laboratory at the University of 
Edinburgh, UK.  
2.3.2 Breeding strategy of Mecp2-KO and Mecp2 T158M knock-in 
mice 
At the University of Glasgow, the local Mecp2-KO line of was established and 
maintained by mating heterozygous female with WT males (C57BL/6 background) 
purchased from Harlan laboratories (Shardlow, UK). A similar strategy was 
adopted for the knock-in line by mating Mecp2+/T158M (C57BL/6 background) and 
WT males (C57BL/6). Mice were backcrossed onto a C57BL/6 background (>8 
generations) and maintained on an inbred C57BL/6 background. The mice 
generated for experimental cohorts consisted of hemizygous Mecp2-/y or 
Mecp2T158M/y males and heterozygous Mecp2+/- or Mecp2+/T158M females together 
with their WT littermates as controls. Genders and genotypes of offspring from 
the Mecp2+/- or Mecp2+/T158M females mating with WT males are provided in table 
2-5.  
Table 2-5 Breeding scheme for Mecp2-KO and Mecp2 T158M knock-in mice  
lines KO T158M 
Parents Male WT Mecp2+/y 
+ 
Female Mecp2+/- 
Male WT Mecp2+/y 
+ 
Female Mecp2+/T158M 
Offspring (1) Male WT Mecp2+/y 
(2) Male Hemizygous Mecp2-/y 
(3) Female WT Mecp2+/+ 
(4) Female Heterozygous 
Mecp2+/- 
(1) Male WT Mecp2+/y 
(2) Male Hemizygous Mecp2 T158M /y 
(3) Female WT Mecp2+/+ 
(4) Female Heterozygous 
Mecp2+/T158M 
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2.3.3 Ethic and husbandry 
All work was conducted in accordance with the standards of the European 
Communities Council Directive (86/609/EEC) and under the authority of a 
project license under the UK Animals (Scientific Procedures) Act (1986). Mice 
were bred and housed at the University of Glasgow Biological Services main 
campus facilities. After weaning, all experimental mice of the same sex and 
parentage were caged together as litter mates (2-5 mice per cage). Bedding was 
changed twice a week. The mice were maintained on a 12-hour dark/light cycle 
and at 25 degree Celsius with free access to distilled water and standard rodent 
diet. 
In some cases, symptomatic mice were provided with a supplement of soft diet 
(moistened rodent pellet) and baby food (Carnation®) if required. 
2.3.4 Genotyping  
2.3.3.1 DNA extraction and PCR genotyping 
Ear punches were used to identify individual mice at weaning (3 weeks) and 
resultant ear punch biopsies were used for genotyping. 
To extract DNA, each ear sample was placed into 20μl of DNA releasy (Anachem 
Ltd) for 5 minutes at 75°C in the PCR machine and then the temperature setting 
increased to 96°C for 2 minutes. Then hold this sample at 20°C. 
PCR amplification for genotyping was carried in out in a GeneAmp thermal cycler 
(Applied Biosystems, UK; PCR system 9700) using reaction mixes and conditions 
given in Tables 2-6 and 2.7. For the KO line, primers P7 and P5 were employed 
to amplify the WT allele while primers-P6 and P5 were used to amplify the KO 
Mecp2 allele. For the T158M line, primers Ex4 Fwd A and Me2 UTR1 were used to 
amplify the WT allele and primers GFP Fwd 3A and Me2 UTR1 were used for the 
Mecp2 T158M allele. For the KO line, the PCR products produced by the P5/P7 
primers (WT allele) are 416bp, and PCR products of the P5/P6 primer set 
(Mecp2-KO allele) are 470bp. For the Mecp2T158M line the PCR products are 
107bp for the GFP Fwd 3A/ Me2 UTR1 primer set (WT allele), and 300bp for the 
Ex4 Fwd A / Me2 UTR1 primer set (Mecp2-T158M allele). 
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Table 2-6 PCR reaction setup for genotyping of Mecp2-null mice, 
Mecp2T158M mice and their WT littermates 
Lines KO T158M 
i.  Extracting DNA 1 µl 1 µl 
ii. Maxima Hot Start 
Green Master mix 
13µl 13µl 
iii. Nuclease Free 
Water 
8µl 8µl 
iv. Forward Primer 
P5 1µl (0.4µM) 
Ex4 Fwd A (0.4µM) for WT 
GFP Fwd 3A (0.4µM) for T158M 
v. Reverse Primer - P7 1µl (0.4µM) for WT 
Me2 UTR1 (0.4µM)  
- P6 1µl (0.4µM) for KO 
Final Volume 24 µl 24 µl 
Final Product (base pair) WT allele: 416bp 
Mecp2-KO allele: 470bp 
WT allele: 107bp 
Mecp2-T158M allele: 300bp 
 
Table 2-7 Thermocycling conditions for genotyping  
Step Temperature (°C) Time (seconds) 
1) Initial Denaturation 95 240 (4 minutes) 
2) Denaturation 95 30 
3) Annealing 61 30 
4) Extension 72 45 
Repeat steps 2) to 4) 35 cycles 
5) Final extension 72 600 (10 minutes) 
6) Hold 4 ∞ 
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2.3.3.2 Agarose gel electrophoresis 
DNA molecules were separated by 1-2% agarose gel electrophoresis in 0.5 TBE. 
Agarose was dissolved by boiling and subsequent cooling down (~40°C). A final 
concentration of 200 ng/ml of ethidium bromide was added. Gels were then 
poured in a gel tray and allowed to set at room temperature for one hour. 
After PCR, products were loaded with 5X DNA loading dye and electrophoresed 
for one hour at 100-120 volts. An aliquot of a 100bp DNA ladder (1.5-2 μg) was 
also electrophoresed and used as a marker. Gels were imaged using a UV 
transilluminator (UV-TM-40; Upland, USA; wavelength 254nm) and photographed 
using a Canon digital camera (PC1192; Japan). 
2.3.5 Allocating animals to experimental groups and blinding 
system 
After genotyping each mouse, numbers of WT and mutant mice in each cage of 
littermates were balanced by humanely euthanizing excess WT mice at random. 
All the experimental mice used in the behavioural tests were identified uniquely 
(within each cage) via ear notches and given a new ID code by Biological Services 
staff, while any birth IDs were not visible thereafter. Experimenters were thus as 
blind to the genotype of each mouse in a cage of littermates as it was possible 
to be (mutant mice are often smaller and affected in somewhat obvious ways, 
but efforts were made to ignore any such signs). Original and new IDs for each 
mouse were sent by Biological Services staff to my supervisor, and unblinding for 
genotype was only carried out after all major data polishing steps had been 
completed and just before analyses. 
For the gene therapy experiments, the blinding system were applied after the 
viral delivery in young adult mice. The experimenters did not know genotype 
and the treatment at the time of weekly weight and score the mice (moreover, 
for neonatal delivery, mice were sexed but genotype was unknown; unique ID 
codes were assigned at weaning and experimenters kept blind to genotype). 
When they died or an experimental end-point was reached, and tissues were 
collected and data processed before unblinding.  
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2.3.6 Phenotypic severity scoring and weight measurement 
All the experimental mice (and stock mutant mice) underwent weekly 
observational phenotyping from weaning (postnatal day 33-35) onwards using an 
established scoring system for mice modelling Rett syndrome (Guy et al., 2007). 
There are six cardinal features that are recorded as RTT-like phenotypes and 
which can be used to monitor the disease trajectory in a semi-quantitative 
manner. These features are: breathing abnormality, bodily tremors, hind limb 
clasping, gait, mobility and general appearance. Each of these traits scores 2 for 
severe phenotype, 1 for mild phenotype and 0 for phenotype indistinguishable 
from WT Table 2-8. An aggregate severity score can be created from the total 
score of the above features which varies from 0-12. The breathing and tremors 
are observed whilst the mouse is standing still. Hind limb clasping is tested by 
suspending the mouse by the base of the tail with its forelimbs on a hard 
surface. (Gadalla et al., 2013; Garg et al., 2013; Guy et al., 2007; Robinson et 
al., 2012). Scoring was conducted blind to genotype. The score was also used to 
trigger humane endpoints, with animals culled due to severe breathing 
problems, severe overall condition or if the mice showed a 20% loss in 
bodyweight relative to peak bodyweight. At these end points, the mouse was 
euthanized humanely.  
2.4 Behavioural tests 
All scoring and behavioural tests were conducted, where possible, at the same 
time of day (range 10:00-16:00). All behavioural tests were conducted in the 
same dedicated procedure room. Multiple tests were conducted on individual 
mice; however, the mice were given one day of rest between each test. To 
eliminate potential residual odours and potential contaminants, 70 % ethanol 
was used to clean the apparatus. 
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Table 2-8 phenotyping score 
Test Location Phenotype 
Score 
0 +1 +2 
On hand 
  
Tremor: Mouse 
observed while 
standing on the 
flat palm of 
the hand. 
no tremor intermittent 
mild tremor 
continuous 
tremor or 
intermittent 
violent 
tremor 
 
Breathing: 
Movement of 
flanks observed 
while mouse is 
standing still. 
normal 
breathing 
periods of 
regular 
breathing 
interspersed 
with short 
periods of 
more rapid 
breathing or 
with pauses in 
breathing 
very irregular 
breathing - 
gasping or 
panting 
General 
condition: 
Mouse 
observed for 
indicators of 
general well-
being such as 
coat condition, 
eyes, body 
stance. 
clean, shiny 
coat, clear 
eyes, normal 
stance 
eyes dull, 
coat 
dull/ungroom
ed, somewhat 
hunched 
stance 
eyes crusted 
or narrowed, 
piloerection, 
hunched 
posture 
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On table 
 
Hindlimb 
clasping 
legs splayed 
outwards 
hindlimbs are 
drawn 
towards each 
other (without 
touching) or 
one leg is 
drawn in to 
the body 
both legs are 
pulled in 
tightly, 
either 
touching 
each other or 
touching the 
body 
 
In arena 
 
Mobility as wild-type reduced 
movement 
when 
compared to 
wild-type: 
extended 
freezing 
period when 
first placed on 
bench and 
longer periods 
spent 
immobile 
no 
spontaneous 
movement 
when placed 
on the 
bench; mouse 
can move in 
response to a 
gentle prod 
or a food 
pellet placed 
nearby 
Gait 
abnormality 
as wild-type hind legs are 
spread wider 
than wild-type 
when walking 
or running 
with reduced 
pelvic 
elevation, 
resulting in a 
“waddling” 
gait 
more severe 
abnormalities
: tremor 
when feet 
are lifted, 
walks 
backwards or 
'bunny hops' 
by lifting 
both rear 
feet at once 
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2.4.1 Open field test 
The open field test is an established measure of anxiety and motor function 
(Brielmaier et al., 2012; Choleris et al., 2001). The arena is an infra-red 
transparent Perspex box (40x40cm), where the mice were placed in the centre 
(in low but even light level) and recorded for 15 minutes while exploring the 
arena. During the test, the experimenter could not be seen by the mice. The 
activity of the mouse in the arena was continually monitored using an overhead 
digital infrared camera and tracked using Ethovision XT tracking software 
(Noldus, USA). The digital tracks produced by the mouse were subjected to off-
line analysis using the software. The distance moved by each mouse over 15 
mins was calculated. 
 
Figure 2.1 the open field arena which is recorded by IR camera. The arena is 
a square sized 40 cm x 40 cm and made from IR transparent black material  
 
2.4.2 Novel object recognition test 
The novel object recognition test was used to evaluate recognition memory in 
mice (Antunes and Biala, 2012; Li et al., 2012; Vogel-Ciernia et al., 2013; Vogel-
Ciernia and Wood, 2014). Mice were placed in a 40cm x 40cm arena with new 
bedding and were allowed 10 minutes to habituate with the environment. The 
next day, mice were placed in the first arena with two objects that were 
identical (either two plastic figurines or two bottles) and permitted 10 minutes 
to explore the objects, enabling familiarity with them. Following a waiting 
period of an hour, the mouse was reintroduced into the area where one of the 
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objects had been replaced with a novel object that was unfamiliar to the mouse. 
Mouse exploratory activity and time spent sniffing were tracked using Ethovision 
XT tracking software (Noldus, USA). Latency to reach each object and time spent 
at respective objects were analysed offline. Time spent exploring each object 
was scored by an experimenter, blind to all conditions. A discrimination index 
was calculated as follows: (time exploring the novel object – time exploring 
familiar object)/total object exploration time *100. 
 
Figure 2.2 Novel object test phase and recognition training. (A) Mice were 
placed in the arena with two identical objects 5cm from each edge; mice 
explored for 10 minutes so that novel objects would become familiar objects 
(FO). (B) After a delay of one hour, the mice were placed in the arena with one 
object that is familiar from one novel object (NO) and the last trial (FO), 
placement of both were in the arena corners of 5cm x 5cm and was allowed 10 
minutes for exploring. In both trials, the mice were placed facing away from the 
objects to avoid development of biased preference based on initial positioning 
relative to the objects. 
2.4.3 Rotarod performance test 
Motor learning and coordination were measured over three consecutive days 
using a rotarod device. On each day, each mouse was subjected to three 
experimental sessions separated by rest periods of 15 minutes. During each 
session, the rotating rod (Jones and Roberts Accelerating Rotarod 7650; Ugo 
Basile, Varese, Italy) was gradually accelerated over a time period of five 
minutes from 4 to 40 rpm (Brielmaier et al., 2012). Mice were assessed by the 
time spent on the rotarod until falling, passively rotating or a maximum of 300 s 
had elapsed (Brielmaier et al., 2012; Yang et al., 2012). 
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To evaluate motor skill learning, a steep learning curve was deployed, with 
assays conducted over 3 consecutive days, with 3 consecutive tests on each day. 
The results from the first day of testing were not included as this was a training 
session. The data from the two subsequent days were collected, and the mean 
of six trials (3 per day) was used as the data point for each mouse. These 
datapoints were compared between groups statistically. 
  
2.4.4 Treadmill motor challenge test (Exercise tolerance) 
Exercise endurance and fatigue were tested using a treadmill. Exercise capacity 
was investigated with the use of an accelerating elevated treadmill (Kemi et al., 
2004). At the treadmill’s base, an electrified grid provides a mild aversive 
stimulus (electric shock) when stood upon, acting as a deterrent in preventing 
mice from stopping for reasons that are motivational, to ensure the 
measurement of the true exercise capacity. The treadmill test was applied to 
the mice after two days of training on the treadmill. Treadmill speed was 
initially 10 cm/s with speed increasing every two minutes by 2 cm/s till it 
becomes impossible for mice to cope with the speed and they allow themselves 
passively to be subject to shock on the grid without returning to the treadmill. 
At this point, the trial was terminated, and the time was recorded. 
2.4.5 Social interaction test 
Mice were assessed for memory and social affiliation. Mice were placed in a 
three-chamber arena made from darkened plastic, as indicated in Figure 2.3. 
The subject mouse’s bedding from its home cage was added to each arena in 
order to familiarize the mouse to the chamber and it was allowed 10 minutes 
exploring and interacting with the stranger and the familiar mice. An overhead 
digital camera was used in filming the analysis and the experiment with the use 
of Ethovision XT software. Zones were defined around the stranger and familiar 
mice and the time spent sniffing the other mice in their zone was collected (Moy 
et al., 2007; Nadler et al., 2004; Yang et al., 2012; Yang et al., 2011). A social 
novelty test was performed by introducing a new stranger mouse in the chamber 
and switching the familiar littermate to the other chamber. The time spent in 
each side chamber was analysed subsequently (Samaco et al., 2012). 
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Figure 2.3 Setting up of Arena for social interaction test. Mice were placed in 
a three-chamber arena. The subject mouse was placed in the central chamber 
(8cm x 20cm). The chamber on the left (13.5cm x 20cm) housed a mouse that is 
a cage mate and is familiar to the subject. A stranger mouse was also housed in 
an adjacent chamber (13.5cm x 20cm) on the right. Both mice were contained in 
an aluminium mesh cylinder. The programme detected the mouse when it moved 
within 1cm of either stranger or familiar mouse cage. The arena in total was 
35cm x 20cm. 
2.4.6 Light/Dark box test 
As a further test of anxiety levels, mice were subjected to a dark/light box test. 
This test relies on the mouse’s natural tendency to avoid areas that are brightly 
lit; but also, its inner desire to explore new areas (Bourin and Hascoët, 2003; 
Brielmaier et al., 2012; Campos et al., 2013). Mice were maintained in the 
darkened test room for one hour prior to being transferred to the two-
compartment test box (Figure 2.4). Mice were placed in the darkened third of 
the box that makes up a dark compartment. This was attached to the second 
compartment which is illuminated by an application on iPhone named “Photon 
Beard highlight” at 400 lux. The door connecting the two compartments was 
removed and the activity recorded for 10 minutes using an overhead digital 
camera (Panasonic CCTV camera, Model WV-BP334) and Ethovision XT tracking 
software. In the resulting video file, the dark and the light compartment were 
marked as separate zones and software was set up to calculate and track the 
transitions between the zones, the time point at which mice entered the light 
area and spent time in each zone.  
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Figure 2.4 Two-compartment arena used in the light-dark box test. The arena 
consists of two IR, transparent compartments with a small 5cm x 7 cm channel 
which is connected to allow mice to move freely between them. The dark 
compartment with its lid, 20 cm x 25 cmx 25 cm, is made from IR transparent 
black plexiglass, and the light compartment diameter is 20 cm x 25 cmx 25 cm 
and it is made from clear material. Arrow indicates other experimental arena 
markers which the mouse cannot see. Mice usually explore when they are in an 
unfamiliar environment, but if the mouse is stressed, it always stays in the dark 
environment and has minimal movement. 
2.4.7 Splash test 
A final test for anxiety in the mice was to artificially stimulate grooming 
behaviour using the splash test (Piato et al., 2008; Yalcin et al., 2005; Yalcin et 
al., 2007). Each mouse was quickly sprayed twice until its coat was damp with a 
sucrose solution (10%) and then put back in its cage where it was then observed 
for grooming behaviour (Figure 2.5). Behaviour was recorded for 15 minutes 
using a Nikon D5200 camera. The performance of each mouse in terms of the 
observed behaviours was manually counted. Specific behaviours were measured 
after recording by a point system or counting scale every time the mouse shook 
itself, scratched, licked its hair, groomed its face, or dug into the bedding. 
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Figure 2.5 This experiment is a test of mouse stress by observing the 
grooming behaviour in its home cage. A mouse was sprayed with a 10% sucrose 
solution that made the mouse feel discomforted which will provoke grooming 
behaviour in an unstressed mouse. In contrast if the experimental mouse is 
stressed it will not groom. The photo shows the mouse grooming itself in its own 
cage after being sprayed with sucrose solution. 
 
2.4.8 Breathing test (Whole body plethysmograph) 
Respiratory phenotypes were evaluated in conscious and unrestrained mice with 
a whole-body plethysmography apparatus (EMMS, Bordon, U.K.). Mice were 
placed in a Plexiglas chamber and left for 20 minutes to become familiar with 
the environment, and then their breathing was monitored for 30 minutes. To 
analyse differences in movement and grooming levels between groups, data was 
recorded while mice remained at quiet rest. A continuous bias airflow supply 
allowed the mouse to be kept in the chamber for extended periods of time. 
10% sucrose 
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Figure 2.6 Images of the whole-body plethysmograph used for assessment of 
the breathing phenotype. Mice were placed in plexiglass chambers with a 
source for air supply. Pressure changes were detected and analysed by a 
pressure transducer (EMMS, Bordon, U.K.) software. 
The temperature and humidity of the air result in pressure changes as air enters 
and leaves the mice’s lungs. The breathing pattern of the mouse was detected 
by a pressure transducer and was represented using a respiratory waveform. 
Then, breathing frequency, frequency variability (using the coefficient of 
variability of the waveforms) and the frequency of apnoeas (expiratory pauses 
more than three respiratory cycles in length) of the waveform pattern were 
analysed using pClamp 10.2 (Molecular Devices Inc., California, USA). 
2.5 Adeno-associated viral vectors and Vector 
administration 
2.5.1 Vector preparation 
All recombinant AAV vectors were generated at the University of North Carolina 
(UNC) Gene Therapy Centre Vector Core facility (website). The vectors were of 
the self-complementary design (scAAV) which is scAAV2 ITR [inverted terminal 
repeat]-flanked genomes packaged into AAV9 or AAV9.47 serotype capsids 
(Clément and Grieger, 2016). Viral particle preps were produced from 
suspension HEK293 cells using proprietary methods developed by the UNC Gene 
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Therapy Vector Core. All MeCP2-expressing constructs utilized the human 
MECP2_e1 coding region with a C-terminal Myc epitope tag unless stated 
otherwise. Viral particle preps were prepared in a final formulation of high-salt 
PBS (containing 350 mmol/L total NaCl) supplemented with 5% sorbitol. These 
were stored at -80°C. 
Before each injection, the frozen scAAV9 viral particle aliquots were thawed and 
diluted to 100 μL in PBS/350 mm NaCl containing 5% sorbitol. Control injections 
were made using the same diluent lacking vector (“vehicle control”).  
2.5.2 Vector injection 
2.5.2.1 Tail vein injection 
Tail vein injections were carried out by a member of biological services staff in 
biological services facilities. For injection into unanaesthetised young adult male 
mice, injections were made via the tail vein at 4–5 weeks of age. The mice were 
placed in a heating device to produce venodilatation and then were locked in a 
restraining device that allowed only the tail to protrude. 70% alcohol was 
applied to the tail and a 0.3ml Insulin syringe with a 30 g needle (MICRO-FINE 
PLUS U100 SYRINGE 0.3ml 30G) was used to deliver the viral vectors into the 
mouse tail vein. The maximum volume delivered was 100 µl. A member of 
Biological Services staff administered the tail vein injections. 
2.5.2.2 Cerebroventricular injection into neonatal mice 
For delivery of viral vectors to neonatal mice, unanaesthetised male littermates 
were sexed (0-3 days postnatally) and bilateral injections were made directly 
through the skin and into the brain. Bilateral injections of viral particle preps 
(~3 μl/site) were given using a 10 μl Hamilton syringe and 33 g needle 
(Finescience Instruments, Germany) connected via an ultra-narrow gauge 
silicone tube. Two people were required for the neonatal brain injection. Dr. 
Kamal Gadalla held the pup’s head in place and inserted the needle into the 
brain. I then slowly administered the viral vector by injection. The sites of brain 
injection were over the temporal cortex, ~1-2 mm lateral to the midline, ~1-2 
mm anterior to lambda and at a depth of ~2mm, approximately coinciding with 
b a 
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the lateral ventricle. The injected pups were returned quickly to their home 
cage containing their mother and non-injected female littermates. 
 
 
Figure 2.7 Cerebroventricular injection in neonatal mice (a) Neonatal 
injection site (b) Experimental design of direct brain injection to neonatal mice. 
 
2.6 Immunohistochemistry (IHC) 
After behavioral phenotyping was completed, mice were administered a non-
recovery intraperitoneal injection of pentobarbitone (Euthatal 50 mg). On deep 
anaesthesia and absence of sensory reflexes, mice were transcardially perfused 
with 4% paraformaldehyde (0.1 mol/L PBS, pH=7.4). After 10 minutes (~50ml 
perfusion), brain and other tissues were removed and post-fixed in the same 
fixative for ~4 hours before being stored in PBS. Thereafter, 80 μm sagittal 
sections of brain, spinal cord, and liver were obtained by using a vibrating 
microtome (Leica VT1200).  
After that, the 80 μm sections were incubated in 50% (v/v) ethanol in distilled 
water for 30 minutes and were washed three times in 0.3 mol/L PBS, followed 
by incubation in 10 mM sodium citrate (pH 6, 85°C, 30 minutes) for antigen 
retrieval. Sections were incubated in the blocking solution (5% normal goat 
serum in 0.3mol/L PBS with 0.3% Triton X-100) for 1 hour at room temperature. 
Samples were then incubated for 48 hours on a shaker at 4°C with the following 
primary antibodies: rabbit anti-Myc (Abcam, ab9106), mouse monoclonal anti-
MeCP2 (Sigma, WH0004204M1), and chicken anti-GFP (Abcam, ab13970).  
The primary antibodies were washed off (3× 0.3 mol/L PBST), and secondary 
antibodies were applied to the sections overnight at 4°C: Alexa Fluor 488 goat 
anti-mouse/rabbit (Invitrogen; 1/500), Alexa Fluor 546 goat anti-mouse/rabbit 
(Invitrogen; 1/500), Alexa Fluor 649, goat anti-mouse (Jackson ImmunoResearch 
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Laboratories, 112-495-003JIR). Finally, sections were incubated with DAPI 
nuclear stain (Sigma; 1/1,000) for 30 minutes at room temperature before 
mounting into standard glass microscope slides using Vectashield (Vector 
Laboratories)  
2.7 Image analysis 
Image stacks were captured using a Zeiss LSM710 or Zeiss Axiovert LSM510 laser 
confocal microscope (Zeiss) and were used to analyse expression patterns, 
transduction efficiency, and quantification of vector-derived MeCP2 levels within 
nuclei. 
The z series were collected at 1 μm intervals through the section of interest 
using a 40× objective. To guard against biases due to limited antibody 
penetration, stack images were taken close to the surface of sections to a 
maximum depth of 20μm. To evaluate transduction efficiency, images were 
captured as described earlier, and the proportion of DAPI-stained nuclei that 
were also Myc-immunopositive was calculated for random fields (n = 12 images 
per region: minimum of 4 images from each of a minimum of three mice) from 
sections of hippocampus (CA1 region), layer 5 of primary motor cortex, 
thalamus, hypothalamus, brain stem, and striatum.  
The levels of vector-derived MeCP2 per nucleus in WT mice were quantified in 
confocal stacks (20μm thick).  
To calculate the percentage of transgenic expression in neurons, anti-Myc 
antibodies were used to identify the transduced cells, and the proportion of 
NeuN-immunopositive cells that were also Myc-immunopositive was determined. 
Anti-Mecp2 immunofluorescence was used for intensity measures of the cellular 
Mecp2 level. ImageJ software (http://rsbweb.nih.gov/ij/) was used to determine 
mean MeCP2-channel fluorescence intensity within transduced (Myc +ve) and 
non-transduced (Myc −ve) cells. Fluorescence in the DAPI channel was used to 
define the nuclear boundary. 
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2.8 Statistical analysis 
GraphPad PRISM (GraphPad Software©) was used for statistical analysis as well as 
for graph presentation. To test differences between treatment groups, General 
linear models, One-way ANOVA, Two-way ANOVA, Student’s t-test, and the 
Mantel-Cox test (for survival curves) were used as appropriate. p < 0.05 was used 
to define statistical significance. In multi-group post-hoc comparisons, multiple 
testing correction for pairwise tests among groups was applied using Tukey’s 
post hoc analysis. 
Some behavioural tests carried out on the viral-vector-treated mice in Ch.4 and 
Ch.5 involved measurements of individual mice on different occasions. Within-
subject analyses could not be carried out for these as group size differed across 
time points as mice died or were humanely euthanized. For tests with multiple 
timepoints where group size remained the same across the timepoints, general 
linear model statistics were used to analyse all predictor variables including 
time. 
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Chapter 3 Validation of behavioural tests in RTT 
mouse models 
3.1 Introduction  
RTT mouse models have been an important tool in pre-clinical studies, assessing 
putative pharmacotherapies and genetic therapies in RTT syndrome, caused by 
mutations in the MECP2 (methyl-CpG-binding protein 2) gene. Ever since it was 
first described in the 1960s by Andreas Rett (Rett, 1966) and after that by Bengt 
Hagberg in 1983 (Hagberg et al., 1983), there has been no effective treatment 
for RTT. 
In vivo experiments in animal models, are a first, important and essential step to 
evaluate effectiveness and safety of putative therapies, to build up information 
about a possible drug, or other therapy, before moving onto the clinical phase. 
In RTT, human and mouse MeCP2 proteins are orthologs with 95% amino acid 
sequence identity. Loss of MeCP2 function in knock-out mice gives a comparable, 
although somewhat less severe, RTT like phenotype when compared to human 
patients (Brown et al., 2016; Guy et al., 2001). Hemizygous male mice with RTT 
do not show fatality at birth but show overt signs of neurological deficits from 3-
8 weeks of age. Typically, the RTT-like phenotype in male mice is characterised 
by gait and motor impairments, breathing difficulties, tremor and severe 
regression leading to a premature death at 50-60 days of age. In comparison to 
hemizygous males, heterozygous female mice exhibit milder phenotype 
characterised by weight-gain, reduced activity and gait impairments. In 
addition, the RTT-like phenotype appears to progress at a slower rate in females 
than in males, with onset of overt signs at approximately 6 months of age, which 
is then followed by phenotypic stabilization and a normally non-altered lifespan 
(Chen et al., 2001; Guy et al., 2001). 
 
Recently, a new knock-in (KI) model of RTT has been developed to test 
hypotheses about mutant MeCP2 function that cannot be tested using a KO 
model. Missense mutations in RTT vary in severity and there is evidence that the 
severity correlates between human and mouse models - for example, mutations 
that cause milder forms of RTT in human cases also seem to cause less severe 
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RTT-like phenotypes in mice (Brown et al., 2016). RTT-associated missense 
mutations localizing to the MBD, including p.T158M, the most common human 
MECP2 missense mutation, have been shown to reduce DNA binding affinity and 
overall MeCP2 protein stability offering an explanation for the clinical phenotype 
(Ballestar et al., 2000; Brown et al., 2016; Neul et al., 2008; Yusufzai and 
Wolffe, 2000). The T158M mutation occurs in 12% of typical RTT cases and 
causes a methionine for threonine change at amino acid position 158 (Neul et 
al., 2008). The generated Mecp2T158M mouse model mimics the human missense 
mutation and exhibits typical RTT-like features, offering a suitable model system 
in which to study the T158M mutation effects on RTT phenotype (Brown et al., 
2016). 
However, due to the RTT mouse model being recently generated, the line has 
only undergone basic phenotyping which has not been validated or extended in 
another laboratory. There is therefore a need to carry out additional behavioural 
tests in the KO and KI RTT mouse model using data on physical disability and 
validate the KI model for RTT. It is also of interest to provide baseline data for 
evaluation of potential treatments for preclinical efficacy. (Antunes and Biala, 
2012; Grayson et al., 2015; Yang et al., 2015). 
3.2 Study aims  
The overall aim of the work in this chapter was to conduct a detailed 
characterisation of phenotypes and identify specific behavioural tests in both 
male and female RTT mouse models as a prerequisite for downstream testing of 
therapeutic interventions. This included testing the newly developed T158M line 
modelling the most common RTT-causing variant. The specific objectives of this 
chapter are:  
(1) To determine the characteristic baseline RTT-like phenotypes in male and 
female mice of different genotypes. 
(2) To modify behavioural tests for the RTT mouse to render them less sensitive 
to impaired mobility. 
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3.3 Method 
To study the characteristics of RTT phenotypes, wild-type (WT), Mecp2 knock-
out (KO) and Mecp2 T158M knock-in (KI) lines which were born during the same 
time period were examined. After weaning at three weeks, WT and mutant 
individual littermates of the same sex were caged together. Mice were weighed 
and scored for RTT-like phenotypes weekly (see section 2.3.4); however, during 
the experiments, if I found a mouse that had reached a severe condition, I 
applied the approved humane termination procedures. The results for each 
behavioral test were calculated from mice of the same genotype. 
To carry out additional behavioural tests, mice whose total RTT-like score was 
more than three were used because they completely present the RTT-like 
phenotype. Males were used at approximately 5-6 weeks while females were 
tested from six months onwards. More than ten mice per genotype were used 
repeatedly in each behavioral test. Moreover, I attempted to include 
treat/reward for some of the initially planned experiments that it was needed 
in, for example, T-maze or touch screen (Arime and Akiyama, 2017; Kim et al., 
2015; Leach and Crawley, 2018; Nichols et al., 2017; Sakai et al., 2016; 
Zeleznikow-Johnston et al., 2018). But, after fasting for 8 hours, the KI and KO 
mice did not eat any food during the test, thus precluding conclusions being 
drawn from these experiments. I had to remove tests from my initial plan that 
depended on the treat/reward mechanism. 
In this chapter, the behavioural tests have been grouped under five categories: 
mobility and function, learning and cognitive processes, social interaction, 
stress, and breathing (see Chapter 2, Section 2.4 These were applied in a 
particular order. The mice were given at least one day’s break before the next 
test. For the testing in male mice, initiation of testing for each mouse took 
place when it reached six weeks of age. Although the overall order of tests was 
standardised, different mice could enter the programme of tests at different 
points, as they were introduced into the programme whenever they reached the 
correct age and batches of mice were tested in the same way in the same week 
for reasons of efficiency. The order of tests for each mouse is given in table 3.1. 
For the female mice, every mouse had the range of tests administered in the 
same order, although some mice were not used in some tests as they did not 
77 
 
meet criteria for inclusion - details are given in table 3.2. Most of the behavioral 
tests were video recorded and analysed by Ethovision X program, except the 
breathing test which was recorded as a graph on the computer and the rotarod 
test which I recorded manually (with assistance from students I was supervising, 
after which we compared and confirmed our results with each other). I did not 
carry out a power calculation initially (see Section 2.3 for group size 
justification), but I did run post-hoc power calculations based on the group 
differences and variances observed (see Section 3.4.3.1 and Figure 3.5). For 
both the open-field and rotarod tests in male mice of the KO line (vs WT), I 
would have been able to see the observed difference at an alpha of p < 0.05 
with 80% power at n = 9 per group. For the open field test in female 
heterozygotes, I would have had 80% power to detect the observed difference 
with n= 21 per group, but for the rotarod test, I would have been able to see the 
observed difference at an alpha of p < 0.05 with 100% power at n = 13-15 per 
group, as was in fact used. Thus, the results from this chapter are reliable due 
to the number of mice used and because the same conditions were applied in 
each experiment, as I mentioned above.  
Table 3-1. Order of behavioural experiments performed for each mouse in behavioural tests 
in male RTT mouse models * means the mice were exclude from the experiment because its 
own condition. 
Genotype 
number 
open field 
w/0 
bedding 
open field 
with 
bedding 
NOR Rotarod 
Motor 
learning 
treadmill 
Social 
interaction 
Light-
dark 
Splash 
test 
breathing 
WT L590 1 
  2 3 4 5 age >7W   
WT L619 1 
    2 3 4 5 age >7W 
WT L621 1 
    2 3 4 5 6 
WT L625 5 
  age >7W   1 2 3 4 
WT L630 5 
  age >7W   1 2 3 4 
WT L631 5 
  age >7W   1 2 3 4 
WT L633 5 
  age >7W   1 2 3 4 
WT L649 3 
  age >7W     1 2 
WT L656 3 
  age >7W     1 2 
WT L740 
   1 2 3 4 5 6 age >7W 
WT L742 
 1 2 3 4 5 6 7 8 age >7W 
WT L777 8 
  1 2 3 4 5 6 7 
WT T221 
 1 2 3 4 5 6 7 age >7W  
WT T222 
 1 2 3 4 5 6 7 age >7W  
WT T224 
 1 2 3 4 5 6 7 age >7W  
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Genotype 
number 
open field 
w/0 
bedding 
open field 
with 
bedding 
NOR Rotarod 
Motor 
learning 
treadmill 
Social 
interaction 
Light-
dark 
Splash 
test 
breathing 
WT T248 
 age >7W  1 2 3 4 5 6 7 
WT T249 
 age >7W  1 2 3 4 5 6 7 
WT T250 
 3 4 5 6 age >7W   1 2 
WT T251 
 3 4 age >7W     1 2 
WT T260 
 2 3 age >7W      1 
WT T261 
 1 2 age >7W       
WT T262 
 1 2 age >7W       
WT T263 
 1 2 age >7W       
WT T295 
 1 2 age >7W       
WT T302 
  1 age >7W       
WT T306 
  1 age >7W       
WT T307 
  1 age >7W       
WT T310 
  1 age >7W       
  Total 10 11 15 10 10 11 15 14 15 13 
Mecp2-/y L588 1 
  2 3 4 5 dead   
Mecp2-/y L589 1 
  2 3 4 5 age >7W   
Mecp2-/y L595 1 
  2 3 4 5 6 age >7W  
Mecp2-/y L596 1 
  2 3 4 5 6 age >7W  
Mecp2-/y L603 
     1 2 3 4 age >7W 
Mecp2-/y L620 
     1 2 3 4 age >7W 
Mecp2-/y L660 
 4 5 age >7W    1 2 3 
Mecp2-/y L666 
 4 5 age >7W    1 2 3 
Mecp2-/y L667 
 4 5 age >7W    1 2 3 
Mecp2-/y L668 
 4 5 age >7W    1 2 3 
Mecp2-/y L739 
 1 2 dead       
Mecp2-/y L741 
7   1 2 3 4 5 
video not 
record 
6 
Mecp2-/y L745 8 
  1 2 3 4 5 6 7 
Mecp2-/y L746 8 
  1 2 3 4 5 6 7 
Mecp2-/y L756 2 
     1    
Mecp2-/y L757 1 
     2 x x 3 
Mecp2-/y L776 2 
  3 4 dead    1 
Mecp2-/y L778 2 
  3 4 5 6   1 
Mecp2-/y L779 
 video not rec 1        
Mecp2-/y L781 
 1 2        
Mecp2-/y L782 
 1 2        
Mecp2-/y L788 
 1 2        
Mecp2-/y L790 
 1 2        
Mecp2-/y L792 
 1 2        
Mecp2-/y L793 
 1 2        
Mecp2-/y L640 
     1 2 3 dead  
Mecp2-/y L641 
     1 2 dead   
Mecp2-/y L650 dead 
     1 2 3 4 
Mecp2-/y L651 
 4 5 age >7W    1 2 3 
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Genotype 
Mouse 
number 
openfield 
w/0 
bedding 
openfield 
with 
bedding 
NOR Rotarod 
Motor 
learning 
treadmill 
Social 
interaction 
Light-
dark 
Splash 
test 
breathing 
Mecp2-/y L657 
 4 5 age >7W    1 2 3 
Mecp2-/y L659 
 4 5 age >7W    1 2 3 
   Total 11 14 15 9 9 12 15 16 12 14 
Mecp2T158M/y T223 1 
 x 2 3 4 age >7W    
Mecp2T158M/y T252 1 
 x 2 3 4 5 age >7W   
Mecp2T158M/y T256 1 
 x 2 3 4 5 age >7W   
Mecp2T158M/y T257 1 
 x 2 3 4 5 age >7W   
Mecp2T158M/y T264 1 
 x 2 3 4 5 age >7W   
Mecp2T158M/y T271 1 
 x 2 3 4 5 6 7 8 
Mecp2T158M/y T274 
 age >7W    1 2 3 4 5 
Mecp2T158M/y T292 
 age >7W    1 2 3 4 5 
Mecp2T158M/y T293 
 age >7W    1 2 3 4 5 
Mecp2T158M/y T296 
 age >7W    1 2 3 4 5 
Mecp2T158M/y T301 
 5 6 age >7W   1 2 3 4 
Mecp2T158M/y T308 
 5 6 age >7W   1 2 3 4 
Mecp2T158M/y T309 
 5 6 age >7W   1 2 3 4 
Mecp2T158M/y T323 
 3 4 5 6 age >7W   1 2 
Mecp2T158M/y T324 
 3 4 5 6 age >7W   1 2 
Mecp2T158M/y T327 
 3 4 5 6 age >7W   1 2 
Mecp2T158M/y T329 
 x 3 4 5 age >7W   1 2 
Mecp2T158M/y T332 
 x 3 4 5 age >7W   1 2 
Mecp2T158M/y T333 
 x 3 age >7W     1 2 
Mecp2T158M/y T337 
 x 3 age >7W     1 2 
Mecp2T158M/y T339 
 x 3 age >7W     1 2 
Mecp2T158M/y T343 
 x 2 age >7W      1 
  Total 
 6 12 11 11 12 12 8 16 17 
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Table 3-2. Order of behavioural experiments performed for each mouse in behavioural tests 
in female RTT mouse models - * means the mice were humanely euthanized to collect tissue. 
genotype 
Mouse 
number 
Open field NOR Rotarod 
Motor 
learning 
treadmill 
Social 
interaction 
Light-dark Splash test breathing 
WT L610 1 2 3 4 5 6 7 8 9 
WT L611 1 2 3 4 5 6 7 8 9 
WT L624 1 2 3 4 5 6 7 8 9 
WT L627 1 2 3 4 
play 
behaviour 6 7 8 9 
WT L642 1 2 3 4 5 6 7 8 9 
WT T268 1 2 3 4 5 6 7 8 9 
WT T272 1 2 3 4 5 6 7 8 9 
WT T280 1 2 3 4 5 6 7 8 9 
WT T337 1 2 3 4 5 6 7 8 9 
WT T390 1 2 3 4 
play 
behaviour 6 7 8 9 
WT T393 1 2 3 4 5 6 7 8 9 
WT T407 1 2 3 4 5 6 7 8 9 
WT T409 1 2 3 4 5 6 7 8 9 
Total  13 13 13 13 11 13 13 13 13 
Mecp2+/- L102 1 2 3 4 
Overweight, 
did not move 6 * * * 
Mecp2+/- L607 1 2 3 4 5 6 * * * 
Mecp2+/- L609 1 2 3 4 
Overweight 
not move 6 * * * 
Mecp2+/- L613 1 2 3 4 
Overweight 
not move 6 * * * 
Mecp2+/- L623 1 2 3 4 5 6 * * * 
Mecp2+/- L628 1 2 3 4 
Overweight 
not move 6 7 8 9 
Mecp2+/- L643 1 2 3 4 5 6 7 8 9 
Mecp2+/- L644 1 2 3 4 5 6 7 8 9 
Mecp2+/- L646 1 2 3 4 5 6 7 8 9 
Mecp2+/- L678 1 2 3 4 5 6 7 8 9 
Mecp2+/- L679 1 2 3 4 
Overweight 
not move 6 7 8 9 
Mecp2+/- L84 1 2 3 4 5 6 7 8 9 
Mecp2+/- L85 1 2 3 4 5 6 7 8 9 
Mecp2+/- L89 1 2 3 4 5 6 7 8 9 
Mecp2+/- L98 1 2 3 4 5 6 7 8 9 
Total  15 15 15 15 10 15 10 10 10 
Mecp2+/T158M T253 1 2 3 4 5 6 7 not used 8 
Mecp2+/T158M T254 1 2 3 4 5 6 7 not used 8 
Mecp2+/T158M T255 1 2 3 4 5 6 7 not used 8 
Mecp2+/T158M T267 1 2 3 4 5 6 7 not used 8 
Mecp2+/T158M T273 1 2 3 4 
Overweight 
not move 6 7 not used 8 
Mecp2+/T158M T279 1 2 3 4 5 6 7 8 9 
Mecp2+/T158M T323 1 2 3 4 5 6 7 8 9 
Mecp2+/T158M T325 1 2 3 4 
Overweight 
not move 6 7 8 9 
Mecp2+/T158M T334 1 2 3 4 
Overweight 
not move 6 7 8 9 
Mecp2+/T158M T335 1 2 3 4 5 6 7 8 9 
Mecp2+/T158M T336 1 2 3 4 5 6 7 8 9 
Mecp2+/T158M T352 1 2 3 4 5 6 7 8 9 
Mecp2+/T158M T391 1 2 3 4 5 6 7 8 9 
Mecp2+/T158M T392 1 2 3 4 5 6 7 8 9 
Mecp2+/T158M T408 1 2 3 4 5 6 7 8 9 
Total  15 15 15 15 12 15 15 10 15 
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3.4 Results 
3.4.1 RTT model genotyping by PCR 
To achieve an adequate number of mice in each experimental cohort two 
colonies of mice representing KO and KI RTT mouse models were established by 
crossing heterozygous female mice (Mecp2+/- and Mecp2+/T158M) with WT male 
mice (both on a C57BL/6 background). PCR genotyping was carried out after 
offspring were weaned and separated into cages. The results of an example of a 
genotyping experiment as shown in Figure. 3.1, demonstrating hemizygous, 
heterozygous and WT individuals in both lines.  
a) Mecp2 KO colony b) Mecp2 T158M colony  
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Figure 3.1 Results of PCR genotyping of wild-type, hemizygous and 
heterozygous mice from both lines; Mecp2 KO and Mecp2 T158M. Genotype for 
each individual is represented in two neighboring gel lanes indicated by 
brackets. Genomic DNA of known heterozygous female mouse was used in a PCR 
as a positive control and nuclease-free water instead of DNA was used in a PCR 
as a negative control. (A) Genotyping results for the Mecp2 KO line. Common 
forward primer, and wild-type and mutant reverse primers were used to amplify 
DNA fragments from the wild-type Mecp2 allele (416bp) and the Mecp2 KO allele 
(470bp). (B) Genotyping results for the Mecp2 T158M line. WT and mutant 
forward primers and a common reverse primer were used to amplify DNA 
fragments from wild-type Mecp2 allele (107bp) and Mecp2T158M allele (300bp). 
Genotypes of selected individuals are indicated above the brackets; WT - wild-
type, HEMI - hemizygous male, and HET – heterozygous female. 
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3.4.2 Phenotype severity assessment in KO and KI mice 
All the experimental mice, both mutant and WT, were assessed using a 
standardised and widely adopted phenotype scoring system (Brown et al., 2016; 
Derecki et al., 2012; Gadalla et al., 2013; Gadalla et al., 2017; Guy et al., 2007) 
weekly from the age of four weeks in males and six months in females.  
Hemizygous and heterozygous mice of each line exhibited RTT-like 
characteristics, mostly reduced mobility and gait abnormalities and, in rare 
cases, breathing difficulties and tremor. Some wild-type mice showed stop/start 
movements and therefore scored 1 for mobility. The aggregate severity score, as 
shown in Figure 3.2, was significantly different in mutant and wild-type 
individuals. 
Due to the different age of onset and severity of progression of the RTT-like 
phenotype by sex, I separated the mice in the main analysis into male and 
female. In both male and female mice, I compared the characteristics of male 
WT with male KO and male KI. All symptomatic (scoring more than 2) and WT 
male mice at age 6-8 weeks were compared. Symptomatic female mice were 
compared with WT in the same way when RTT-like phenotypes were present 
after 6 months. 
3.4.2.1 Male 
In males, the RTT-like phenotype is observable from 4-5 weeks (Brown et al., 
2016; Guy et al., 2001). In this experiment I used symptomatic mice, aged 6-7 
weeks. In males, phenotype severity score differed significantly between KO, WT 
and KI (Aggregate severity score; WT 0.14 ±0.36; Mecp2T158M/y 2.06 ± 1.05; 
Mecp2-/y 0.69 ± 0.85; **** = P<0.0001; Figure 3.2a). Mecp2T158M/y and Mecp2-/y also 
showed significantly different body weights from each other (Average body 
weight; WT 21.68 ± 2.33; Mecp2T158M/y 17.85 ± 2.83; Mecp2-/y 14.98 ± 2.11; **** = 
P<0.0001; Figure 3.2b). Mecp2-/y is more severe than KI. 
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Figure 3.2 Composite body weight measurements and severity score in wild-
type, Mecp2-/y and Mecp2T158M/y mice (a) Graph showing the RTT-like phenotype 
severity score comparisons the age at 6 weeks. (b) Graph showing bodyweight 
comparisons the age at 6 weeks. WT (n=26), Mecp2-/y (n=20), and Mecp2T158M/y 
(n=13). Data presented as mean ± SEM. Statistical test results: (a) ANOVA test, F 
(2, 58) = 34.99, p < 0.0001 (b) ANOVA test, F (2, 58) = 47.64, p < 0.0001 Tukey's 
post-hoc tests: **** = P<0.0001; ** = p<0.01, ns = non-significant.   
a 
b 
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3.4.2.2 Female 
In females, the onset of RTT starts at 6-8 months with the age range in this 
group being much wider than that in the males.  
For the aggregate severity score in my experimental symptomatic mice aged 
between 6-8 months, both Mecp2+/- and Mecp2+/T158M mice present significantly 
higher than the WT (Aggregate severity score; WT 0.00 ± 0.00; Mecp2+/T158M 2.06 
± 1.16; Mecp2+/- 2.06 ± 0.96; **** = P<0.0001; Figure 3.3a). The trend in body 
weight differences between genotype does not mirror that of the males. WT 
body weight is significantly lower than both mutants (Average body weight; WT 
24.34 ± 2.86; Mecp2+/T158M 29.00 ± 4.38; Mecp2+/- 29.19 ± 4.29; ** = P<0.01; 
Figure 3.3b). 
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Figure 3.3 Composite body weight measurements and severity score in wild-
type, Mecp2+/-and Mecp2+/T158M female mice (6-8 months old). (a) Graphs 
showing RTT-like phenotype severity score; (b) Graph showing bodyweight. WT 
(n=13), MeCP2+/-(n=15) and MeCP2+/T158M (n=15) . Data presented as means ± 
SEM. Statistical test results: (a) ANOVA test, F (2, 40) = 24.31, p < 0.0001  (b) 
ANOVA test, F (2, 40) = 6.549, p = 0.0035 Tukey's post-hoc tests: ** = p<0.01, **** 
= p<0.0001 ns = non-significant.   
a 
b 
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3.4.3 Establishment and validation of detailed behavioural tests in 
the male RTT mouse models 
To optimize additional behavioural tests I used WT, KO and KI male mice to 
characterise the baseline of each genotype and to validate the experiment and 
to indicate the robustness of the genotypes. 
Before testing I weighed the mice and scored them for RTT-like aggregate 
severity. Mice with complete mobility impairment (scoring 2 for mobility) were 
excluded from these experiments. All animals had a one-day recovery period 
between phenotyping experiments.  
3.4.3.1 Open field test  
Mice were placed into the centre of the 40x40cm arena and allowed to move 
freely and explore for 15 minutes. To examine movement and mobility, compiled 
recorded footage was analysed using Ethovision XT10. Figure 3.4 shows distance 
moved for the WT and KO mice in the presence and absence of bedding. 
The Mecp2-/y mobility was very impaired in the open-field arena. However when 
I placed bedding from the mouse homecage into the arena, the mobility of  
Mecp2-/y increased (distance moved ; no bedding 939.70 ± 560.79 cm; with 
bedding 1494.03 ± 571.75 cm; * = p<0.05; figure 4.5a), whereas the wild-type 
did not change significantly (distance moved; no bedding 2259.68 ± 609.24 cm; 
with bedding 2861.66 ± 780.08 cm; figure 4.5b) Because of this result, I 
incorporated bedding in to other tests to counter the effect of reduced mobility 
of KO and KI mice performance.  
 
The result  of the locomotor activity test between the genotypes in the open-
field arena with bedding shows that there were no significant differences found 
in the other pairwise comparisons. (Distance moved; WT 2861.65 ± 780.08 cm; 
Mecp2T158M/y 2263.17 ± 1039.88 cm; Mecp2-/y 1494.03 ± 571.75 cm; *** = P<0.001; 
Figure 3.5)  
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Figure 3.4 The comparison of locomotor assessment in wild-type and Mecp2-/y 
male mice in open field arena with and without bedding. Column plot showing 
average group values (mean ± SEM) for distance moved in Mecp2-/y (a) and WT 
(b). Mecp2-/y without bedding (n=11) and Mecp2-/y with bedding (n=14). WT 
without bedding (n=10), WT with bedding (n=11). Data presented as mean ± SEM. 
Statistical test results: (a) t-test, t=2.432, DF=21.81 * = p<0.05 (b) t-test, 
t=1.980 DF=18.6; NS = not significant 
 
 
 
 
Figure 3.5 The general locomotor assessment in WT, Mecp2-/y and 
Mecp2T158M/y male mice. Column plot showing average group values (mean ± 
SEM) for distance moved with bedding in WT, Mecp2-/y Mecp2T158M/y. WT (n=11) 
Mecp2-/y (n=14) and Mecp2T158M/y (n=6); Data presented as mean ± SEM. 
Statistical test results: One-way ANOVA test, F (2, 28) = 10.37, p= 0.0004 Tukey’s 
post hoc test: *** = p<0.001   
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3.4.3.2 Novel object recognition test  
To examine the learning and memory of the mice, I conducted the novel object 
recognition test as shown in chapter 2. However, I modified the test by 
extending the time allowed for the mice to explore the test section and the 
added objects. After analyzing the data for the exploration time in the test 
period between 10 and 15 minutes, RTT mice benefitted from the additional 5 
minutes that the 15-minute period allowed for exploration due to their mobility 
problems. 
The results were expressed as a discrimination index. WT mice spent a 
significantly greater proportion of their time exploring the novel object than the 
Mecp2-/y mice. While the Mecp2T158M/y mice showed no difference in time spent 
with the novel object compared with the other lines (% of time spent with novel 
object; WT 25.02 ± 19.24; Mecp2T158M/y 3.60 ± 25.83; Mecp2-/y 0.53 ± 30.85; * = 
P<0.05; Figure 3.6) 
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Figure 3.6 Discrimination index for learning and cognition baseline in novel 
object recognition test in WT, Mecp2-/y and Mecp2T158M/y male mice in 15 
minutes. Column plot shows group average (mean ± SEM) for the proportion of 
time spent with the novel object compared with the familiar object. WT (n=15), 
Mecp2-/y (n=15) and Mecp2T158M/y (n=12). Data presented as mean ± SEM. 
Statistical test results: One-way ANOVA test, F (2, 39) = 3.936, ANOVA p=0.027; 
Tukey’s post hoc test: * = p<0.05  
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3.4.3.3 Rotarod test 
Rotarod tests were used to measure motor function and balance. The average 
time on the rod was compared between groups. The end of the experiment 
occurred when the mouse dropped off or rolled with the rod. 
The results showed that the wild-type mice stayed on the rod significantly longer 
than both Mecp2-/y and Mecp2T158M/y (Time on rod; WT 247.83 ± 45.76 sec; 
Mecp2T158M/y 132.14 ± 42.83 sec; Mecp2-/y 122.87 ± 42.87; **** = P<0.0001; Figure 
3.7). However, there is no difference of motor function between mutant lines in 
this experiment (figure 3.7). Most of WT male mice generally showed good 
performance, however a small number in the WT group refused to run and 
instead jumped off the rod. 
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Figure 3.7 Rotarod performance of WT, Mecp2-/y and Mecp2T158M/y male mice 
using rotarod machine. Column plot showing average group values (mean ± SEM) 
of duration on a rod. WT (n=10), Mecp2-/y (n=9) and Mecp2T158M/y (n=11). Data 
presented as mean ± SEM. Statistical test results: One-way ANOVA test, F (2, 27) 
= 23.41, ANOVA p < 0.0001. Tukey’s post hoc test: **** = P<0.0001  
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3.4.3.4 Motor learning 
To evaluate motor learning skills, the average time spent on the rod on each day 
were compared. There were significant differences in the rotarod performance 
between WT, Mecp2-/y and Mecp2T158M/y.  Only WT showed motor learning, as 
demonstrated by increased time on the rod from days one to three (Average 
time on rod WT: day one 214.83 ± 55.28.04 sec; day two 223.42 ± 60.82 sec; day 
three 257.89 ± 94.94 sec Figure 3.8) while Mecp2-/y and Mecp2T158M/y showed 
similar performance with no significant improvement in their motor learning, 
(Average time on rod Mecp2-/y: day one 104.5 ± 33.91 sec; day two 117.50 ± 
36.14 sec; day three 134.57 ± 54.68 sec Figure 3.8); (Average time on rod 
Mecp2T158M/y; day one 123.5 ± 51.07 sec; day two 134.0 ± 55.54 sec; day three 
130.4 ± 54.78 sec Figure 3.8). Mecp2-/y mice remained on the rod for a shorter 
time than both the other lines. 
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Figure 3.8 Motor learning curve of WT, Mecp2-/y and Mecp2T158M/y male mice 
using rotarod machine over 3 days. Line plot showing daily average group 
values (mean ± SEM) of duration on a rod WT (n=17), Mecp2-/y (n=9) and 
Mecp2T158M/y ; Data presented as mean ± SEM. Statistical test results: General 
Linear model, F(2) = 15.248, P = <0.001; Paired Samples Test (WT Day1-Day3 ** = 
P<0.01 
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3.4.3.5 Treadmill motor challenge test 
To investigate potential differences in exercise fatigue between phenotypes, the 
treadmill motor challenge test was used. The time was recorded until the mouse 
was unable to maintain locomotor activity on the treadmill. Results show that 
the mean time on the treadmill for WT mice was significantly greater than for 
both mutant groups. (Time spent on treadmill; WT 1077.93 ± 268.14 sec; 
Mecp2T158M/y 843.62 ± 176.00 sec; Mecp2-/y 479.70 ± 165.63 sec; **** = P<0.0001; 
Figure 3.9). This equated to a 56% and 25% reduction from the WT levels of 
performance in the KO and KI line respectively. The KO line was more severely 
affected then the KI. 
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Figure 3.9 Treadmill motor test of WT, Mecp2-/y and Mecp2T158M/y male mice. 
WT (n=11), MeCP2+/- (n=12) and MeCP2+/T158M (n=12). Data presented as mean ± 
SEM. Statistical test results: One-way ANOVA test, F (2, 32) = 24.70, p<0.0001. 
Tukey’s post hoc test: * = p<0.05; *** = p<0.001, **** = P<0.0001. 
 
  
91 
 
3.4.3.6 Social interaction test 
Tests of social novelty preference provide robust and quantifiable measures of 
social withdrawal and social cognition deficits analogous to that observed in 
intellectual disability(Schaevitz et al., 2010). To gain further access to the social 
interactions of the mouse, the freely accessible, 3-chamber arena, smaller than 
a standard arena, with bedding from home cages included, was used in this 
experiment. The cage-mate and another mouse that the test mouse had had no 
prior interaction with were placed in a small cage on the other side of the 
arena. Generally, WT mice showed an interest in the unfamiliar mouse (Time WT 
spent with stranger; Stranger 1 (familiar) 53.35 ± 23.58 sec; Stranger 2 
(unfamiliar) 146.47 ± 65.49 sec; *** = p<0.001; Figure 3.10). The results clearly 
show that both mutants showed significantly less interaction with the unfamiliar 
mouse than the WT.  
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Figure 3.10 Social interaction test in WT, Mecp2-/y and Mecp2T158M/y male 
mice. The graph shows average group values (mean ± SEM) of time spent with 
their cage-mate and unknown mouse. WT (n=15), Mecp2-/y (n=15), Mecp2T158M/y 
(n=12). Statistical test results: Stratified t-tests were carried out for each 
genotype separately. For WT, t=4.554, DF=24, *** = p<0.001 between Stranger 1 
(Familiar) and Stranger 2 (Unfamiliar); For both mutant lines, there was no 
significant difference in time spent with each stranger mouse. 
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3.4.3.7 Light-dark box test 
To estimate anxiety levels, the standard light-dark test (Bourin and Hascoët, 
2003; Brielmaier et al., 2012; Campos et al., 2013; Li et al., 2015) was applied in 
this experiment. The mouse was placed in the dark chamber that had free 
access to the light chamber (20 x 13.5, 50 lumen). The video tracking data were 
analyzed by Ethovision XT10 programme. The normal mice explored the new 
arena, while the mice experiencing anxiety stayed in the dark. The results show 
that WT were more enthusiastic to explore the light chamber than both mutants. 
(Latency to enter the light area; WT 38.16 ± 34.12; Mecp2T158M/y 83.84 ± 113.35; 
Mecp2-/y 102.22 ± 67.52; * = P<0.05; Figure 3.11a). There is no significant 
difference between all groups in time spent in the dark (Time spent in the dark; 
WT 233.56 ± 16.43; Mecp2T158M/y 207.60 ± 57.48; Mecp2-/y 196.94 ± 65.49; Figure 
3.11b). 
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Figure 3.11 Exploration and anxiety-related measures of the light-dark test in 
WT, Mecp2-/y and Mecp2T158M/y in male mice. Column plot shows average group 
values (mean ± SEM) for the (a) latency to enter the light area and (b) time 
spent in dark area. WT (n=14), Mecp2-/y (n=16), Mecp2T158M/y (n=8). Statistical 
test results: (a) One-way ANOVA test, F (2, 35) = 3.175, p=0.0541, Tukey’s 
multiple comparison test.* = p<0.05 in WT vs. Mecp2-/y; (b) One-way ANOVA test, 
F (2, 35) = 1.976, ANOVA p =0.1538. 
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3.4.3.8 Splash test 
A splash test was also used to measure anxiety. Anxiety levels can be observed 
without the mobility factor which impedes the RTT mice in previous tests. In the 
test, there was no difference in grooming time between each group. (Grooming 
count; WT 168.73 ± 61.78; Mecp2T158M/y 217.62 ± 72.26; Mecp2-/y 220.08 ± 61.96; 
Figure 3.12). 
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Figure 3.12 Anxiety assessment of wild-type, Mecp2-/y and Mecp2T158M/y male 
mice by splash test. Column plot shows average group values (mean ±SEM) for 
time grooming. WT (n=15), Mecp2-/y (n=12), Mecp2T158M/y (n=16). Statistical test 
results: One-way ANOVA test(2, 40),  F (2, 40) = 2.805, p=0.0724. 
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3.4.3.9 Breathing test  
Abnormal breathing patterns and apneas were investigated using the whole-body 
plethysmography apparatus (EMMS, Bordon, UK) in 8-week-old male mice. 
Mecp2-/y and Mecp2T158M/y mice presented with apneas, a characteristic of an 
erratic breathing pattern (figure 3.13a), in contrast to the regular breathing 
pattern in WT. The number of apneas in Mecp2-/y was significantly higher than 
WT and KI. (Apneas; WT 0.00 ± 0.00; Mecp2T158M/y 0.36 ± 0.51; Mecp2-/y 1.19 ± 
0.69; **** = P<0.0001; Figure 3.13b). 
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Figure 3.13 Persistent breathing phenotype in WT, Mecp2-/y, Mecp2T158M/y 
male mice. (a) Representative whole-body plethysmograph traces showing 
regular and erratic breathing patterns/apneas (arrows) in WT and null mouse 
respectively. (b) apnoeas per minute. WT (n=13), Mecp2-/y (n=14), Mecp2T158M/y 
(n=17). Data presented as mean ± SEM. Statistical test results: One-way ANOVA F 
(2, 41) = 20.17, p<0.0001, Tukey’s post hoc comparison: **** = p<0.0001 (WT vs 
Mecp2-/y), *** = p<0.001 (Mecp2-/y vs Mecp2T158M/y),.   
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3.4.4 Establishment and validation of detailed behavioural tests in 
female RTT mouse models 
To investigate this set of behavioural tests in female mice, I used 6-month-old, 
symptomatic heterozygous Mecp2+/- and Mecp2+/T158M mice and their WT cage-
mates, as previously conducted with the male mice. (3.4.3) Before testing, I 
weighed and scored the mice for RTT-like aggregate severity. It should be 
considered that the increased body weight phenotype in heterozygous females 
that may affect mobility in some tests. 
3.4.4.1 Open field test  
The mobility tests started with an open field test over 10 minutes, which showed 
the mobility of the Mecp2+/- mice was significantly lower than that of the WT 
mice. However, the Mecp2+/T158M line showed no significant difference in the 
distance moved compared to both the other lines. (Distance moved; WT 3835.01 
± 1287.53 cm; Mecp2+/T158M 2630.00 ± 1129.58 cm; Mecp2-/y 2593.34 ± 1509.10 
cm; * = P<0.05; Figure 3.14) 
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Figure 3.14 The general locomotor assessment in WT, Mecp2+/-, Mecp2+/T158M 
female mice. Column plot showing average group values (mean ± SEM) for 
distance move in WT, Mecp2+/-and Mecp2+/T158M. WT (n=13), Mecp2+/-(n=15) and 
MeCP2+/T158M (n=15); Statistical test results: One-way ANOVA test F (2, 40) = 
3.901, p=0.0283, Tukey’s post hoc comparison: * = p<0.05. 
96 
 
3.4.4.2 Novel object recognition test  
The novel object recognition test data were analyzed using the discrimination 
index. The results showed that the WT could significantly recognize the familiar 
object and spent more time exploring the novel object than the Mecp2+/- and 
Mecp2+/T158M (% of time spent with novel object; WT 24.19 ± 6.71; Mecp2+/T158M  
3.12± 8.24; Mecp2+/- -2.12 ± 14.11; **** = P<0.0001; Figure 3.15). 
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Figure 3.15 Discrimination index of learning and cognition baseline in novel 
object recognition test in WT, Mecp2+/-, Mecp2+/T158M female mice in 15 
minutes. Column plot shows group average (mean ±SEM) for the proportion of 
spending time with the novel object comparing with the familiar object. WT 
(n=13), Mecp2+/-(n=15) and Mecp2+/T158M (n=15). Statistical test results: One-way 
ANOVA test, F (2, 40) = 24.74, p<0.0001, Tukey’s post hoc comparison**** = 
p<0.0001 (WT vs Mecp2-/y ang Mecp2-/y vs Mecp2T158M/y). 
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3.4.4.3 Rotarod test 
To further study the motor functions and balance in female RTT mice, the 
rotarod test was used.  
The results clearly show that both the Mecp2+/- and Mecp2+/T158M lines displayed 
a phenotype. Time on the rod of Mecp2+/- and Mecp2+/T158M mice was significantly 
lower than the WT (Time on the rod; WT 243.07.25 ± 48.78 sec; Mecp2+/T158M 
129.46 ± 56.59 sec; Mecp2+/- 116.67 ± 37.03 sec; **** = P<0.0001; Figure 3.16). 
The mutant groups were not significantly different from each other. 
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Figure 3.16 Motor deficit test of WT, Mecp2+/-, Mecp2+/T158M female mice using 
rotarod machine. Column plot showing average group values (mean ±SEM) of 
duration on a rod. WT (n=13), Mecp2+/-(n=15) and Mecp2+/T158M (n=15). Statistical 
test results: One-way ANOVA test, F (2, 40) = 30.44, p<0.0001 Tukey’s post hoc 
comparison :**** = p<0.0001 (WT vs Mecp2-/y and Mecp2-/y vs Mecp2T158M/y). 
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3.4.4.4 Motor learning 
Motor learning skills were tested in females using the rotarod. Mice of all three 
genotypes, particularly WT mice, showed some ability to learn, with 
improvement between Day 1 and Day 3. (Average time on rod WT; day one 
224.85 ± 49.25 sec; day two 249.83 ± 54.72 sec; day three 254.52 ± 39.53 sec, 
Figure 3.17). Mecp2T158M/y also showed similar improvement (average time on rod 
Mecp2+/T158M; day one 117.96 ± 56.21 sec; day two 131.06 ± 62.46 sec; day three 
139.36 ± 52.48 sec Figure 3.17). Moreover, Mecp2+/- mice generate an 
improvement in their motor skills between day 1 and day 2. (average time on 
rod Mecp2+/-; day one 108.99 ± 36.81 sec; day two 121.1 ± 40.90 sec; day three 
119.91 ± 34.44 sec Figure 3.17) 
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Figure 3.17 Motor learning curve of WT, Mecp2+/-, Mecp2+/T158M female mice 
using rotarod machine over 3 days. Line plot showing average group values 
(mean ± SEM) of duration on a rod. WT (n=13), Mecp2+/- (n=15) and Mecp2+/T158M 
(n=15). Data presented as mean ± SEM. Statistical test results: General Linear 
model, F(2) = 27.919, P = <0.001; Paired Samples Test **** = P<0.0001 (WT Day1-
Day3 and Day1-Day3, KI Day1-Day2, and KO Day1-Day2), * = P<0.01 (WT Day1-
Day2)  
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3.4.4.5 Treadmill motor challenge test 
The other test for mobility in female mice was the treadmill motor challenge 
test. The result presented the same pattern as shown in the rotarod test. The 
Mecp2+/- and Mecp2+/T158M have a significantly lower level of exercise capacity 
from the WT (Time spent on treadmill; WT 857.45 ± 231.33 sec; Mecp2+/T158M 
341.08 ± 228.67 sec; Mecp2+/- 158.7 ± 70.79 sec; **** = P<0.0001; Figure 3.18). 
Although the results from the Mecp2+/- clearly show that most of them have a 
very low exercise capacity the results in the Mecp2+/T158M are more variable than 
those for the KO heterozygotes. Moreover, KO and KI heterozygous mice present 
more severe motor deficit compared with the male at the age tested. 
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Figure 3.18 Motor function and locomotion assessment in WT, Mecp2+/-, 
Mecp2+/T158M female mice. Plot showing the proportion of mice that were able 
to perform at an acceleration speed on treadmill. WT (n=11), Mecp2+/- (n=10) 
and Mecp2+/T158M (n=12). Data presented as mean ± SEM. Statistical test results: 
One-way ANOVA test, F (2, 30) = 36.54, p<0.0001. Tukey's post-hoc tests: **** = 
p<0.0001 (WT vs Mecp2-/y and Mecp2-/y vs Mecp2T158M/y)  
  
100 
 
3.4.4.6 Social interaction test 
To examine the social interaction of the female mice in the three-chamber 
arena, the percentage of the time the mouse spends with its cage-mate was 
compared to that spent with a WT female mouse that they had never seen 
before. The results show that the WT spent more time with the unfamiliar 
mouse than their cage-mate. (Time WT spent with stranger; Stranger 1 (familiar) 
39.95 ± 8.24 sec; Stranger 2 (unfamiliar) 60.04 ± 8.24 sec; *** = p<0.001; Figure 
3.19). 
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Figure 3.19 Social interaction test in WT, Mecp2+/-, Mecp2+/T158M female mice. 
Graph shows average group values (mean ± SEM) of time spent with their cage-
mate and unknown mouse. WT (n=13), Mecp2+/-(n=15) and Mecp2+/T158M (n=15); 
Statistical test results: Stratified t-tests were carried out for each genotype 
separately. For WT, t=6.211 DF=24, *** = p<0.001 in WT: Stranger 1 (Familiar) vs. 
WT: Stranger 2 (Unfamiliar); For both mutant lines, there was no significant 
difference in time spent with each stranger mouse.  
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3.4.4.7 Light-dark box test 
To examine anxiety levels, the time in the light chamber was analyzed in all 
groups. (Latency to enter the light area; WT 32.70 ± 30.98 sec; Mecp2+/T158M 
67.43 ± 112.57 sec; Mecp2+/- 104.76 ± 66.52 sec; Figure 3.20a). (Time spent in 
the dark; WT 381.89 ± 80.94 sec; Mecp2+/T158M 379.41 ± 137.11 sec; Mecp2+/- 
477.40 ± 57.83 sec; Figure 3.20b). 
 
L
a
te
n
c
y
 t
o
 l
ig
h
t 
(s
e
c
)
W ild  T yp e M ec p2
+ /-
M ec p2
+ /T 1 5 8M
0
1 0 0
2 0 0
3 0 0
4 0 0
5 0 0 N S
N S N S
 
T
im
e
 s
p
e
n
t 
in
 d
a
r
k
 a
r
e
a
 (
s
e
c
)
W ild  T yp e M e c p 2 + /- M ec p2
+ /T1 5 8 M
0
2 0 0
4 0 0
6 0 0
8 0 0 N S
N S N S
 
Figure 3.20 Exploration and anxiety related measures of the light-dark test in 
WT, Mecp2+/-, Mecp2+/T158M female mice. Column plot shows average group 
value (mean ± SEM) for the (a) latency to enter the light area and (b) time spent 
in dark area. WT (n=13), Mecp2+/-(n=10) and Mecp2+/T158M (n=15). Statistical test 
results: (a) One-way ANOVA test, F (2, 35) = 2.253, p=0.1201. (b) One-way 
ANOVA F (2, 35) = 3.253, p=0.0506.  
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3.4.4.8 Splash test 
To further analyze anxiety, the time mice spent grooming after splashing of the 
fur with a sugar solution was counted and recorded. Results showed that all 
groups spent up to 15 minutes grooming and cleaning. There were no significant 
differences between the groups in this test (Grooming count; WT 168.31 ± 66.56; 
Mecp2+/T158M 214.53 ± 60.12; Mecp2+/- 206.20 ± 47.07; Figure 3.21). 
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Figure 3.21 Anxiety assessment of WT, Mecp2+/-, Mecp2+/T158M female mice by 
splash test. Column plot shows average group values (mean ±SEM) for time 
grooming. WT (n=13), Mecp2+/-(n=10) and Mecp2+/T158M (n=15). Statistical test 
results:  One-way ANOVA test, F (2, 35) = 2.285, p=0.1168. 
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3.4.4.9 Breathing test 
Apneas and abnormal breathing patterns were investigated in the same way as 
for the male mice in the plethysmography chamber. The results showed that the 
Mecp2+/- mice presented a significantly higher number of apneas than the WT 
and Mecp2+/T158M mice. The KI mice presented fewer apneas but statistically, was 
not that different from the WT (Apneas; WT 0.00 ± 0.00; Mecp2+/T158M 0.34 ± 
0.54; Mecp2+/- 2.00 ± 2.79; ** = P<0.01; Figure 3.22). 
 
W T M ec p2
+ /-
M ec p2
+ /T 1 5 8M
0
2
4
6
8
1 0
A
p
n
o
e
a
s
 p
e
r
 m
in
u
te
N S
** *
 
Figure 3.22 Persistent breathing phenotype in WT, Mecp2+/-, Mecp2+/T158M 
female mice. Column plot shows average group values (mean ±SEM) for the 
breathing frequency. WT (n=13), Mecp2+/-(n=10) and Mecp2+/T158M (n=15). 
Statistical test results: One-way ANOVA test, F (2, 35) = 5.897, p=0.0062, 
Tukey’s post hoc comparison: * = p<0.05 (WT vs Mecp2T158M/y) and ** = p<0.01 
(WT vs Mecp2+/-).  
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3.5 Discussion 
Recently, RTT mouse models have been used widely in researching gene-based 
therapies (Gadalla et al., 2017; Garg et al., 2013; Matagne et al., 2017; Sinnett 
et al., 2017). The Mecp2 KO model models the situation in RTT in terms of loss 
of function of Mecp2 (Chen et al., 2001; Guy et al., 2001). The KO mouse has a 
severe phenotype including movement disability, breathing abnormalities and 
learning deficits. The new KI model models the human disease as closely as 
possible (Brown et al., 2016). In this study, I have investigated a range of 
behavioural phenotypes in these two models of RTT, comparing genotype effects 
on mobility performance, learning, cognition, social interaction, anxiety-like 
behavior and breathing tests in hemizygous male Mecp2-/y and Mecp2T158M/y mice 
and heterozygous female Mecp2+/- and Mecp2+/T158M mice with an aim to better 
characterise the RTT-related phenotype in the KO and T158M lines and identify 
the best line to use in order to evaluate the treatment for RTT symptoms in the 
future. 
After the creation of the Mecp2 KO mouse model in 2001(Chen et al., 2001; Guy 
et al., 2001), there have been numerous reports of studies using these models, 
e.g. (Gadalla et al., 2013; Matagne et al., 2013; Matagne et al., 2017; Robinson 
et al., 2012; Ross et al., 2016; Sztainberg et al., 2015). In addition to full KO 
mouse models, KI models of some of the most common human RTT mutations 
have also been developed (Brown et al., 2016; Goffin et al., 2012; Lyst et al., 
2013; Shahbazian et al., 2002). T158M is the most common missense mutation, 
its molecular consequence is to moderately reduce binding specificity for 
methylated DNA. Male hemizygous KI mice with this mutation present severe 
hypoactivity, gait impairment, weight loss and breathing irregularities from 
roughly 6 weeks of age and subsequently die between 12-14 weeks of age (Brown 
et al., 2016; Goffin et al., 2012) while showing a similar breathing pattern to 
that of the Mecp2 null mice. In comparison, female heterozygous Mecp2 T158M 
KI mice show minimal phenotypes with only minor tremor and hindlimb clasping 
detected, (Brown et al., 2016). However, when this mutation was modelled on a 
different genetic background, female Mecp2 T158M KI mice showed a reduction 
in bodyweight and breathing abnormalities which, at least in the females 
highlighted the effects of the background strain on the phenotype. It is clear 
that the absence of Mecp2 from the brain only leads to a severe phenotype, 
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resulting in early death in male KO mice, however, these studies have not 
carried out rigorous phenotyping and have instead relied on gross markers of 
disease such as reduced brain size and weight loss (Chen et al., 2001; Giacometti 
et al., 2007; Guy et al., 2001). 
In agreement with (Guy et al., 2001) and (Brown et al., 2016), phenotype 
severity assessment in my study shows that hemizygous MeCP2+/- and 
Mecp2T158M/y male mice present the RTT-like phenotype early and severely with 
onset at 6-8 weeks of age. Their mobility and body weight were also reduced 
when compared with the WT. The total phenotype scoring in KI were counted 
from gait abnormality and mobility disorders, while the total score of the KO 
includes the score from tremor and breathing abnormality alongside gait and 
mobility. Heterozygous Mecp2+/- and Mecp2+/T158M female mice, were 
symptomatic for the RTT-like phenotype, exhibiting reduced locomotion, gait 
abnormalities and an increase in body mass, which is also normally associated 
with the RTT-related phenotype in female mice. (Garg et al., 2013). The Mecp2 
T158M KI female model shows the same severity with the KO as observed by the 
aggregate severity score at the time point of 6-8 months old. 
However, comparison of survival between Mecp2-/y and Mecp2T158M/y male mice in 
this study and in more detail in Chapter 4 (section 4.4.1) showed that the 
lifespan of Mecp2T158M/y males was significantly longer. Reduction of binding 
capacity of the MeCP2 T158M mutant protein to heterochromatin implies that it 
is not a complete loss of function mutation (Lamonica et al., 2017). 
 
The major aspect of the RTT-like phenotype stems from mobility impairments. 
Many studies have observed movement patterns and mobility in the Mecp2 
mouse model in the open field test (Gadalla et al., 2013; Matagne et al., 2013; 
Matagne et al., 2017; Ross et al., 2016; Sztainberg et al., 2015), rotarod test 
(Matagne et al., 2017; Ross et al., 2016; Sztainberg et al., 2015), gait analysis 
(Gadalla et al., 2014; Ross et al., 2016), the balance beam (Ross et al., 2016), 
and exercise tolerance (Ross et al., 2016). All studies agree that the male KO is 
the most severe phenotype with regards to movement compared with that of the 
KI and WT. In addition to this, the (Lamonica et al., 2017) reports that the 
movement performance in females when comparing KI and KO indicates similar 
results. The general locomotion assessment was tested in a 15-minute-long, 
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open field test, without forcing the performance. Hemizygous male mice, Mecp2-
/y and Mecp2T158M/y demonstrated less movement than the WT. An idea to add in 
the mouse’s own bedding to ease adaptation was adopted. It was expected that 
this would encourage the mouse to move about more freely like it does in its 
own cage. This is supported by the previous report indicating that Mecp2-/y 
mobility is affected by the surface of the floor, not only due to intrinsic mobility 
impairment. (Orefice et al., 2016). The result of mobility in the mutant male 
mice showed that they moved better in the arena with the bedding than 
without. However, the overall result shows that the hemizygous male mice still 
spent less time moving than wild-type individuals. This result presents with the 
same trend as that of the female heterozygous mice. 
In addition, rotarod and treadmill tests were analyzed for motor deficits, 
showing that hemizygous male mice and heterozygous female mice 
demonstrated poor motor performance with weak co-ordination and balance on 
a rotarod and reduced exercise endurance on the treadmill. The performance of 
heterozygous females on the rod and on the treadmill was significantly different 
from the WT. However, although the mutant presents a lower motor ability than 
the WT, the Mecp2T158M/y and Mecp2+/T158M demonstrated that they had better 
performance than the Mecp2-/y and Mecp2+/- respectively. 
To evaluate motor learning skills, the rotarod test was administered over three 
consecutive days. Comparing with the previous study which used four 
consecutive days (Brown et al., 2016; Shiotsuki et al., 2010), the trend of the 
time on the rod between day one to day three showed improvement. The trend 
in my experiment only showed significant improvement in both male and female 
WT and slight improvement in female KI on day three. The learning curve can 
imply that the WT has better learning skills than both mutants. Results using 
males of each line agreed with findings of a previous study (Brown et al., 2016). 
This test is not suitable to see the differences between the mutant lines because 
there was limited learning over the three days, so it was not possible to 
demonstrate impairment of learning. 
It is possible that the reduction of activity might be a result of anxiety-like 
behavior since when its own bedding was scattered in the arena, all mutant mice 
appeared to be more active than they were without the bedding. However, the 
activity of the mutants was still significantly different to that of the WT. It was 
most likely due to either motor deficits or reduced motivation. 
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Non-anxiety-based reduction in exploratory activity has previously been reported 
in the Mecp2+/- mice (Guy et al., 2001) but the exact cause for such behavior has 
not been determined yet. Interestingly, observation results showed that the 
average speed of hemizygous Mecp2-/y and Mecp2T158M/y male mice individually 
with and without its own bedding was not that different from the speed 
exhibited by the wild-type mouse (not shown). This was also observed in the 
heterozygous Mecp2+/- and Mecp2+/T158M female mice. Therefore, it is possible 
that the reduction in mobility in Mecp2+/- and Mecp2+/T158M mice with and 
without bedding comes from an unwillingness to move rather than motor 
deficits. 
Motor performance and locomotion tests that we carried out did not provide 
evidence for any significant differences between the KO and KI models. Both 
phenotypes in hemizygous Mecp2-/y and Mecp2T158M/y male mice and heterozygous 
Mecp2+/- and Mecp2+/T158M female mice, suggest that differences in the 
genotypes’ specific effects are too subtle to be detected by such current tests. 
 
Another major aspect of the RTT like phenotype is breathing abnormalities  
which, in RTT mouse models, generally present as disturbed breathing patterns 
including apnoea and irregular breathing frequency (Ogier et al., 2007; Ramirez 
et al., 2013; Voituron et al., 2010) as can also be seen in human RTT patients 
(Neul et al., 2010). Global reactivation of Mecp2 expression in mice can reverse 
these issues and the breathing phenotype is therefore is a viable therapeutic 
target. Previous research reported that GABAergic and serotonergic control of 
the brain respiratory network is the main contributing factor to breathing and 
apnoea that characterise RTT in human patients and RTT mouse models (Abdala 
et al., 2010; Chao et al., 2010; Viemari et al., 2005; Voituron and Hilaire, 2011). 
In agreement with previous studies (Elian and Rudolf, 1991; Julu et al., 2001; 
Julu and Witt Engerström, 2005; Marcus et al., 1994; Weese-Mayer et al., 2008; 
Weese-Mayer et al., 2006) the male KO mouse presents the most severe case of 
breathing abnormality in terms of apnoea with some KI mice also presenting 
apnoea at around the age of 6-8 weeks. Most KO female mice at the age of 6-8 
months present apnoea, as do some of the KI also, in agreement with previous 
research (Lamonica et al., 2017). 
 
108 
 
Other RTT characteristics in humans are resistance to learning new things, 
restricted interests and social isolation (Schaevitz et al., 2010). These 
characteristics also appear in previous studies in hemizygous KO mice, 
heterozygous KO mice (Schaevitz et al., 2010; Stearns et al., 2007), 
Mecp2tm1.1Meg knock-in mice (Cohen et al., 2011) and Mecp2T158A knock-in mice 
(Goffin et al., 2012), previous studies of KO and KI RTT mouse models have 
presented this. Earlier studies on learning in the RTT mouse model have 
indicated an impact of motor and mobility deficits on learning and social 
interaction. However, including a mouse’s own bedding in the arena during the 
NOR test, gave more credible and more reliable memory test results and 
reduced the level of doubt about the effect of movement-related factors. My 
results demonstrate that learning in KO and KI in both males and females was 
very similar; however, when compared to the WT, their ability to learn was very 
poor, apart from male KI, who scored similarly to WT. The results I achieved are 
consistent with previous papers on the NOR test in the RTT mouse. 
 
In terms of the learning tests, I suggest including the motor learning test as a 
standard in evaluating both males and females as they indicate clearly the 
differences between WT, KO and KI. However, in male mice, there are learning 
ability differences between WT and RTT mouse models. 
 
Previous studies on the social interaction tests used the standard size of the 
three-chamber arena; however, to minimize any mobility issues, I used a half 
size of the arena from the standard reducing the distance to each stranger 
mouse. My results on KI and KO in both males and females are consistent with 
the reduction in social responsiveness reported in RTT and in RTT mouse studies 
carried out before. One study presents the KO preferring to interact with the 
stranger while the WT does not (Schaevitz et al., 2010) in contrast with my 
result and another report on the RTT mouse (Moretti et al., 2006) showing the 
RTT mouse model spending significantly more time away from the stranger. The 
different types of Mecp2 KI mice have differing genetics effect Mecp2 expression 
in the amygdala which, in turn, affects their learning levels and abilities 
(Gemelli et al., 2006; Moretti et al., 2005). This is clearly shown in the social 
interaction test in the three-chamber arena which is an ideal test to ascertain 
social abilities.  
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Likewise, anxiety analysis depends on the genetic background and experimental 
model. In my experiment, both light-dark box and splash test suggest that the 
KO and KI mouse do not have any anxiety. The result from light-dark test 
consistent with the other experiments in KO mice (Castro et al., 2014; Samaco 
et al., 2013). Many previous reports on anxiety in RTT mouse model required 
movement ability. The anxiety test using an open file where mice ambulate 
between the center of the arena and the edge of the field (more anxious 
behaviour), male Mecp2tm1Hzo mutants and heterozygous female Mecp2tm1.1Jae 
seem more anxious than wild types (De Filippis et al., 2010; Lonetti et al., 
2010). However, the result might be affected by the severe motor impairments 
of RTT mouse. Other anxiety studies using the elevated plus and zero mazes 
present that male Nulls and Mecp2tm1.1Joez mutants seem less anxious than wild 
types (Goffin et al., 2012; Kerr et al., 2012; Pelka et al., 2006; Stearns et al., 
2007). However, some studies have reported that male Mecp2tm1Hzo mutant mice 
display reduced anxiety compared to WT (De Filippis et al., 2010; McGill et al., 
2006). Those other studies did not add the home cage bedding. 
 
Furthermore, anxiety measures with a splash test do not require RTT mouse to 
ambulate. Thus, the splash test is the best test to examine anxiety in the mice 
because the outcome from this test is more accurate than other tests that 
require mobility from the mice.  
 
On concluding my experiment, my conclusion is that the current phenotype 
scoring system is not suitable for the RTT mouse due to the scale not fully 
representing the symptoms of the mice. For example, more levels of movement 
should be added, for example, movement after prodding the mice. This can be 
recognized in WT, which will stop moving but will immediately move again if 
they are prodded. On the other hand, the RTT mouse who present hypoactivity 
doesn’t move when it is gently encouraged to do so. A new better has now been 
developed and is in use in my lab group (Gadalla et al., unpublished). In 
addition, additional scoring levels need to be added to breathing levels, apnea 
and tremor in order to fully monitor the severity of the RTT phenotype. One 
surprising issue on finding a suitable object for the NOR is that some male KO 
mice that do not move at all in the open field test can move towards and climb 
onto the test object and then play with it. (I didn’t use that object on my NOR 
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experiment due to not wanting the mice to play with the object, only learn and 
recognize the familiar object). This indicates that some mice that do not move 
don’t in fact have impaired mobility. Both tests work for KO and KI lines. 
 
From the reliable result above, I suggest that the following tests be used to 
demonstrate improvement in mouse models of RTT open field with bedding to 
test for mobility, motor learning test on the rotarod to test for learning, 3-
chamber arena with reducing the arena size to test for social interaction and the 
splash test to test anxiety. 
 
In conclusion the male KO mice may still be the best line for screening the 
improvement of the phenotype after treatment as the phenotype exhibits a 
rapid progression and shows clear and significant differences from the WT.  I 
went on to use the KO for screening for vector optimization on the next chapter 
because it clearly indicates the onset and symptoms of RTT in KO and is reliable 
for screening for the best vector treatment. Some RTT-like symptoms are 
reversible (Guy et al., 2007; Lioy et al., 2011; Robinson et al., 2012) and RTT 
features most likely come from dysfunction of neurons rather than neuro 
degeneration (Guy et al., 2007). Then, the progression of the treatment on the 
KO can be clearly seen. 
In long-term studies, I suggest that the female heterozygous T158M be used to 
examine the result of treatments because the phenotype expressed in this line is 
milder than the KO female but still presents a significant difference from WT 
(Brown et al., 2016). 
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Chapter 4 Assessment of safety and efficacy of 
vector-derived MeCP2 on the progression of the 
RTT-like phenotype in a dose escalation study 
 
4.1 Introduction  
Previous studies indicate that RTT has the possibility of being treated, as I have 
highlighted above. The justification for this is firstly that RTT is caused by 
mutations in a single gene, MECP2, (Amir et al., 1999; Gadalla et al., 2011; Lyst 
and Bird, 2015); secondly, that features are due to dysfunction of neurons and 
supporting cells, rather than neural degeneration (Armstrong, 2002); thirdly, 
that there are several excellent mouse models in which many of the somatic, 
behavioural and physiological changes observed in individuals with RTT are 
reproduced; and finally, that phenotypic reversibility has been reported in 
mouse models following reactivation of Mecp2 (Guy et al., 2007; Lioy et al., 
2011; Robinson et al., 2012). 
 
Previous attempts at MECP2 gene transfer using AAV9 vectors were confounded 
by limited brain transduction efficiency and toxicity (Gadalla et al., 2013; 
Matagne et al., 2016), while efficacy in other studies using self-complementary 
AAV (scAAV) (Garg et al., 2013) may have been compromised by use of a 
construct exceeding the packaging capacity of the vector. 
To explore the relationship between vector dose and therapeutic benefits, 
Mecp2 KO mice were assigned into experimental cohorts. A dose escalation 
experiment was conducted using an scAAV2/9 vector (called 1st generation 
vector after this) and was used to deliver a Myc-tagged human MECP2_e1 cDNA 
under the control of a short, 229bp region of the murine Mecp2 endogenous core 
promoter (MeP229) (Gadalla et al., 2013; Gray et al., 2011a). 
 
The main purpose of the work described in this chapter was to address issues of 
vector dose and relate this to therapeutic efficacy, adverse effects and brain 
transduction and MeCP2 expression levels. For this, I focused on using our ‘first 
generation’ scAAV9/MeP229/MECP2 vector (a self-complementary AAV9 using a 
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229 base pair fragment of the endogenous Mecp2 promoter to drive expression of 
the human e1 isoform of MeCP2) delivered systemically via intravenous 
injection. 
 
4.2 Aims 
The overall aim of the work described in this chapter was to assess the 
importance of vector dosage for AAV9/MECP2 gene transfer in RTT. In particular, 
I wanted to assess the effective and safe limits of the 1st generation vector 
(scAAV9/MeP229/MECP2) in male mice modelling RTT.  
The specific objectives of this chapter are: 
(1) To investigate the effect of peripherally-delivered 
scAAV9/MeP229/MECP2 on RTT-like phenotypes in a dose-escalation 
experiment. 
(2) To identify potential adverse effects in response to dose escalation.  
(3) To investigate the relationship between phenotypic observations or 
toxicity and patterns and levels of MeCP2 expression in the brain and 
peripheral tissues. 
(4) To provide a baseline in terms of efficacy and safety against which next 
generation cassette designs can be assessed. 
(5) To investigate the efficiency and toxicity of 1st generation vector in 
MeCP2 knock-in mice that express endogenous mutant MeCP2 protein. 
 
4.3 Methods  
The vector I used in this chapter is the same vector that a member of staff in my 
lab group, Dr. Kamal Gadalla, reported previously (Gadalla et al., 2013).  This 
vector construct consists of human MECP2_e1 isoform coding sequences carrying 
a C-terminal Myc-tag fusion which was cloned into scAAV2 vector with backbone 
(to be packaged in AAV9 capsid particles) under the control of murine Mecp2 
endogenous core promoter (MeP, 229bp). This construct (scAAV9/MeP-hMECP2, 
henceforth referred to as scAAV9/MeP229/MECP2 or the 1st generation vector), 
is summarised in figure 4.1. 
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Figure 4.1 MECP2_e1/Myc fusion constructs were cloned into AAV2 backbones 
under a MeP promoter (LORRAINE - I have edited the diagram to delete ‘tail’ 
as the ‘PolyA’ referred to is the 3’-UTR and polyadenylation signal) 
 
To evaluate the efficiency of the 1st generation vector, hemizygous Mecp2-/y 
mice and their WT littermates were genotyped (see section 2.2.3) and then 
weighed and scored weekly for the RTT-like severity on mobility, gait 
abnormality, hind limb clasping, tremor, breathing and general condition using 
the standard phenotype scoring system (Guy et al., 2001; see section 2.2.5) to 
follow the condition of mouse closely throughout the experimental time. Mice 
that weighed more than 9 grams at the age of ~35 days were included in the 
experiment.  To globally administer viral vector, the male KO, KI and WT 
littlemate mice were carefully injected with the 1st generation vector at the 
following different doses: 1x1011, 1x1012 and 1x1013 vg/mouse (referred to 
henceforth as low dose, moderate dose and high dose, respectively) diluted in 
PBS in a total volume of 100 µl (see on section 2.5.1) through the tail vein using 
sterile technique (see on section 2.5.2.1). The control groups were the Mecp2-/y 
and WT littermates treated with PBS solution.  
 
The survival data was recorded when the mouse was found dead, lost more than 
20% of the peak bodyweight or lived for more than a year. In the last two cases, 
the mouse was euthanized humanely and brain, spinal cord and other tissues 
collected for immunohistochemistry (see section 2.6) to analyse expression 
patterns, transduction efficiency, and quantification of vector-derived MeCP2 
levels within cell nuclei. 
 
4.4 Results  
4.4.1 1st generation vector safety and efficacy at different doses 
by IV delivery in the Mecp2 KO mouse model of RTT 
Previous studies have demonstrated that a therapeutic dose can increase mouse 
survival (Gadalla et al., 2013; Matagne et al., 2013). However, in my 
experiments, the highest dose (1013 vg/mouse) showed lethality shortly after 
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treatment within 3-8 days after injection in KO Mecp2-/y mice (median survival = 
6.14 ± 0.23 weeks), as shown in Figure 4.2. Similarly, this dose was also 
associated with lethality in WT mice (median survival = 7.62 ± 0.21 weeks, n = 3; 
not shown). Contrastingly, vehicle treated WT showed 100% survival over the 
trial. On the other hand, KO Mecp2-/y mice treated with the moderate dose 
(1x1012 vg/mouse) showed significantly increased survival (median survival = 27.3 
± 6.93 weeks compared to the to the KO treated with vehicle (median survival = 
11.6 ± 4.09 weeks) while the low-dose (1011 vg/mouse) showed no survival 
advantages over the KO vehicle control (median survival = 9.36 ± 4.06 weeks. 
                    
 
Figure 4.2 Survival plot of Mecp2 KO mice treated with 3 different doses of 
scAAV9/MeP/MECP2. The plot shows the median survival of KO mice compared 
to the KO treated with vehicle (median survival 11.6 weeks), and with  
the low-dose (median survival = 9.36 weeks; p = 0.2, Mantel-Cox test, n = 9), 
moderate dose (median survival = 27.3 weeks, p = 0.001, Mantel-Cox test, n = 7) 
and high dose (median survival = 6.14 days, p= 0.004, , Mantel-Cox test , n = 5); 
mice given the high dose showed high mortality shortly after treatment. Arrow 
indicates age at injection. 
 
  
115 
 
I focus on the group receiving the moderate dose showing a mild increase in 
difference of bodyweight at 11 weeks (mean ± SEM bodyweight measured at 11 
weeks of age = 19.52 ± 3.8 g, Figure 4.3) compared to vehicle-treated mice 
(mean bodyweight = 13.93 ± 2.46 g). However, the average bodyweight of this 
group remained lower than WT controls (mean bodyweight = 25.24 ± 2.16 g).  
              
4 9 1 4 1 9 2 4
0
1 0
2 0
3 0
4 0
w
e
ig
h
t 
(g
)
 
Figure 4.3 Graph showing the average body weight of wild-type and Mecp2-/y 
treated with vehicle and Mecp2-/y treated with 1012 vg/mouse dose.  
WT treated with vehicle (n = 9) Mecp2-/y (treated with vehicle n = 10) and 
Mecp2-/y treated with 1012 vg/mouse dose (n = 7) Data presented as mean ± SEM. 
* means treated Mecp2-/y mice were significantly different from the vehicle 
control group at the age of 11 weeks. One-way ANOVA F (2, 33) = 35.51,  
p < 0.0001; Tukey’s post hoc comparison: ** = p<0.01 (Mecp2-/y injected with 
moderate dose vs Mecp2-/y injected with vehicle and WT injected with vehicle vs 
Mecp2-/y injected with moderate dose), ***** = p<0.0001 (WT injected with 
vehicle vs Mecp2-/y injected with vehicle). 
       
I then evaluated the performance of AAV-mediated gene delivery of MECP2 in 
improving/preventing the RTT-like phenotype. WT and KO mice were compared 
in terms of the standard observational scoring system (Guy et al., 2001; Lioy et 
al., 2011; Weng et al., 2011). The result showed that the vehicle-treated Mecp2-
null group developed the characteristic appearance of RTT-like signs from 4 
weeks, which then increased in severity over the following weeks as described 
WT injected with vehicle 
Mecp2-/y injected with moderate dose 
Mecp2-/y injected with vehicle 
* 
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previously. The group treated with the moderate dose of vector showed an 
identical phenotype trajectory indicating the absence of any treatment effect 
(mean aggregate severity score at 11 weeks in Mecp2-/y treated with 1012 
vg/mouse dose = 5.18 ± 0.96, Mecp2-/y treated with vehicle = 5.35 ± 1.14, and 
WT treated with vehicle = 0.83 ± 0.5).  
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Figure 4.4 RTT-like severity score of wild-type and Mecp2-/y treated with 
vehicle and Mecp2-/y treated with 1012 vg/mouse dose. WT treated with 
vehicle (n = 9) Mecp2-/y treated with vehicle (n = 8) and Mecp2-/y treated with 
1012 vg/mouse dose (n = 9). Data presented as mean ± SEM. One-way ANOVA  
F (2, 24) = 78.78, Tukey’s post hoc comparison: ***** = p<0.0001 (WT injected 
with vehicle vs Mecp2-/y injected with vehicle and WT injected with vehicle vs  
Mecp2-/y injected with moderate dose). * means treated Mecp2-/y mice were 
significantly different from the vehicle control group at the age of 11 weeks.  
 
From the data presented above, it is apparent that peripheral (IV) delivery of 
the first-generation vector at a tolerated dose of 1012 viral genome/mouse 
(1x1014vg/kg) resulted in enhanced survival, a modest effect on bodyweight, but 
no impact on RTT-like phenotypes based on observational scoring. Moreover, the 
cohort receiving the highest dose showed acute toxicity and lethality at 3-8 days 
post-injection. 
  
Mecp2-/y injected with vehicle 
Mecp2-/y injected with moderate dose 
WT injected with vehicle 
* 
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4.4.2 1st generation vector transduction efficiency and level of 
vector-derived MeCP2 in the brain in Mecp2 KO mice 
Patterns of transduction within CNS in treated Mecp2-/y mice were measured 
using anti-myc (detecting the tag on the vector-derived MeCP2), anti-MeCP2 (for 
total MeCP2), anti-NeuN (neuronal marker) and antibody immunofluorescence 
labelling (figure 4.5) to evaluate distribution and level of vector-derived MeCP2 
in different tissues.  
 
Figure 4.5 Flattened confocal stack images of the CA1 region of the 
hippocampus taken from Mecp2-/y mice treated intravenously with different 
doses of the 1st generation vector. (i) shows anti-Myc immunostaining, (ii) 
shows merge with DAPI nuclear stain, and (iii) shows merge with anti-NeuN stain. 
Arrows denote transduced cells.  
 
In addition, vector-derived MeCP2 protein expression distributed in a punctate 
pattern within the nuclei corresponding to previously observed results for 
endogenous MeCP2 in WT mice revealed very low levels of brain transduction. 
Samples from the low dose cohort revealed low transduction efficiencies across 
brain regions of 0.5 to 1% (Figure 4.6). The moderate dose resulted in ~3-5% 
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transduction efficiency, whereas the high dose reached significantly higher 
transduction efficiencies (~10-20% of cells).  
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Figure 4.6 Dose-dependent transduction efficiency (Mycpositive nuclei as a 
proportion of DAPI-positive nuclei) across different brain regions. Data is 
presented as mean ± SEM (n = 3 mice per group). CA1 indicates hippocampal 
region. Data presented as means ± SD. Two-way ANOVA F (6, 24) = 1.660,  
P = 0.1742; Tukey’s post hoc comparisons: * means p value is <0.05. ** means  
p value is <0.01. 
 
In order to measure cellular levels of vector-derived MeCP2 relative to native 
levels, WT mice were treated with the 1st generation vector. The low and 
moderate doses were tolerated and had no observable effect on bodyweight or 
the phenotype severity score (Figure 4.2). However, WT mice treated with the 
high dose exhibited the acute toxicity and rapid lethality observed in the 
knockout mice (Figure 4.2). This result agrees with quantification of cellular 
levels of MeCP2 in mice given this high dose, which revealed that transduced 
hippocampal pyramidal cells expressed vector-derived MeCP2 at a mean level 
equivalent to 120% of the endogenous level, which results in total cellular levels 
of MeCP2 just over two-fold higher than normal for these cells (Figure 4.7).   
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Figure 4.7 Intravenous injection of AAV9/hMECP2 into wild-type mice 
resulted in toxicity at the high dose. (a) Flattened confocal stack image taken 
from CA1 region of the hippocampus of wild type mice injected with the high 
dose. Tissues were immunostained with anti-Myc and anti-MeCP2 antibodies. 
Arrows indicate transduced cells whilst arrowheads indicate non transduced 
cells. (b) Relative quantity of cellular MeCP2 in the transduced cells 
(standardised to non-transduced cells) in the CA1 region of the hippocampus in 
wild type mice (N=2), data presented as means ± SD. 
 
4.4.3 1st generation vector transduction efficiency and level of 
vector-derived MeCP2 in the liver in Mecp2 KO mice 
To further investigate toxic effects encountered after systemic injection of the 
1st generation vector at high doses, levels of vector-derived MeCP2 expression 
were tested in a range of peripheral tissues. A bio-distribution estimate of the 
levels of vector genome in the liver was high (Figure 4.8).  
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Figure 4.8 Vector biodistribution analysis of mice injected intravenously with 
1012 vg/mouse showing high transduction efficiency in the liver and heart 
and low transduction efficiency in the CNS. Data are presented as mean ± SEM 
(n = 3 mice per group). 
 
Abnormal pathology was observed in liver (Figure 4.9B), caused presumably 
because endogenous MeCP2 levels are much lower in liver cells than in brain 
neurons (Ross et al., 2016; Skene et al., 2010). Issues are typically below 
detection threshold for immunohistochemistry using available antibodies. 
However, vector-derived MeCP2 levels in a subset of liver cells (using anti-Myc-
immunolabelling) of treated WT mice were found to be higher than MeCP2 levels 
seen in neurons (Figure 4.9b) and were thus around 20 times higher than levels 
found endogenously in such cells.  
 
 
121 
 
 
  
 
 
Figure 4.9 Intravenous injection of 1st generation vector resulted in high 
level of vector-derived MeCP2 expression in the liver. a) Representative 
confocal images of liver taken from WT mice injected intravenously with 1st 
generation vector at the dose of 1013 vg/mouse. Sections were immunostained 
with anti-Myc (green), anti-MeCP2 (red) and DAPI nuclear stain (blue). White 
arrows indicate transduced cells, whereas yellow arrows indicate non-transduced 
cells. Scale bars indicate 20 μm. B) Representative confocal images of liver 
taken from mice that were injected intravenously with 1x1013 vg/mouse using 
the same confocal settings. Arrows indicate nuclei with a high level of vector-
derived MeCP2 expression (based on fluorescence intensity of the anti-Myc 
antibody) and arrowheads indicate nuclei with low expression levels. Scale bar in 
(a) & (b) = 20 µm. 
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Histological investigation of liver sections from mice injected with vehicle or low 
dose of the vector showed largely normal liver structure with occasional areas of 
mononuclear infiltration (figure 4.10 a-b). In contrast, mice injected with higher 
doses of the vector showed a dose-dependent increase in pathological features 
including cellular destruction and vacuolation, loss of hepatocytes and 
mononuclear cell infiltration (figure 4.11 c-d).   
 
 
 
Figure 4.10 Toxicity issues revealed after systemic administration of high 
vector dosage. (a) mice treated with different doses of scAA9/MeP/MECP2 
vector (b)-(d) stained with H&E. Note disorganization of normal hepatocellular 
cord with swelling (circle), vacuolation and loss of hepatocytes (arrows). 
Mononuclear cell infiltration (thick blue arrow) is also evident.  
 
In summary, IV injection of 1st generation vector provides low efficiency of the 
transduction in the brain, whereas very high transduction in the liver. 
 
To assess whether the observed lethality and liver pathology was due to 
overexpression of the vector-derived MeCP2 or due to the vector. I tested the 
delivery of a high dose of AAV9 vector (1013 vg/mouse) but with a different 
cargo. For this I chose a GFP reporter construct using an identical promoter 
a b 
c d 
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(figure 4.11). The results revealed no noticeable effect on gross observations of 
the animals (no clinical signs or lethality over an 8-week period, n = 3 mice). 
When liver samples from mice dosed with the scAAV9/GFP were assessed by 
anti-GFP immunolabelling, results revealed widespread expression of GFP but, 
when viewed by hematoxylin and eosin labelling, showed the absence of any 
pathological markers observed in the MECP2 vector-treated mice (figure 4.12). 
These results suggest that the acute liver toxicity was indeed due to 
overexpression of vector-derived MeCP2 in liver cells, which ordinarily express 
very low levels of the native protein.  
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Figure 4.11 Diagram Showing AAV vector constructs (a) Construct of 
scAAV9/MeP229/GFP-SV40pA (control vector without MeCP2) (b) Construct of 1st 
generation vector  
  
  
 
Figure 4.12 Comparison of liver toxicity between 1st generation Mecp2 
vector treatment and the GFP vector treatment in Mecp2 KO mice injected 
with 1013 vg/mouse. Figure (a) and (b) show an overexpression of mecp2 and 
liver damage in mice treated by scAAV9/Mecp2 Figure (c) and (d) present no 
liver toxicity in liver sections in mice that were injected with a high dose of 
scAAV9/GFP. CV; central vein. 
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4.4.4 Effect of IV delivery of 1st generation vector on survival, 
bodyweight and phenotype severity score in Mecp2T158M/y mice 
From the above information, I concluded that the moderate dose (1x1012 
vg/mouse) is the only dose that led to some treatment benefits in Mecp2 KO 
mice. The next question was whether the presence of endogenous mutant MeCP2 
might reduce the therapeutic effect of vector-derived MeCP2. Male mice 
expressing native MeCP2 tagged with GFP as a fusion protein and harbouring the 
common RTT-causing p.T158M mutation, Mecp2T158M/y (Brown et al., 2016), 
display a phenotype very similar to that of Mecp2 KO mice (Figure 4.13 a-c) but 
with somewhat enhanced survival (median survival of 20.3 weeks in Mecp2T158M/y 
KI mice and 12.4 weeks in Mecp2 KO mice, p = 0.0016, Mantel-Cox test).  
 
Figure 4.13 The comparison between WT, KO and treated Mecp2T158M/y cohort 
in different parameter (a) Survival plot of Mecp2T158M/y treated mice compare 
with vehicle control (b) Graph showing bodyweight of Mecp2T158M/y mice treated 
with the vector and groups treated with the vehicle (Mecp2T158M/y and WT) mice. 
* means treated Mecp2-/y mice were significantly different from the vehicle 
control group at the age of 11 weeks. One-way ANOVA F (2, 33) = 41.16,  
p < 0.0001, Tukey’s post hoc comparison. * = p<0.05 (WT injected with vehicle vs 
Mecp2T158M/y injected with moderate dose), ***** = p<0.0001 (WT injected with 
vehicle vs Mecp2-/y injected with vehicle), ** = p<0.01 (Mecp2T158M/y injected with 
moderate dose vs Mecp2-/y injected with vehicle (c) Graph showing the mean 
aggregate severity between groups. Data presented as means ± SEM. At 11 weeks 
One-way ANOVA F (2, 25) = 19.24, p < 0.0001, Tukey’s post hoc comparison.  
** = p<0.05 (WT injected with vehicle vs Mecp2T158M/y injected with moderate 
dose), ***** = p<0.0001 (WT injected with vehicle vs Mecp2-/y injected with 
vehicle). 
Intravenous delivery of a moderate dose (1x1012 vg/mouse) of the 1st generation 
vector to 4-5-week-old Mecp2T158M/y mice resulted in significantly increased 
survival (figure 4.14a; median survival = 38.3 weeks in vector-treated mice vs 
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20.3 weeks in vehicle-treated mice; p = 0.0019, Mantel-Cox test, n = 8-15 per 
group). There was a modest increase in bodyweight in the vector-treated cohort 
(figure 4.14b; p < 0.05, one-way ANOVA using data at 20 weeks of age). 
However, there was no difference in the RTT-like aggregate severity score 
between groups (figure 4.14c), consistent with a low brain transduction 
efficiency (~ 2-4%) as revealed by anti-Myc labelling (not shown).  
 
 
 
Figure 4.14 Survival plot, bodyweight measurements and bodyweight 
measurements of WT and Mecp2T158M/y KI mice treated vehicle and 
Mecp2T158M/y KI mice treated with the moderate dose of 1st generation vector 
(a) Survival plot of Mecp2T158M/y treated mice (median survival 38.3 week) 
compared to the vehicle control (median survival 20.3 week). Red arrow 
indicates time of injection. One-way ANOVA F (2, 28) = 35.56, p < 0.0001, 
Tukey’s post hoc comparison. ** = p<0.01 (WT injected with vehicle vs 
Mecp2T158M/y injected with moderate dose and Mecp2T158M/y injected with 
moderate dose vs Mecp2T158M/y injected with vehicle), ***** = p<0.0001 (WT 
injected with vehicle vs Mecp2T158M/y injected with vehicle) ( (b) Graph showing 
bodyweight measurements of Mecp2T158M/y mice treated by AAV9/hMECP2 
vector and groups treated by vehicle (Mecp2T158M/y and wild-type) mice across 
the experimental time. One-way ANOVA F (2, 38) = 45.98, p < 0.0001, Tukey’s 
post hoc comparison. **** = p<0.0001 (WT injected with vehicle vs Mecp2T158M/y 
injected with moderate dose and WT injected with vehicle vs Mecp2T158M/y 
injected with vehicle) (c) Graph showing the average aggregated severity score 
of the RTT-like phenotype between groups. 
 
 
 
 
a c b 
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4.4.5 The expression of 1st generation vector in Mecp2T158M/y brain 
To explain the transduction efficiency of vector-derived MeCP2 in Mecp2T158M/y 
brain, the p.T158M mutation affects the chromatin binding capacity of MeCP2, 
leading to loss of the punctate element of MeCP2 labelling in the nucleus (Brown 
et al., 2016). Immunolabelling of hippocampal neurons from treated Mecp2T158M/y 
mice showed WT patterns of MeCP2 expression, with restored localization to 
DAPI bright spots (not shown), with a transduction efficiency of ∼2%–4%, as 
revealed by Myc-positive cells (figure 4.15). This is consistent with vector-
derived MeCP2 being able to localize normally to heterochromatin, despite the 
presence of mutant endogenous MeCP2 protein within the same nucleus.  
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Figure 4.15 Transduction efficiency in the brain of treated mice (Myc-positive 
nuclei as a proportion of DAPI-positive nuclei; n = 3 mice).  
 
4.5 Discussion 
 
Previous studies suggested the therapeutic strategies aiming to reduce RTT-like 
phenotypes in mice model of RTT, however, we still lack sufficient information 
about safety and effectiveness of cassette design and other variables including 
viral production, dosing protocol and phenotype measures. In my study, I used a 
vector previously designed by our lab group which mainly consists of the human 
MECP2_e1 gene and the MeP229 core promoter fragment  to generate more 
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information about the safety and efficiency based on dose effect and the 
toxicology that was reported before (Gadalla et al., 2013).  
 
The dose escalation results with AAV/MECP2 revealed a narrow therapeutic 
window following systemic administration. Moreover, the RTT-like phenotype 
severity score was not improved across the range of doses tested. This issue is 
not due to such phenotypes being inherently resistant to reversal of phenotypes 
(Guy et al., 2007; Robinson et al., 2012) but can be explained by the low levels 
of brain transduction afforded by IV administration in my study. 
 
In contrast, there was an effect of vector-derived MeCP2 on extending survival 
and increasing body weight at the moderate dose, shown at 11 weeks (the 
median survival time for the control vehicle treated Mecp2-/y mice).  
Survival rates did improve between the low dose group (1011 vg/mouse) and 
moderate dose group (1012 vg/mouse) without significant change in mean 
bodyweight (Figure 4.3). This indicates that the increase in survival and 
bodyweight is caused by either sufficient transduction level in critical brain 
regions, or maybe by expression in  sufficient cells of peripheral tissues relevant 
to mortality. This is in agreement with the recent study which suggests that the 
level of MeCP2 in peripheral organs can impact bodyweight (Ross et al., 2016). 
The possible explanation that this issue may indirectly effect the survival 
measure that I used, 20% bodyweight loss as an endpoint criterion. Another 
explanation is that I may have underestimated the transduction efficiency due to 
the sensitivity of the immunohistochemistry assay. However, the last hypothesis 
can be explained by the result of biodistribution validation using qPCR that I sent 
to confirm with another lab group, which confirmed that my result is correct. 
The highest virus dose leads to significantly greater transduction efficiency in 
the brain (10-20%) compared to moderate and low doses and would be expected 
to lead to greater survival. However, mice injected with this dose showed 
markedly reduced lifespan and presented with severe liver pathology and 
lethality. Usually the expression of MeCP2 is at a much lower level in liver cells 
compared to neurons (Ross et al., 2016). In this study, I also present the 
hepatotoxicity in the moderate and low dose. The 1st generation vector resulted 
in liver toxicity. 
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This issue, as confirmed by the experiment of delivery of a similar dose of only 
GFP tag vector to identify the reason for this toxicity that comes from vector 
backbone or excessive MeCP2 expression. So, the dose dependent liver pathology 
can likely be attributed to the overexpression of exogenous MeCP2. 
 
The previous RTT gene therapy studies (Gadalla et al., 2013; Garg et al., 2013; 
Matagne et al., 2017) used Mecp2 knockout mice to examine the result of 
improvement in terms of efficiency and toxicity of viral vector. In fact RTT 
patient cells contain mutant MeCP2 protein that might be active and be the 
cause of disturbance in the action of vector-derived MeCP2 by quasi-dominant 
negative action. In this study, although Mecp2T158M/y knock-in mice  (Brown et 
al., 2016; Gadalla et al., 2017) presents RTT-like scores in the same trend with 
Mecp2-/y, it also has prolonged survival. This shows that the mutant allele may 
produce MeCP2 with some remaining function. A notable finding is that AAV-
mediated systemic delivery of MECP2 to the knock-in line leads to a similar 
therapeutic effect as Mecp2-/y treated with the same vector. Accordingly, the 
conclusion seems to be that the mutant MeCP2 does not interfere with vector-
derived WT MeCP2. This conclusion indicates the potential of gene therapy in 
human patients with missense MECP2 mutations. 
 
These results from the delivery of the first-generation vector are very important 
in identifying the most suitable dose of the viral vector. We can look to use the 
1012 vg/mouse dose when optimising viral vectors in further experiments. 
However, this dose of the first generation viral vector is not therapeutic 
regarding phenotype. In the high-dose treated group, the result of transduction 
efficiency shows that the toxicity might involve the overexpression of MeCP2 in 
the liver and this could be a cause of hepatotoxicity. This result correlates with 
a previous paper that links AAV9 with hepatotoxicity (Gadalla et al., 2013). 
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Chapter 5 Development of a novel MECP2 
expression cassette with enhanced safety features 
5.1 Introduction 
In the previous chapter (Chapter 4), I found that relatively high doses of my  
1st generation vector were required in order to achieve therapeutically relevant 
levels of brain transduction after systemic delivery. This entailed the delivery of 
very high viral titers to the systemic circulation when the primary target for 
gene therapy in Rett syndrome is likely to be the nervous system (Ross et al., 
2016). Indeed, the high dose of the peripherally delivered vector was 
problematic and the mice treated in the high-dose group presented signs of 
hepatotoxicity and high mortality after IV delivery. According to the liver section 
examination, there is a relationship between overexpression of vector-derived 
MeCP2 in liver cells and liver cell damage. Peripheral genotoxicity is a known 
issue with gene therapy approaches (Gadalla et al., 2013; Matagne et al., 2017) 
and several strategies have been developed to mitigate against such effects 
(Gadalla et al., 2013) 
Recent studies reported new modifications to the expression cassette and capsid 
that were predicted to result in lower peripheral cellular expression levels and 
reduced liver tropism. This included the use of expression cassettes utilizing (1) 
an alternative, compact, and presumably weaker, JeT promoter (Tornøe et al., 
2002), (2) a short synthetic 3’-UTR and polyadenylation signal (SpA) which is 
predicted to general lower expression levels (Levitt et al., 1989), and (3) the 
original 1st generation expression cassette packaged in a scAAV9.47 capsid, 
which emerged from an in vivo screen for liver de-targeted capsid sequences 
relative to AAV9 (Karumuthil-Melethil et al., 2016; Pulicherla et al., 2011). In 
addition, my lab colleague, Dr Ralph Hector, designed a new modified cassette, 
hereafter referred to as the 426 vector, combining various aspects of 
endogenous and artificial MeCP2 expression controls. The 426 vector construct 
includes putative regulatory elements (RE) in the extended mMeP426 promoter 
and endogenous distal 3’-UTR (see figure 5.1 below). The extent of the mMeP229 
promoter (used in the 1st generation vector) is indicated by the dashed line. Two 
non-endogenous cytosine nucleotides precede the ATG start codon. The RDH1pA 
3’-UTR consists of several exogenous microRNA (miR) binding sites incorporated 
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as a ‘binding panel’ adjacent to a portion of the distal endogenous MECP2 3’-
UTR, including the distal polyadenylation signal and its accompanying regulatory 
elements.  
5.2 Study aims 
The main aim of the work described in this chapter was to find the most 
effective vector from a series of new cassette designs developed from 1st 
generation vector attempting to improve MeCP2 expression within the 
physiological limit, without producing overt overexpression-related liver toxicity 
and to improve RTT-like aggregate severity score. The specific objectives of this 
study were: 
• To assess the safety and effectiveness of new cassette design 
vectors on RTT-like phenotypes after systemic administration 
• To assess the effect of new cassette design vectors on cellular 
expression levels of MeCP2. 
• To improve the RTT-like aggregate severity score by increasing the 
proportion of MeCP2-expressing cells in the brain by direct 
cerebroventricular injection in neonatal mouse  
5.3 Methods 
In this chapter, I tested four new cassette design vectors developed from the 1st 
generation vector (chapter 4) aiming to reduce the toxicity from MeCP2 
overexpression. The vectors I used in this study are: 
1) scAAV9/JeT/MECP2 (JET) aiming to reduce the overexpression with a small 
synthetic promoter that is predicted to drive low expression (Figure 5.1a). 
2) scAAV9/SpA (SpA) aiming to reduce the overexpression using short synthetic 
polyA makes the mRNA unstable (Figure 5.1b). 
3) scAAV9.47/MECP2 (9.47) aiming to de-target to the liver and thereby 
potentially increasing the brain transduction by using the scAAV9.47 capsid 
which is selected for its relatively low transduction of liver cells (Figure 5.1c). 
4) scAAV9/MeP426 (MEP426) aiming to reduce overexpression using a longer 
segment of the endogenous mMecp2 promoter and exogenous microRNA (miR) 
binding sites in the 3’-UTR (Figure 5.1d). 
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To evaluate the efficiency of all vectors, I used the same method that I applied 
on the 1st generation vector (chapter 4), with the IV tail injection with moderate 
dose (1012 vg per mouse), and on the same line and age of mouse model (Mecp2 
KO male mice with their WT littermates), age of 4-5 weeks). I also recorded 
bodyweight and RTT-like aggregate severity score weekly and analysed the 
expression patterns, transduction efficiency, and quantification of vector-
derived MeCP2 levels in brain and spinal cord.  
a) 1st generation vector 
 
b) scAAV9/JeT/MECP2 
(JeT) 
 
 
c) scAAV9/sPA (SpA) 
 
d) scAAV9.47/MECP2 (9.47) 
 
 
 
e) scAAV9/MeP426 
(MEP426). 
 
 
 
 
Figure 5.1 Diagram showing AAV vector constructs of vectors a) 1st generation 
vector b-e) a range of modifications to the expression cassette and capsid 
modifying from the 1st generation vector b) a synthetic and presumably weaker 
promoter, JeT promoter c) a short synthetic polyadenylation (SpA) signal d) the 
original 1st generation vector packaged in a scAAV9.47 capsid, which emerged 
from an in vivo screen for liver de-targeted capsid sequences relative to AAV9. 
e) 2nd generation vector incorporating an extended Mecp2 promoter and 
additional 3′ UTR regulatory elements   
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5.4 Results 
5.4.1 The efficacy and safety of SpA, JeT and 9.47 vectors in the 
KO mouse model, dosing at 1012 vg/mouse by IV injection. 
Aiming to reduce the toxicity from MeCP2 overexpression occurring with the 1st 
generation vector, I tested three newly developed cassette design vectors that 
were predicted to result in lower cellular expression levels and/or reduce liver 
toxicity in Mecp2-/y KO mice. This included 1) JeT promoter vector, 2) short 
synthetic 3’-UTR/polyA signal (SpA) vector, and 3) the scAAV9.47 capsid.  
The result with the JeT promoter, short synthetic polyA and scAAV9.47 vectors 
shows significantly extended survival (median survival = 24.71 ± 9.99 weeks, 
32.53 ± 9.34, and 27.45 ± 9.49 weeks) compared to the KO treated with vehicle 
(median survival = 11.6 ± 4.09 weeks). However, there is not much difference 
from the result with the 1st generation vector. (Figure 5.2) 
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Figure 5.2 Survival of Mecp2 KO mice treated with SpA containing vector, 
vector utilising JeT, and vector utilising AAV9.47 capsid (a) Survival plot of 
Mecp2-/y mice treated with promoter compared to vehicle-treated Mecp2-/y mice. 
The plots show the median survival of KO mice compared to the KO treated with 
vehicle (median survival 11.6 weeks). The red arrow indicates the time of 
injection. (b) Column plot showing the mean survival of Mecp2-/y mice treated 
with promoter compared to vehicle-treated Mecp2-/y mice. Data presented as 
mean ± SEM. One-way ANOVA F (2, 33) = 35.51, p < 0.0001, Tukey’s multiple 
comparison tests; ** = p<0.01  
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There is the same trend in body weight measurement for Mecp2-/y mice treated 
with the JeT promoter, short synthetic polyA and scAAV9.47. The result shows 
significant improvement on body weight measurement (body weight in JeT 
promoter group = 20.84 ± 1.11 g, SpA group = 20.84 ± 1.11g, and 9.47 group = 
20.84 ± 1.11g, respectively) at 11 weeks of age compared to the KO treated with 
vehicle (median survival = 15.62 ± 3.40 g weeks). However, the average body 
weight of all Mecp2-/y treated group continued lower than WT controls (mean 
body weight = 25.24 ± 2.16 g). Figure 5.3 
5 1 0 1 5 2 0 2 5 3 0 3 5
0
1 0
2 0
3 0
4 0
A g e  (w e e k s )
A
v
e
r
a
g
e
 b
o
d
y
 w
e
ig
h
t 
(g
m
)
 
W
T
 v
e
h
ic
le
M
e
c
p
2
- /
y  v
e
h
ic
le
 
J
e
t  
p
ro
m
te
r
s
p
A
9
.4
7
 c
a
p
s
id
0
1 0
2 0
3 0
n s
**
B
o
d
y
 w
e
ig
h
t 
(g
m
)
 
Figure 5.3 Body weight measurement of Mecp2 KO mice treated with SpA 
containing vector, vector utilising JeT, and vector utilising AAV9.47 capsid. 
(a) bodyweight measurements across the experimental time and (b)body weight 
comparison at 11 weeks old. Data presented as mean ± SEM. Statistical test 
results: ANOVA test, F (5, 49) = 19.64, p < 0.0001 , Tukey post hoc comparison 
test; ** = p-value < 0.01, between Mecp2-/y treated with and Mecp2-/y treated 
with each viral vector) 
In contrast, treatment of Mecp2-/y mice with new cassette vectors had no impact 
on the RTT-like phenotype severity score at the age of 11 weeks. The mean 
aggregated severity score in Mecp2-/y treated with JET = 6.66 ± 0.81, Mecp2-/y 
treated with SpA = 6.71 ± 1.11, Mecp2-/y treated with 9.47 = 6.42 ± 0.97,  
Mecp2-/y treated with vehicle = 5.35 ± 1.14, and WT treated with vehicle = 0.83 
± 0.5. Figure 5.4.  
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These results are summarized in Figure 5.5; although the new modification 
vector showed the improvement from the vehicle-treated group, none of them 
resulted in any improvement from the 1st generation vector (Figure 5.5).  
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Figure 5.4 of Rett-like phenotype severity score of Mecp2 KO mice treated 
with SpA containing vector, vector utilising JeT, and vector utilising AAV9.47 
capsid. Graph showing the progress of Rett-like phenotype severity score in (a) 
all new cassette design compare to control groups(b) JET group compared to 
control groups, and (c) SpA group compared to control groups, and (d) 9.47 
group compared to control groups across the experimental. #. # Means end of 
experiments at 11 weeks. Statistical test results: ANOVA test, F (5, 48) = 48.87,  
p < 0.0001. Tukey post hoc comparison test; ** = p-value < 0.01, between WT and 
all Mecp2-/y treated in every groups. 
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Figure 5.5 summary of Novel vector design features and efficacy. (a) A 
summary of the design differences for three of the novel vectors described in 
the text. (b) Efficacy of these three novel vectors after intravenous injection of 
1x1012 vg/mouse to 4-5 weeks old Mecp2-/y mice, , expressed as increase in 
median survival relative to the vehicle controls (left; compared using Mantel-Cox 
test) and mean body weight at the age of 11 weeks (right) relative to the vehicle 
controls (one-way ANOVA with Tukey’s post-hoc pairwise comparisons); * p < 
0.05, ** p < 0.01, *** p < 0.001. 
 
In relation to the liver toxicity that occurred in Mecp2-/y mice injected with the 
1st generation vector, the result of histological investigations of liver sections in 
JeT, SpA and 9.47 treated groups (3 mice in each group) also revealed 
vacuolation of hepatocytes (Figure5.6). This result confirmed that these 
modified vectors cause the development of liver pathology and were unable to 
reduce the toxicity as had been predicted. 
 
Figure 5.6 Comparison of liver toxicity between 1st generation vector 
treatment and the novel vectors treatment (1012 vg/mouse; for 30 days ) in 
WT mice aged 35 days). Representative liver sections from mice injected with 
JeT, 9.47 or SpA vectors. Arrows indicate examples of vacuolation of 
hepatocytes that were not seen in vehicle-treated samples; scale bar indicates 
20 μm. CV; central vein 
CV 
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5.4.2  Development of a Second-Generation Vector that Reduced 
Liver Toxicity after Systemic Administration 
In order to reduce toxic levels of exogenous MeCP2 expression and liver tropism, 
the knowledge about the relationship between Mecp2 expression in transduction 
cells and the vector backbone, which were obtained from my experiment in the 
1st generation vector and the novel cassette vector in Mecp2 KO mice were used 
to modify the second-generation vector (426 vector).  
This 2nd generation vector was designed by my lab college, Dr Ralph Hector, 
based on two main modifications of the vector backbone both aiming to control 
the endogenous vector-derived MeCP2 level in transduced cells. The first 
modification is an extension of an endogenous Mecp2 core promoter fragment 
(MeP229) using in the 1st generation vector which had been shown largely to 
recapitulate the endogenous tissue-level pattern of MeCP2 expression (Gray et 
al., 2011a). The previous study (Gadalla et al., 2013) and my study showed that 
this core promoter fragment is missing a number of predicted upstream 
regulatory elements that may be important in cell-type-specific regulation of 
MeCP2 expression. (Adachi et al., 2005; Liu and Francke, 2006; Liyanage et al., 
2013; Lyst et al., 2013). Figure 5.7. In addition to the extended promoter, 
another modification of a novel 3′ UTR, consisting of a fragment of the 
endogenous MECP2 3′ UTR and a selected panel of binding sites for microRNAs 
(miRNAs) known to be involved in regulation of Mecp2 (Feng et al., 2014; Jovicic 
et al., 2013; Klein et al., 2007) (Figure5.7). These elements were incorporated 
into the second-generation cassette design to build in as many intrinsic 
regulatory elements as possible. 
To test the therapeutic efficacy of the 2nd generation vector, a moderate dose 
(1x1012 vg/mouse) was delivered intravenously into 4-5-week-old Mecp2-/y mice 
via tail vein injection as I applied to the previous experiment. There was a 
significant extension of survival in the vector-treated mice compared to the 
vehicle-treated mice (median survival = 29.9 ± 9.00 weeks and 11.6 ± 4.09 
weeks, respectively; p < 0.0001, Mantel-Cox, Figure 5.8a). There was also a 
significant improvement in body weight at the age of 11 weeks (426 group BW = 
21.72 ± 3.34 kg; vehicle-treated group = 13.93 ± 2.46 kg; p < 0.05, one-way 
ANOVA, with Tukey’s post-hoc pairwise comparison test, Figure 5.8b). In 
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contrast, there was no effect on RTT-like aggregate severity score (Figure 5.8c). 
Mean aggregated severity score in Mecp2-/y treated with 2nd generation, Mecp2-/y 
treated with 1st generation, Mecp2-/y treated with vehicle, and WT treated with 
vehicle are 5.11 ± 1.26, 5.18 ± 0.96, 5.35 ± 1.14, and = 0.83 ± 0.5, respectively). 
The 426-vector thus showed no therapeutic advantages over the 1st generation 
vector after systemic delivery (Figure 5.8a-c) in terms of extending survival or 
improving the Rett-phenotypic score.  
 
Figure 5.7 Design of the 2nd generation vector construct. Putative regulatory 
elements (RE) in the extended mMeP426 promoter and endogenous distal 3’-UTR 
are indicated. The extent of the mMeP229 promoter (used in the 1st generation 
vector) is indicated by the dashed line. Two non-endogenous cytosine 
nucleotides precede the ATG start codon. The RDH1pA 3’-UTR consists of several 
exogenous microRNA (miR) binding sites incorporated as a ‘binding panel’ 
adjacent to a portion of the distal endogenous MECP2 polyadenylation signal and 
its accompanying regulatory elements. References with an asterisk indicate 
human in vitro studies, not rodent studies. 
 
 
In addition, to compare of liver safety from exogenous endogenous vector-
derived MeCP2 overexpression between 2nd generation vector and the 1st 
generation vector regarding liver safety, three 35-day-old male WT mice were 
injected intravenously with either 2nd generation vector and the 1st generation 
vector at a dose of 1x1012 vg/mouse and were sacrificed after 30 days. The liver 
tissues were examined for vector-derived MeCP2 expression (using anti-Myc tag 
antibody) and signs of liver pathology (Figure 5.9). There was no significant 
difference in transduction efficiency between vector constructs (Figure 5.9b), 
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but cellular levels of vector-derived MeCP2 (anti-Myc) in mice treated with 1st 
generation vector were significantly higher than those in mice treated with 426-
vector (figure 5.9c; p < 0.001, unpaired t-test). Analysis of the distribution of 
cellular MeCP2 expression levels in transduced cells showed that MeCP2 
expression is higher in mice injected with the first-generation vector (with fewer 
cells exhibiting very high expression levels) than the second-generation. We can 
conclude from this that second generation vector is capable of controlling the 
degree of MeCP2 overexpression better than the 1st generation vector.  
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Figure 5.8 Therapeutic Efficacy of Second-Generation Vector after Systemic 
Delivery to Mecp2−/y Mice. (a) Survival plot for Mecp2−/y mice treated 
intravenously with 1 × 1012 vg per mouse of the second-generation vector 
(median survival = 29.9 weeks) or an identical dose of first-generation vector 
(median survival = 27.1 weeks) or vehicle (median survival = 13.93 weeks). Arrow 
indicates age at injection. (b) Plots showing mean body weight. At 11 weeks, 
Statistical test results: ANOVA test, F (3, 41) = 21.95, p  < 0.0001 Tukey's post-hoc 
tests: * = P<0.05; between   Mecp2-/y injected with vehicle vs. Mecp2-/y injected 
with 426 (c) aggregate severity scores. Statistical test results: ANOVA test,  
F(3, 39) = 53.75, p  < 0.0001 Tukey's post-hoc tests: .**** = p-value < 0.0001, 
between WT and all Mecp2-/y treated in every groups. 
a 
c b 
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 Figure 5.9  Expression of vector-derived MeCP2 in the livers of mice treated 
with second-generation vector compared with first-generation vector (a) 
Flattened confocal stack images from livers of mice 1 month after being injected 
intravenously at 5 weeks of age with the second-generation vector or first-
generation vector at 1 × 1012 vg per mouse; confocal settings were the same in 
each case. Tissues were immunolabeled with anti-Myc and DAPI nuclear stain. 
Arrows indicate transduced cells (Myc-positive), and arrowheads indicate non-
transduced cells. Scale bar indicates 20 μm. (b) Transduction efficiencies in the 
liver for both vectors. Mann-whiney test p = 0.1000 (c) Quantification of cellular 
levels of vector-derived MeCP2 measured as anti-Myc immunofluorescence in 
transduced cells in the liver t-test t=12.29 df=4, p = 0.0003 (n = 3 mice, 1,400 
transduced cells). Data are presented as mean ± SEM. (d) Frequency distribution 
of cellular levels of vector-derived MeCP2 in the liver, measured as in (c).  
  
a 
c b d 
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To estimate the degree of toxicity in the liver, liver samples from three mice of 
each treated group were analysed for signs of liver pathology. There was none of 
the disrupted hepatic architecture or vacuolation previously observed with the 
1st generation vector (Figure 5.10a). The density of inflammatory foci was 
significantly higher in liver samples from mice injected with 1st generation 
vector than those injected with 426-vector (Figure 5.10b). 
 
 
 
 
Figure 5.10 Comparison of liver toxicity between 1st generation vector 
treatment and the novel vectors treatment (1012 vg/mouse; for 30 days ) in 
WT mice aged 35 days). (a) Representative liver sections showing vacuolation of 
hepatocytes (arrows) and sites of mononuclear cell infiltration (dashed circles). 
CV, central vein. White scale bar indicates 20 μm. (b) Reduced Expression of 
Vector-Derived MeCP2 in the Livers of Mice Treated with Second-Generation 
Vector Quantification of the density of inflammatory foci in the livers of treated 
mice (n = 3 per group). Data are presented as mean ± SEM. Statistical test 
results: (a) ANOVA test, F (2, 6) = 19.63, p =  0.0023. Tukey's post-hoc tests: 
* = p < 0.05; ** = p < 0.01; *** = p < 0.001; ns, no = t significant. 
 
a 
b 
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In summary, the 2nd generation vector seems to have a clearly beneficial effect 
of reducing liver toxicity while the brain transduction efficiency does not 
present a significant difference in RTT-like phenotype score compared with the 
1st generation vector.  
 
5.4.3 Neonatal Cerebroventricular Injection of the Second-
Generation Vector Improved the RTT-like Aggregate Severity 
Score 
From the previous set of experiments delivered 2nd generation vector by 
systemic administration to young adult male mice, it is apparent that the 2nd 
generation 426 vector demonstrate an improvement of the safety profile when 
compared to the original 229 construct. However, the 2nd generation vector still 
showed a relative lack of efficacy in relation to the RTT-like neurological 
phenotypes, consistent with the low brain transduction efficiencies observed in 
my study. This agrees with the previous study showed that phenotype severity 
and degree of improvement after gene restoration correlate with the proportion 
of MeCP2-re-expressing cells in the brain (Robinson et al., 2012). Thus, I decided 
to test the 2nd generation vector delivered by direct brain injection in neonatal 
male KO and WT mice (0-3 days postnatally) aiming to afford widespread 
transgene expression (Gadalla et al., 2013). The mice were delivered 2nd 
generation vector by cerebroventricular injection at a dose of 1x1011 vg/ mouse 
(see section 2.5.2.2). 
 
The results show that there was a pronounced enhancement of survival of  
Mecp2-/y mice treated with the 426-vector in comparison to vehicle-treated mice 
(median survival = 38.5 ± 11.39 and 12.4 ±c 5.37 weeks, respectively; p < 
0.0001, Mantel-Cox test, Figure 5.11a), while there was only a minor effect of 
vector on bodyweight. The mean bodyweight of Mecp2-/y mice treated with the 
426-vector at 11 weeks was 19.05 ± 1.85, while Mecp2-/y mice treated with 
vehicle had a mean bodyweight of 15.62 ± 3.40 kg. (Figure 5.11b). A more 
remarkable observation was the clear improvement in the RTT-like aggregate 
severity score in the 2nd generation vector treated group (RTT-like aggregate 
severity score at 11 weeks = 2.07 ± 2.01) compared to vehicle-treated Mecp2-
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null mice (RTT-like aggregate severity score at 11 weeks = 6.17 ± 1.23) (p < 0.01 
at 11 weeks, one-way ANOVA, with Tukey post hoc pairwise comparison) (Figure 
5.11c). However, some WT treated with the 2nd generation vector found 
unexpected adverse effect showed as a mild hind-limb abnormality phenotype. 
(RTT-like aggregate severity score at 11 weeks = 1.87 ± 1.80) 
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Figure 5.11 Survival plot, bodyweight measurements and bodyweight 
measurements of Mecp2-/y and WT neonatal mice treated with the 426-vector 
1x1011 vg/ mouse and Mecp2-/y and WT mice treated with vehicle by direct 
brain injection.  
(a) Survival plot showing extended survival of neonatally treated Mecp2−/y mice 
(median survival = 38.6 weeks; p < 0.0001, Mantel-Cox test) compared with 
vehicle-treated animals (median survival = 12.4 weeks). (b and c) Plots showing 
mean (b) body weight. Statistical test results at 6 weeks: ANOVA test, F (3, 46) = 
38.57, p < 0.0001. Tukey's post-hoc tests: ** = P<0.01 between Mecp2−/y mice 
treated with vehicle and Mecp2−/y mice treated with 426 vector (c) aggregate 
severity scores. Statistical test results at 6 weeks: ANOVA test, F (3, 43) = 38.24, 
p < 0.0001. Tukey's post-hoc tests: ** = P<0.01 between Mecp2−/y mice treated 
with vehicle and Mecp2−/y mice treated with 426 vector. Tukey's post-hoc tests: 
**** = P<0.001 between WT and Mecp2−/y mice) 
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To confirm that the improvement of the survival and RTT-like phenotype in 
Mecp2-/y mice treated with the 426-vector may involve an increase of the 
proportion of MeCP2-expressing cells in the brain, brain tissue from three mouse 
in each group were analyzed for Vector-derived MeCP2 (revealed by anti-Myc tag 
immunolabelling). The result showed that the vector-derived MeCP2 was 
detectable in all brain regions, with transduction efficiencies across brain 
regions ranging from ~10-40% (Figure 5.12).  
 
   
Figure 5.12 Direct Brain Delivery of Second-Generation Vector to Neonatal 
Mecp2−/y Mice Revealed Therapeutic Efficacy Representative confocal images 
from the cortex of injected wild-type mice. White arrows indicate transduced 
cells; arrowheads indicate non-transduced cells; scale bars indicate 20 μm. 
 
 
Moreover, the distribution analysis revealed that the modal cellular MeCP2 level 
in transduced cells in cortex was approx. twice that of endogenous MeCP2 
(consistent with an exogenous expression level equal to the endogenous level), 
with some cells expressing higher levels of exogenous MeCP2 (Figure 5.13). 
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Figure 5.13 Distribution analysis of 2nd generation vector delivered MeCP2 in 
mouse brain by direct brain injection method. (a) Graph showing transduction 
efficiency in different brain regions (n = 3 mice). Statistical test results: ANOVA 
test, F (3, 43) = 38.24, p = < 0.0001. Tukey's post-hoc tests: **** = P<0.0001 
(Striatum vs. Cortex,   Striatum vs. Thalamus,   Cortex vs. Brainstem, and   
Thalamus vs. Brainstem), *** = P<0.001 (Striatum vs. CA1), ** = P<0.01 (CA1 vs. 
Thalamus, CA1 vs. Brainstem), * = P<0.05 (Cortex vs. CA1) (b) Frequency 
distribution of MeCP2 levels in transduced and non-transduced (“native”) cells in 
the mouse cortex (n = 3 mice; 954 transduced cells) data presented as mean ± 
SEM. 
 
5.4 Discussion 
The monogenicity of RTT and the demonstrated reversibly of the RTT-like 
phenotype after delayed activation of silent Mecp2 in mice (Robinson et al., 
2012) suggest gene therapy as a potential avenue to treat RTT. Several attempts 
have been conducted at the preclinical level to deliver MECP2 exogenously in 
RTT-mouse models (Gadalla et al., 2013; Matagne et al., 2013; Matagne et al., 
2017), they showed promising outcomes either when MECP2 was delivered 
intracranially to mouse neonates (Gadalla et al., 2013) or intravenously to young 
adult and adult mice (Gadalla et al., 2013; Garg et al., 2013; Matagne et al., 
2017). However, the differences in vector design and dosage adopted in both 
experiments highlight the importance of conducting dose escalation and vector 
comparison studies to determine the most efficacious/safe vector to move 
forward to testing in higher primates and eventually in clinical trials. 
In this chapter, a first attempt to reduce toxic MeCP2 expression and liver 
pathology involved construction of the expression cassette and capsid. However, 
vector modifications to reduce liver transduction and hence toxicity through 
using putative weaker synthetic promoters and polyadenylation signals was not 
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sufficient to avoid liver toxicity and AAV9.47 capsid that was shown to de-target 
the liver relative to AAV9 (Karumuthil-Melethil et al., 2016; Pulicherla et al., 
2011), showed no advantage over AAV9 in terms of liver pathology. The mice 
that were treated with 9.47 vector also present vacuolation of hepatocytes as 
well as mice that were treated with the 1st generation at the same dose. This 
proved to be contrary to my predictions of no toxicity.  
Consequently, I focused my efforts on the second-generation vector which 
includes endogenous regulatory elements that may better regulate vector-
derived MeCP2 levels in transduced cells. This included the incorporation of both 
an extended endogenous promoter and an endogenous 3′-UTR fragment.  
Our 426 extended promoter is based on several studies which assessed the well-
conserved human MECP2 and mouse Mecp2 promoter regions and identified the 
presence of some putative regulatory elements within a 1-kb window 
immediately upstream of the transcription start site (Adachi et al., 2005; Liu and 
Francke, 2006; Liyanage et al., 2013). Subsequently, the extended endogenous 
promoter (426 bp) in the 2nd generation vector included a putative silencer 
element at position −274 to −335 relative to the RefSeq transcription start site 
(Figure 5.8). 
The significantly reduced MeCP2 expression in the liver, with subsequent 
reduction of the hepatotoxicity encountered with the 1st generation vector, also 
presumably involved the regulatory site combination deployed in the 3’-UTR, 
which contained a non-consensus distal MECP2 polyadenylation signal (TATAAA), 
as well as a number of clustered putative 3’UTR regulatory elements  (Bagga and 
D'Antonio, 2013; Coy et al., 1999; Newnham et al., 2010) and a number of miRNA 
binding sites (predicted using bioinformatic tools; Lewis et al., 2005; 
Rehmsmeier et al., 2004; Vorozheykin and Titov, 2015) for three highly 
conserved miRNAs known to be involved in regulation of MeCP2 in the brain and 
liver; miR-22,(Feng et al., 2014) miR-19, (Jovičić et al., 2013) and miR-132 (Klein 
et al., 2007). As predicted, these regulatory elements, combined, decreased the 
expression of MeCP2 in the liver. The relative importance of different 
modifications (elements within the extended promoter and novel 3′-UTR) was 
not investigated. However, the efficacy of 1st generation vector and 426-vector 
2nd generation vector after IV tail injection of 1012 vg per mouse was not 
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significantly different. The RTT-like severity score in both 1st and 2nd generation 
groups was the same as the vehicle group.  The most important finding with the 
426-vector, therefore, is the lack of prominent liver pathology at a dose where 
this was observed with other cassette designs. The possible reason for this 
improvement after systemic injection, despite low brain transduction efficiency, 
could be to do with the restoration of MeCP2 levels in sufficiently numerous 
critical cells in the brain (for instance the brainstem) or to restoration in critical 
peripheral tissues. One of the previous studies in peripheral Mecp2 KO mice 
reported that the expression of MeCP2 in peripheral organs involved the increase 
of survival and body weight (Ross et al., 2016). In my study, I also looked at 
heart and kidney, but the expression was not as high as in the liver. I decided to 
focus on the liver. To explain the increase in survival and body weight in my 
experiment, perhaps the 2% brain transduction may be enough to enhance 
survival and body weight if it happens to hit the most important cell type. Direct 
brain injection in neonatal mouse, along with potentially more significant impact 
via earlier intervention, benefit to target more cells in the brain as shown in the 
previous study (Gadalla et al., 2013) at dose 4.8 x 1010. In my study I used (1 × 
1011 vg per mouse) approximately equivalent to the 1012 systemic treatment dose 
and led to pronounced survival enhancement. Direct brain injection in neonatal 
mice was associated with an improvement in body weight but, importantly, also 
with an improvement in RTT-like phenotype score after 6 weeks. This 
improvement from the direct brain injection at 1011 vg/mice (5µl per 
hemisphere) was not as complete as that reported in genetic reversal 
experiments, (Robinson et al., 2012) and this is likely to be caused by the 
combined effects of (1) the percentage of  relative inefficiency of MeCP2 re-
expression across the brain (10%–40%), compared to genetic reversal experiments 
(up to 90%), and (2) the possible deleterious counteracting effects of 
overexpressing MeCP2 in a proportion of transduced cells. A significant pool of 
cells overexpressing MeCP2 were apparently transduced with multiple copies of 
vector delivering MECP2. This may also account for the slightly elevated severity 
score in vector-treated WT mice (Figure 5.11c) in the form of mild hindlimb 
clasping. I cannot rule out very subtle consequences of MeCP2 overexpression 
that may be revealed by fine-grained behavioral testing. Overall, the proof-of-
concept experiments involving direct brain delivery in neonatal mice suggest 
that, if transduction efficiency across the brain can reach sufficiently high 
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levels, then a behavioral improvement is conferred by this vector design. For 
example, direct injection into CFS. 
The next step is to prove that the 2nd generation vector is effective and suitable 
for long-term use. I observed as a pilot study in 6-8 months heterozygous KI 
female mice injected directly into the brain with dose 1011 vg/mouse. However, 
some mice in the viral treated group presented severe eye lesions and I had to 
halt the experiment. The lesions were likely to result from the effect of the viral 
vector, however further experimentation is required as I was unable to fully 
clarify the cause of the eye lesions. Future experiments must be aware of this 
adverse effect from the brain injection.  
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Chapter 6 General discussion 
The principal aim of this thesis was to investigate the therapeutic potential of 
delivering an MECP2 exogenously, via a viral vector, to a mouse model of Rett 
syndrome. It was anticipated that such a study would provide fundamental 
information about the pattern and levels of exogenous MeCP2 expression and 
give an insight into the vector and promoter combinations most capable of 
delivering therapeutic benefits. This study was further extended to investigate 
the effect of both global and brain-specific delivery of MECP2, via an AAV2/9-
based vector system, on the prevention/improvement of the RTT-like phenotype 
in a mouse model of Rett syndrome. This chapter will integrate the major 
findings and significant discoveries of this thesis and will evaluate the 
importance of these findings in relation to gene therapy and neuroscience 
research, and, to the evolving field of recent gene therapy in RTT. In addition, I 
will discuss the technical difficulties experienced during this work, the 
limitations of the methodology, and suggest possible ways to overcome these 
limitations. Finally, I will discuss possible future experiments to extend this work 
and derive the maximum benefits from the results I obtained in this study. 
 
6.1 Major findings 
The major findings/discoveries reported in this thesis are as follows: 
1. Concerning the determination of the characteristic baseline RTT-like 
phenotypes in male and female mice of different genotypes in KO and KI lines:  
I. In male mice, the Mecp2 knockout mouse model differed significantly from 
their wild-type cage mates in terms of survival, body weight and a range of 
behavioural tests while, the T158M Mecp2 knock-in model presents with a 
milder phenotype compare with Mecp2 knockout model 
II. In female mice, the knockout and knock-in heterozygotes show the same 
severity of the RTT-like phenotype in the behavioural tests 
2. Concerning the behavioural testing of two RTT mouse models and 
modification of the tests to render them less sensitive to impaired mobility: 
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I.RTT mouse models motor ability showed improvement with the addition of 
their own bedding into the testing arena (distance moved in open field arena 
with bedding incresed around 60% in male knockout mice). 
II. Locomotor assessment in open field test demonstrated that male 
knockout mice had locomotor ability significantly lower than the knock-in 
and WT both in male and female, whereas the groups were affected to 
different degrees in the treadmill motor challenge test and rotarod test. 
III. In learning tests, the RTT mouse model didn’t present learning ability in 
the novel object recognition test, while there were some learning capability 
show on rotarod motor learning tests. 
IV. Reducing the size of the three-chamber arena in the social interaction 
test demonstrated that RTT mice did not engage preferentually with a 
stranger mouse, as is the case for WT mice. 
V. In both anxiety tests, the light-dark test and splash test, the RTT mouse 
models did not present anxiety. 
VI. The breathing test for apneas using the whole-body plethysmography 
apparatus presented significantly different levels of breathing abnormality in 
knockout and knock-in mice. 
3. Concerning systemic administration of first generation vector to Mecp2-/y 
mice:  
I. Dose escalation in first generation vector revealed a narrow therapeutic 
window following systemic administration. 
II. Systemic delivery of first-generation vector resulted in liver toxicity. 
4. Systemic administration of First-Generation Vector Improves Survival in 
Mecp2T158M/y Knock-in Mice. 
5. newer cassette design vectors scAAV9/JeT/MECP2, scAAV9/sPA (sPA), and 
scAAV9.47/MECP2 (9.47) are no better in terms of efficiency and toxicity than 
the first-generation vector. 
6. Development of a Second-Generation Vector that Reduced Liver Toxicity after 
Systemic Administration. 
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7. Neonatal Cerebroventricular Injection of the Second-Generation Vector 
Improved the RTT-like Aggregate Severity Score. 
6.1.1 Phenotypic characteristics and behavioural test results in 
the RTT mouse models. 
RTT mouse models have been generated by deletion of portions of Mecp2 (Chen 
et al., 2001; Guy et al., 2001; Shahbazian et al., 2002) or by knocking-in human 
mutations (Brown et al., 2016; Goffin et al., 2011; Lyst et al., 2013; Pitcher et 
al., 2015). Many of these models have been used for studying the principal 
features that characterize RTT in humans, although there are differences that 
reflect the phenotypic variability seen in patients (Archer et al., 2007; Ghosh et 
al., 2008; Leonard et al., 2017). Despite the severity of RTT-like phenotypes, 
genetic reactivation of silenced Mecp2 in conditional knockout mice resulted in a 
robust and enduring reversal of phenotypes on the targeting in pharmacological 
therapeutic action (Guy et al., 2007; Jugloff et al., 2008; Robinson et al., 2012). 
In this study the male KO mice present early onset and severe phenotypes 
agreeing with the previous literature in term of movement disability, gait 
abnormality breathing abnormality and weight loss (Chen et al., 2001; Guy et 
al., 2001; Shahbazian et al., 2002) comparing with the WT, although male T158M 
KI mice, modelling a common MECP2 missense mutation, show milder phenotype 
including hypoactivity, gait impairment, weight loss and breathing irregularities 
(Brown et al., 2016; Goffin et al., 2011; Lyst et al., 2013; Pitcher et al., 2015). 
However, the severity of RTT-like phenotypes, genetic reactivation of silenced 
Mecp2 in conditional knockout mice resulted in a robust and enduring reversal of 
phenotypes on the targeting in pharmacological therapeutic action (Guy et al., 
2007; Jugloff et al., 2008; Robinson et al., 2012). From this information, I 
suggest that hemizygous Mecp2 KO mice are a more suitable model to use for 
screening tests than hemizygous Mecp2 T158M KI mice, which present the RTT 
phenotype more mildly and gradually.  
In my study, mobility impairments were ameliorated by adding the mutant 
mouse’s own bedding in the testing arena. This finding partly agrees with the 
previous literature suggests that mobility is affected by the surface of the floor, 
not due to its own intrinsic mobility impairment (Orefice et al., 2016). The 
application with this information into some of my experiments, for example 
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light-dark anxiety test and novel object recognition test made my result robust 
that the main responsiveness does not interfere with the hypoactivity of the RTT 
mouse. In addition, adding extra time in an open-field test, tests of mobility 
function, benefit encounter more difference between mouse lines. While other 
groups study the mobility function in the open field test (Gadalla et al., 2013; 
Matagne et al., 2013; Matagne et al., 2017; Ross et al., 2016; Sztainberg et al., 
2015), rotarod test (Matagne et al., 2017; Ross et al., 2016; Sztainberg et al., 
2015) and gait analysis (Gadalla et al., 2014; Ross et al., 2016). My result 
presents that the Treadmill motor challenge test is the best test for detecting 
therapeutic actions in both male and female mouse in term of mobility, balance 
and locomotion function due to the clarity of the different degree presenting 
between Mecp2 mutant mice and WT.  
The other major aspect of the RTT-like phenotype in the mouse model is the 
learning retardation. I found that the result of motor learning on rotarod and 
novel object recognition test presents the significate difference between WT 
and KO agreeing with the previous study, but the result of the newer Mecp2 
T158M KI group is not a significant difference from other groups. I would like to 
test the learning in other experiment but there was a limited time on my PhD. 
The re-sized the three-chamber arena in my study presented the difference 
between the WT and the mutant in both males and females was indicated. The 
smaller arena can present the time of interaction and time of non-interaction 
much more clearly and make me result robust to presenting that my result and 
another report on the RTT mouse (Moretti et al., 2006) showing the RTT mouse 
model spending significantly more time away from the stranger. I also apply the 
splash test testing and anxiety in RTT mouse due to this test does not much 
more require the movement of the mouse. The result showed that all 
experimental mice had no anxiety as the same as the result in the standard 
anxiety test, light-dark test. (Castro et al., 2014; Samaco et al., 2013) 
 
6.1.2 Dose escalation with AAV/MECP2 revealed a narrow 
therapeutic window following systemic administration and 
resulted in liver toxicity 
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In order to explore the relationship between vector dose and therapeutic 
benefits, I examined the effectiveness of peripheral administration of the first-
generation vector first in three different doses. First, the low dose 1011 vg/kg in 
mouse, 4x10e12 vg/kg for human, had no therapeutic effectiveness. The result 
of survival severity score and body weight showed similarities to the control 
group. This is an unexpected result because Gadalla et al (2013) showed survival 
benefits after injecting the same dose. In addition, there was a low transduction 
efficiency after administration of a low dose of vector (less than 5% in the 
brain). Second, the result in post-administration of moderate dose, 1012 vg/kg in 
mouse, showed that only the body weight increased. Severity score showed little 
change from that of the control group. However, there showed a significant 
increase in survival and transduction efficiency is low, like that of the low dose. 
This can explain the extension of survival - it might be due to peripheral 
expression or hitting important cells in the brain. It is likely that to fix RTT, any 
molecular therapy (in this case, vector-derived MeCP2 expression) will need to 
hit a high percentage of neurons to prevent or cure RTT. Moreover, moderate 
dose showed signs of liver damage, vacuolation and loss of hepatocytes, 
confirming the toxicity involved with MeCP2 overexpression. The liver damage 
could be tolerated as these mice survived for a long time, but it is likely that 
there is a threshold for gene expression. Too much expression is toxic and so 
little will not affect the progression of the phenotype. It needs to be expressed 
within the physiological limit (Robinson et al., 2012). Administration of a high 
dose, 1013 vg/kg, showed greatly increased lethality with mortality within 5 
days, preventing body weight and severity score from being tracked. After 
death, I sampled brain tissue for transduction (around 10-20%), but this is 
perhaps not as high as would be needed for a successful RTT therapy. However, 
high transduction efficiency in the liver was observed. This information agrees 
that this vector had a low safety margin. If high transduction efficiency in the 
brain is required, different route of administration or other capsids design that 
able to express in the brain and increase the number of transduction efficiency. 
The challenges are using the same vector to get enough cells in the brain 
without overexpressing mecp2 in the brain and peripheral tissues.  
To transfer therapeutic gene in RTT is whether the presence of endogenous 
mutant MeCP2 might reduce the therapeutic effect of vector-derived wild-type 
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MeCP2. Male mice expressing native MeCP2 tagged with GFP as a fusion protein 
and harbouring the common RTT-causing p.T158M mutation, Mecp2T158M/y, 
display a phenotype very similar to that of Mecp2 null mice. 
6.1.3 Development of a second-generation vector that reduced 
liver toxicity after systemic administration and the efficiency of 
the second-generation vector improved the RTT-like aggregate 
severity score via neonatal cerebroventricular injection  
In chapter 5, I was aiming to reduce the liver toxicity from the first-generation 
vector. Newer cassette design vectors with a weaker synthetic promoter 
(scAAV9/JeT/MECP2), a synthetic short poly A (scAAV9/sPA), and a liver de-
target vector (scAAV9.47/MECP2 (9.47) (Karumuthil-Melethil et al., 2016; 
Pulicherla et al., 2011) were predicted to reduce liver toxicity. However, those 
three vectors result in the hepatotoxicity similar to the first-generation vector. 
Only a second-generation vector, incorporating additional promoter regulatory 
elements and a putative silencer element, showed significantly reduced 
hepatotoxicity comparing with the first-generation vector also in survival and 
body weight in Mecp2-/y. However, the aggregate severity score showed a 
minimal decrease. The transduction efficiency in the brain, using systemic 
injection is still low. The neonatal brain injection study demonstrated that the 
phenotype by increasing the transduction efficiency in the brain. The histology 
from the second-generation vector showed the transduction efficiencies across 
brain regions ranging from 10-40%. This might be related to the combined 
effects of enough of transduction efficiency in trigger cell. The unexpected 
adverse effect is the mild hindlimb clasping in vector-treated WT mice that may 
originate from significant pool of cells overexpressing MeCP2 was apparently 
transduced with multiple copies of vector delivering MECP2. This issue is 
remarkable, and it should receive more information using additional behavioural 
testing. 
 
6.2 Technical considerations 
Most of the technical problems in this study were related to the MECP2 RTT 
model. Hemizygous male Mecp2 KO/KI mice are infertile therefore heterozygous 
female must be mated with WT males to generated hemizygous male mice and 
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heterozygous female mice (the genotype I was interested in). This breeding 
scheme means that the segregation ratio of hemizygous and heterozygous is 25%. 
This low percentage is further complicated by the small litter size (3-5 pups) in 
Mecp2 KO lines which further reduces the chances of getting the desired 
genotype. Moreover, the numbers of pups that reach weaning age and the 
inclusion criteria of body weight (> 9 grams) are also limited, either because of 
failure to compete with the WT or due to the increased incidence of infanticide 
(Jugloff et al., 2006). Many steps were taken to improve the breeding such as 
doubling the number of heterozygous females in each age group, minimizing 
cage disturbance and decreasing environmental noise, especially around the 
delivery time, and avoiding unnecessary handling of the pups to prevent 
infanticide. Moreover, symptomatic RTT mouse needed the special emphasis, for 
example when the mouse loses weight or the RTT-like phenotype score was more 
than five, close monitoring, baby food or moving to a warm chamber was 
supplied. However, when the mouse presents body weight below 20 per cent 
from the peak body weight or got a scoring for tremor or breathing abnormality 
as two, I had to euthanize them humanely. This sometimes affected the number 
of mice in the experiment and may affect the study of mouse behavioural tests 
or the group of control mice in the study of the effectiveness of the viral vector. 
This problem is very common in the study in KO mouse because it has an onset of 
disease and the progress very quickly (6-8 weeks old) (Brown et al., 2016; Chen 
et al., 2001; Guy et al., 2001; Shahbazian et al., 2002). The preparation of spare 
hemizygous mice needs to be considered in the future.   
Another problem originated in the Mecp2 knockout mice had tail lesions around 
the age of 7-8 weeks. This problem usually began as small lesions around the 
tail-base which then progress to skin ulcers and eventually complete necrosis 
and loss of the tail. This condition is usually accompanied by a perianal infection 
which necessitates culling the affected mice. In my study attempts were made 
to the application of topical antibiotics but this showed very limited benefit.  
One possible reason was that this lesion was due to animals fighting with each 
other, however caging mice individually did not prevent or improve this 
phenotype. Interestingly, this tail problem has been not observed in the cohort 
of mice using in the RTT mouse characteristic and validation of behavioural 
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study (chapter 3). Further investigations are required to identify the underlying 
cause of this problem. 
 
In the setting of the suitable behavioural test, the difficulty occurring in RTT 
mouse model, apart from the limitation of mobility, is that all of the mutant 
mice refuse the mouse treat-reward in experimental arena although they fasted 
for food and water for 6 hours. Under my observation, the RTT mouse, although 
starving, will only take the treat when I put it back to its own cage and saw the 
cage-mate eats a treat. This is why I could not set the test using mouse treat-
reward as the endpoint target of the tests, for example, T-maze or touch screen 
memory test. The difficulty issue on the learning test, novel object recognition 
test, is that the test object must appeal to the mouse and the size cannot be too 
small so the mouse can play with it and also easy to clean. In my study, there 
were more than ten objected that I tested with the RTT mouse model.  
 
6.3 Significance of this study 
Rett syndrome was considered for decades a neurodevelopmental disorder and 
was thought to be incurable. Although MeCP2 function is still incompletely 
understood, enough is known about it that it is considered unlikely that drug 
molecules can be found to replace its function directly. In contemplating the 
basis for rational therapies in RTT, there have been many attempts to identify 
appropriate factors downstream of MeCP2 function and target those 
pharmacologically. The previous study showed that MeCP2 is target genes whose 
expression becomes significantly aberrant in the absence of functional MeCP2 
has a few support in terms of the functions to interpret the DNA methylation 
signal, and ubiquity of DNA methylation suggests that candidates for targeting its 
core chromatin-binding function therapeutically will be multiple and diverse 
(Skene et al., 2010). Many attempts with the pharmacological treatment in pre-
clinical study, For example IGF-1 was studied in Rett mice in parallel with the 
clinical trials and efficacy reported on several assays including locomotor 
activity, heart rate, respiration patterns, and social and anxiety 
behaviour(Castro et al., 2014). However, it did not produce clinically meaningful 
efficacy in humans. The pre-clinical study also examined Statins which is a class 
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of lipid-lowering medications approved to prevent cardiovascular disease.  
Statins improved motor function and prolonged survival (by 15 days) in a single 
trial performed in Rett mice(Buchovecky et al., 2013). A single study reported 
improvements in motor function and survival in Rett mice. But there is no 
clinically meaningful benefit was observed in clinical trial. These also presented 
the same result in Ketamine (Katz et al., 2016; Kron et al., 2012; Patrizi et al., 
2016) and . Desipramine (Roux et al., 2007) which no clinical benefit was 
observed in clinical studies. The trials and studies above support the argument 
that the existing pharmacological approaches could not be the best way to 
treatment for RTT in the human. The main reason is those pharmacological 
attempts action on the 2nd downstream not from the whole phenotype. Gene 
therapy can treatment directly at the early state. 
Research study on RTT using RTT KO mouse model made more explanation about 
the mechanism on MECP2 and the study in KI mouse model, for example, MeCP2 
T158M mice, which models the human disease as meticulously as possible can 
interpret the function of MECP2 mutation occurring in patients. However, the 
study in MECP2 T158M mice still has few publications and the validation of the 
suitable behavioural tests for RTT mouse model are needed to apply for the 
validation therapeutic study in the future. The reversal studies have shown the 
potential reversibility of RTT-like phenotypes in mice models. In this study I 
compared characteristics of two mouse lines, KO and KI, to ascertain the most 
suitable model for the study of RTT. In addition, I provide the safe therapeutic 
dose using in RTT mouse model and highlight the adverse effect liver of this 
approach. I also highlight the potential new cassette, the second-generation 
vector, that reduced the liver toxicity and can have a possible efficiency to 
reducing the RTT-like phenotype when delivery by direct brain injection 
increasing high brain transduction efficiency.  These data however at the proof 
of concept level should have an impact on the future therapeutic approaches not 
only for RTT but also for other related neurological disorders. The importance of 
this study is listed in the following key points;  
1. In this thesis I provide a comprehensive study investigating the two important 
RTT mouse lines with the standard test for RTT-like phenotype tests showing the 
same validation of my test and then extended to validate additional behavioural 
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tests in order to properly design a therapeutic evaluation in term of the best 
mouse model and the best suitable test. 
2. In this thesis, I showed the first proof-of-concept demonstration that impaired 
mobility in RTT mouse models can be improved by adding the mouse’s own 
bedding. This may be a valuable tool for other behavioural studies of RTT mouse 
models involving mobility. 
3. My thesis provides the therapeutic dose in a mouse model of RTT delivered by 
scAAV9/MeP-mediated MeCP2 by systemic injection in young adult mice. This 
data, along with the observed lack of overt adverse effects of this vector in 
mouse hepatocyte and confirmed that the cause from exogenous MeCP2 
overexpression. 
4. My thesis shows that the presence of the mutant protein does not impede the 
functionality of vector-derived MeCP2. This finding was supported by the 
delivery of scAAV9/MeP-mediated MeCP2 in male KI RTT mouse model. This 
result indicated the potential translational application of augmentation gene 
therapy in patients with missense MECP2 mutations.  
5. My thesis provides evidence that the new modified vector, the second-
generation vector, designed to include an extended Mecp2 promoter and 
additional regulatory 3′-UTR elements, significantly reduced hepatic toxicity 
after systemic administration. This show that controlling levels of MeCP2 
expression in the liver is achievable through modification of the expression 
cassette. Moreover, direct brain injection of this vector reducing the physical 
barrier to the brain, into neonatal KO male mice present the improvement of 
RTT-like phenotype. These considerations are essential for the field of RTT gene 
therapy in order to properly design a therapeutic vector and route. 
6.4 Future studies 
This project examined various gene delivery doses and then refined vector 
design and delivery strategies, moving to proof of concept studies in RTT mice. 
This series of studies formed a logical course in reaching the goal of developing 
translational strategies in treating RTT in patients. The results shown in my 
thesis suggest important future experiments in various directions. 
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1. Following the success of the second-generation vector in producing 
therapeutic benefits after direct brain injection in neonates, I would recommend 
several more experiments to further investigate the potential for future human 
translation: 
I. The vast majority of RTT patients are females with a mosaic network of cells 
either expressing normal MeCP2 or lacking functional MeCP2. Therefore, the 
next experiment should be to consider injecting adult heterozygous female mice 
with the second generation. Female mice are the most relevant genetically to a 
human patient and the RTT progress in females is gradual (Guy et al 2007). 
II.  Optimising viral delivery methods to increase transduction efficiency in adult 
mice brain for example administration the second generation vector via 
intrathecal or intra cisterna Magna injection (Sinnett, 2017) to reduce the 
amount of virus particles and also decrease peripheral expression because the 
direct brain delivery of exogenous MECP2 is difficult to apply in human.   
III. Optimising the vector construct to enable targeting of exogenous MECP2 to 
null cells aiming to increase brain transduction through the new design of 
AAV9PHP.B and AAV9PHP.eB (Deverman et. al., 2016, György et. al., 2018, 
Hordeaux et.al., 2018, Rincon et. al., 2018) has been reported to have a higher 
transduction efficiency to the effect of 40 times more than AAV9. Using this new 
vector to deliver MECP2 may increase the therapeutic effect from the systemic 
injection. 
2. Other potential avenues to explore include MECP2 reactivation from the 
inactive X and genome or base editing approaches. A rapid increase of work in 
this area over the last few years has enabled the development of such 
approaches.  Currently, many editing agents are in development including 
CRISPR/Cas9 and the TALEN system.  
 
The emergence of the former as the genome editing system of choice is because 
of its efficiency, ease of synthesis and targeting ability of simultaneous multiple 
loci. The CRISPR system, in bacteria, with its Cas (CRISPR-associated) nuclease 
proteins have provision of an adaptive immunity form by targeting nucleases 
against invading viral DNA (Horvath and Barrangou, 2010). 
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In a study conducted recently, Maresca and colleagues (Maresca et al., 2013) 
provided a demonstration that large sequences of DNA may be captured at 
nuclease-induced double stranded breaks when the DNA is flanked by targeting 
identical sequences to the chromosomal DNA. This process has been found to be 
dependent on NHEJ and the provision of a robust way in ligating DNA constructs 
in the genome’s precise locations.   
 
One therapeutic strategy would be the use of this process in inserting a WT copy 
of MECP2 into the AAVS1 safe harbour locus. This allows for stability of 
transgene expression in the human genome (Tiyaboonchai et al., 2014). Like the 
approaches of current gene therapy, this strategy enables the cell to express 
functional proteins without damaging the WT copy in cells expressin the non-
mutant allele.  
 
This approach has an potential advantage over the current strategies pertaining 
to gene therapy - it could allow dividing cells, such as microglia and astrocytes, 
and neuronal stem cells in passing the WT transgene to daughter cells. The 
targeted nature of the insertion will help to avoid the potential consequences of 
insertional mutagenesis at the endogenous MECP2 locus or at other insertion loci 
in the case of lentiviral delivery of transgenes.   
 
3. Since most of learning and memory tests depend on the mobility ability and 
mouse treat-reward, the following experiments could help determine the 
reasons for this problem: 
I. the novel object recognition test arena needs to be reduced in area. 
II. Provide a smell that is attractive to mice as a treat-reward after weaning, 
aiming to increase the familiarity of the treat-reward.  
 
 
160 
 
 
 
Figure 1.6 Mechanism of action of CRISPR/Cas system. In the CRISPR/Cas9 
genome editing system a guide RNA (gRNA) binds to a target sequence and 
creates a template for the Cas9 nuclease to make a targeted, double-stranded 
break in the DNA, leading to activation of one of the two major repair pathways 
that can be exploited for therapy. (A) When the NHEJ pathway is activated, DNA 
ends are ligated together without the need for a homologous DNA template. This 
pathway could be used to ligate a WT copy of the MECP2 gene into a safe 
harbour in the genome. (B) In the presence of the HR machinery in dividing cells, 
homology-directed repair occurs and an exogenously provided WT template can 
be inserted accurately into the genome in place of a region containing a disease-
causing mutation, thus editing the mutant allele (red) and causing WT MeCP2 to 
be expressed instead (green). HR: Homologous. This figure was adapted from 
(Gadalla, 2015). 
 
6.5 Summary 
The aim of this thesis was an exploration of viral-mediated exogenous MECP2 
delivery to RTT mouse model, and then to use this information to design 
therapies suitable for future clinical translation. This investigation was 
extremely productive in several respects. First, phenotyping of a novel knock-in 
mouse model, in which the Mecp2 T158M missense mutation occurring in human 
patients was recreated, revealed that the majority of the RTT phenotype and 
other additional behavioural tests was milder phenotype than the Mecp2 
knockout mice in both sexes. Thus, hemizygous T158M knock-in mice may be 
used for the therapy screening tests, but phenotypic reversal may not be as 
clear as in the Mecp2 knockout line. Second, this study demonstrates beyond 
doubt that our first generation vector has a narrow therapeutic window 
following systemic administration and that toxicity occurs in liver cells, probably 
due to exogenous vector-derived MeCP2 overexpression. Finally, my study is the 
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first to report results using a new modified vector design, the second generation 
vector, by incorporating an extended Mecp2 promoter and additional regulatory 
3′ UTR elements significantly reduced hepatic toxicity after systemic 
administration and also ameliorates RTT-like phenotypes after direct brain 
injection in mouse neonates. I believe that this study provides the groundwork 
for further studies to identify the newer potential cassette design having more 
efficiency and  the potential of achieving therapeutic benefits in long term 
studies in the heterozygous female Mecp2 mouse model, a more accurate model 
of human RTT, and also for studies to investigate the underlying pathology of the 
hindlimb motor deficit to enable avoiding this problem in future clinical studies.  
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